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“We don't notice things change. We know that things change, we've been told 
since childhood that things change, we've witnessed things change ourselves 
many a time, and yet we're still utterly incapable of noticing the moment that 
change comes--or we search for change in all the wrong places.” 
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Extracellular vesicles (EVs) are membrane-bound nanoparticles produced by cells. Their main 
function is the intercellular transport of information. Their natural biological activity and ability 
to interact with target cells drives the effort for their evaluation as therapeutic agents and their 
clinical translation. Thus, the present work aimed at evaluating two important topics for the 
development of EV-therapeutics, engineering the surface of bacterial EVs to introduce 
targeting moieties and optimizing the lyophilisation of mammalian EVs. 
Different methods for the surface engineering of bacterial EVs were tested. While cholesterol 
insertion and activated esters were not successful in our setup, diazotransfer to install azide 
groups on the EV surface followed by click-chemistry demonstrated high efficiency with low 
impact on vesicle-integrity. Based on these results modular linker-molecules to tether targeting 
moieties to the vesicle surface were synthesized and evaluated in proof-of-concept 
experiments that afforded important insights for future optimization of their design. 
Initial studies on the lyophilisation and storage of mammalian EVs revealed the high stress of 
freezing and dehydration. Thus, optimized protocols for the lyophilisation of EVs were 
developed and successfully produced formulations with long-term stability. 
Taken together, effective surface engineering by diazotransfer and optimized lyophilisation of 




Extrazelluläre Vesikel (EVs) sind von Zellen produzierte Nanopartikel, deren Hauptaufgabe 
der interzelluläre Transport von Informationen ist. Ihre natürliche biologische Aktivität und ihre 
Fähigkeit mit Zielzellen zu interagieren, waren Auslöser für die Untersuchung von EVs als 
Therapeutika mit dem Ziel ihrer klinischen Translation. Ziel der vorliegenden Arbeit war die 
Evaluierung zweier wichtiger Faktoren für die Entwicklung von EV-Therapeutika, die 
Oberflächenmodifikation bakterieller EVs mit Molekülen für aktives Targeting und die 
Lyophilisation von aus Säuger-EVs. 
Verschiedene Methoden zur Oberflächenmodifikation von bakteriellen EVs wurden getestet. 
Während Cholesterol-Insertion und aktivierte Ester wenig erfolgreich waren, zeigte 
Diazotransfer zur Einführung von Azid-Gruppen gefolgt von Click-Chemie-Reaktionen eine 
hohe Effektivität mit geringem Einfluss auf die EV-Stabilität. Zur Einführung von Targeting-
Molekülen wurden verschiedene modulare Linker-Moleküle synthetisiert und in 
Machbarkeitsstudien evaluiert, diese lieferten wichtige Erkenntnisse für ihre zukünftige 
Optimierung. 
Erste Untersuchungen der Lyophilisation und Lagerung von Säuger-EVs zeigten eine hohe 
Beanspruchung der Vesikel durch Einfrieren und Trocknung. Daher wurden die Protokolle für 
die EV-Lyophilisation optimiert und EV-Formulierungen mit Langzeitstabilität erfolgreich 
hergestellt. 
Insgesamt wurden sowohl bei der Oberflächenmodifikation als auch Lyophilisation von EVs 
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Extracellular vesicles (EVs) are biogenic nanoparticles that are produced by cells and shed 
into the surrounding medium. They were initially discovered in the 1950s and 60s in algae (1), 
mammalian cells (2) and gram-negative bacteria (3, 4) and long thought of as just a way for 
cells to get rid of misfolded proteins and other waste-material (5). Today it is known that they 
are produced by cells from all parts of the phylogenetic tree, including gram-positive bacteria 
(6), higher plants (7), mycobacteria (8), archaea (9) and fungi (10). It has been discovered that 
EVs are an important part of the cellular secretome (11) and their main function is the transfer 
of information between cells (12, 13). Through active sorting mechanisms during EV-
production, cargoes can be packaged in high concentrations and in synergistic combination 
with other compounds to convey a specific effect (14). Together with mechanisms for selective 
targeting and uptake of the vesicles (see 1.2 and 1.3), this leads to a more efficient distribution 
of effector-molecules than simple secretion into the surrounding medium (15). The vesicle-
membrane moreover protects sensible cargo-molecules, such as RNA, from degradation in 
the extracellular milieu (16). 
Especially the field of mammalian cell derived EVs got a lot of traction in recent years, when 
the vital role of EVs in many physiological as well as pathological processes was discovered 
(13, 17). Today, mammalian EVs as well as EVs derived from gram-negative bacteria – called 
outer membrane vesicles (OMVs), as they are derived from the bacterial outer membrane (18) 
– are intensely investigated in pharmaceutical applications, for example as therapeutic 
nanoparticles (see 1.5) and drug delivery vehicles (see 1.5.1). 
  
Throughout this work, the term extracellular vesicle or EV is used to refer to extracellular 
vesicles in general regardless of their production organism. 
Explicit reference to EVs produced by mammalian cells is denoted by the term mammalian 
extracellular vesicle or mammalian EV. 
EVs derived from gram-negative bacteria are referred to as outer membrane vesicles or 
OMVs. 
Box 1: EV-nomenclature 
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1.1. Aims of this work 
The overall focus of this work was continuing the development of therapeutics based on EVs 
derived from both bacteria and mammalian cells. The first two parts of this work was aimed at 
increasing the potential of bacterial EVs for drug-delivery, the third part was concerned with 
improving the storage stability of EV-based therapeutics (Box 2).  
1) Development of an efficient method for the surface modification of myxobacterial OMVs 
based on physical or chemical modification. 
2) Based on this method, introduction of targeting moieties to OMVs that increase their 
bacterial binding using a modular approach. 
3) Evaluation of the effect of different storage conditions on the stability of EVs and 
development and optimization of protocols for their lyophilisation, to obtain EV-
formulations with long-term stability. 




Figure 1: Aims of this work. A: Development of a method to introduce azide groups to the 
surface of bacterial EVs e.g. based on diazotransfer with imidazole-1-sulfonyl azide (ISA) B: 
Simultaneous introduction of a bacteria-specific targeting moiety and a fluorescent dye to the 
surface of azide-labeled OMVs to promote targeting of bacteria e.g. using copper-catalyzed 
alkyne-azide cycloaddition (CuAAC). C: Optimization of EV-lyophilisation to generate 
formulations that protect the integrity of lyophilized vesicles using exogenously encapsulated 




There is a discovery void of new antibiotic agents (19), while the prevalence of bacterial 
resistance is steadily rising (20). Thus, new antibiotic agents and ways to increase the 
effectiveness of current antibiotics are highly sought after. OMVs derived from myxobacteria 
are evaluated in our group as antibacterial agents and drug-delivery vehicles for antibiotics, 
with promising early results (21, 22). To further amend these results, the vesicles could be 
equipped with targeting moieties on their surface to increase their interaction with pathogenic 
bacteria at the site of infection. 
The surface modification of OMVs in general and specifically myxobacterial OMVs has not 
seen much evaluation yet. Thus, an effective method for the surface engineering of OMVs 
based on physical or chemical modification needed to be developed first (Figure 1 A). Once 
established, this method would be employed to attain the second goal, introducing bacteria-
specific targeting moieties to the vesicle-surface (Figure 1 B). To broaden the scope of this 
endeavor beyond just one type of targeting moiety or vesicle, a modular linker molecule would 
be employed to connect vesicles and targeting moieties. 
Beyond the properties of myxobacterial vesicles for anti-infective applications, the second main 
part of this work focused on a more overarching issue for the clinical translation of extracellular 
vesicles - their storage. A sufficient storage stability is a crucial requirement for the viability of 
EV-based drugs. Thus, we aimed at gaining further insights into the effect of storage on EV-
stability and evaluated lyophilisation of EVs as an alternative to frozen storage to obtain EV-
formulations with long-term stability (Figure 1 C). 
1.2. Extracellular vesicles derived from mammals and other 
animals 
Eukaryotic cells produce vesicular nanoparticles of various subtypes. During programmed cell-
death apoptotic bodies are formed that contain organelles and other remnants from the dying 
cell (23). These vesicles are distinct from the vesicles produced by cells during their lifetime 
(24). Here two main groups are described, that are the focus of current research in the field, 
microvesicles and exosomes (Figure 2). Microvesicles are produced by blebbing from the cell 
membrane and are mostly sized between 100 and 1000 nm. Exosomes are derived from 
multivesicular endosomes (MVEs) that can fuse with the plasma membrane to release their 
intraluminal vesicles (ILVs). They generally differ in size from 30-200 nm. Other subtypes of 
EVs have emerged, but their physiological roles have not been evaluated in detail yet (25, 26). 
EVs have been identified as effectors in various physiological processes (13). There is clear 
evidence that EVs are able to transfer functional cargos over long distances (27-29) and some 
examples suggest that this transfer at least in part is specific for certain target cells (30-32). 
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There are multiple pathways for their biogenesis, cargo loading and uptake into recipient cells 
that vary between cell types and are not comprehensively understood yet (29, 33, 34).  
 
Figure 2: Microvesicles bud directly from the cell membrane, while exosomes are generated 
in multivesicular endosomes that then fuse with the cell membrane. Apoptotic bodies are 
derived from cells undergoing apoptosis. In their lumen, exosomes and microvesicles contain 
cargos such as nucleic acids and proteins, while their surfaces can be decorated with surface- 
and transmembrane-proteins and receptors. Adapted from Fuhrmann, G., et al. (2015, “Cell-
derived vesicles for drug therapy and diagnostics: Opportunities and challenges”, Nano Today 
10(3): 397-409. With permission from Elsevier. 
Research into the biogenesis of EVs has been hampered by the inability of current vesicle-
isolation methods to cleanly separate microvesicles from exosomes (33). Nonetheless, 
researchers have shed some light on the biogenesis of both exosomes and microvesicles 
(Figure 3).  
The biogenesis of exosomes is complex, with multiple pathways that can lead to the generation 
of MVEs (34, 35) and the composition of exosomes can change during cell maturation (36). 
The most extensively researched pathway for the recruitment of cargos and the generation of 
ILVs is the ESCRT (endosomal sorting complex required for transport) machinery, which 
consists of four protein complexes, ESCRT-0 to ESCRT-III (37). ESCRT-0 is responsible for 
binding cargos (38), which are generally ubiquitinylated (39). ESCRT-0 associates with 
ESCRT-I and –II. These in turn are responsible for the clustering of cargos and the recruitment 
of ESCRT-III (37), which is the driving factor of the scission of the new-formed vesicle into the 
endosome lumen (40). The interplay between syndecan, syntenin and ALIX (ALG-2 interacting 
protein X) has been identified as an important alternative to ESCRT-0-based exosome 
biogenesis. Syndecan is a transmembrane protein that is found on the cell-surface (41). After 
endocytosis, syntenin binds to its cytosolic domain (42). Syntenin in turn interacts with ALIX, 
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which is an accessory protein of ESCRT III (37), which is again responsible for the vesicle-
formation. ALIX is also used as a marker for EV-detection. MVEs however can also be 
generated independent from ESCRT, as shown by knockdown of all four ESCRT components 
(43). One of these ESCRT-independent pathways is governed by the sphingolipid ceramide 
(44). Ceramide can form lipid-raft microdomains to recruit cargo and through its cone-shape, 
it can induce the deformation of the endosomal membrane. The usage of ILV-generation 
pathways can vary by cell-type (37) and cargo, e.g. EGFR was packaged into ILVs in an 
ESCRT-dependent manner, while proteolipid protein was entirely dependent on ceramide (44). 
 
Figure 3: Examples of pathways for cargo recruitment (1), cytoplasmic sorting (2) and budding 
(3) of microvesicles (upper part) and intraluminal vesicles (ILVs) (lower part). ILVs can be 
generated either dependent on ESCRT complexes or independent from them e.g. through 
cross play of syndecan, syntenin and ALIX. ESCRT-0 interacts with typically ubiquitinylated 
cargos. ESCRT-I and –II are recruited by ESCRT-0, bind further cargoes themselves and 
recruit ESCRT-III, which drives the scission of ILVs. Alternatively, cargos can be clustered 
through syndecan, syntenin and tetraspanins, while ALIX recruits ESCRT-III. In case of 
microvesicles, cargo-clustering and cytoplasmic sorting are dependent on ESCRT-I and –II 
and tetraspanins. The translocation of lipids, predominantly phosphatidylserine is another 
factor in microvesicle-production. Budding of the vesicles is effected by ESCRT-III together 
with the cytoskeleton, where myosin is activated through small GTP-binding proteins such as 
ARF6 (ADP-ribosylation factor 6). Both for ILVs and microvesicles, the enrichment of ceramide 
in the budding membrane can also be a driver of vesicle-scission. Adapted with permission by 
7 
 
Springer Nature Customer Service Centre GmbH from van Niel, G., et al. (2018). Nature 
Reviews Molecular Cell Biology 19(4): 213-228. 
The biogenesis of microvesicles has not been investigated as extensively yet; however, there 
is evidence of multiple pathways that might act partially together in the formation of 
microvesicles (Figure 3). ESCRT-I to –III are instrumental in the budding of vesicles from the 
plasma membrane (45), ESCRT-0 seems to be absent however (35). Another important factor 
are cholesterol-rich lipid rafts (34). Membrane vesicles are enriched in this lipid and its 
depletion from cells reduces their production (46). In Caenorhabditis elegans, it has been 
shown that loss of the lipid-asymmetry of the cell membrane also leads to the budding of 
vesicles from the cell surface (47). This loss of asymmetry is initiated by lipid-flipping through 
calcium-dependent flippases (34), which makes the intracellular calcium-concentration 
another factor in microvesicle production (48). Finally also the small GTP-binding protein ARF6 
(ADP-ribosylation factor 6) can, through a cascade of multiple enzymes, lead to activation of 
myosin, which in interaction with actin can effect the scission of the vesicles (35). 
Tetraspanins such as CD9, CD63 and CD81, are used as general markers in the analysis of 
microvesicles and exosomes (33, 49). They are membrane proteins with four transmembrane 
domains that play important roles in many physiological processes throughout the body (50). 
Through association with other tetraspanins and transmembrane proteins, such as syndecan 
(51), as well as lipids (52) and cytosolic proteins, they can form membrane microdomains. 
Tetraspanins take part in the sorting of cargos to EVs (53), such as β-catenin (54) or MHC 
class II (55). They might also directly take part in the formation of ILVs (56). 
Besides proteins, EVs also contain nucleic acids, mainly RNA (28, 34). The mechanisms of its 
encapsulation are however not understood completely yet. Some findings indicate the 
presence of zip code-like sequences that could lead to its enrichment in EVs (57, 58) and also 
interactions with ESCRT-II (59) and tetraspanins - through association with RNA-binding 
proteins - have been identified (60). 
While microvesicles are released directly from the cell membrane, MVEs first need to travel 
through the cytosol and fuse with the phospholipid membrane to set free their ILVs. For 
endosomes there is a balance between exosome release and degradation through fusion with 
lysosomes or autophagosomes (34). Accordingly, impairment of lysosome function led to an 
increase in vesicle-production (61). The fate of MVEs seems to partially depend on the 
mechanism of their biogenesis, with the syndecan-syntenin-ALIX pathway being associated 
with exosome release, while the ESCRT-pathway seems to favor degradation (34, 41). 
Docking to the cell membrane of MVEs destined to release their ILVs as exosomes is mediated 
by small G-proteins of the Rab family (35). Silencing of Rab-proteins has been associated with 
reduced exosome-production (62). The final step of fusion between MVE and plasma 
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membrane is likely mediated by SNARE proteins, which are a key part of membrane-fusion 
events in cells (63). Different SNARE-complexes have been associated with exosome 
production in different cell-types (64-66). 
 
Figure 4: Uptake of EVs into recipient cells is a multistage process. First vesicles bind to the 
cell membrane. This can take place through different interactions, for example through 
integrins on the cell- or vesicle-surface, components of the extracellular matrix (ECM) or the 
recognition of phosphatidylserine on the surface of microvesicles. Already at this stage, EVs 
can transfer information to recipient cells through signal cascades or antigen presentation. 
Endocytosis of EVs depends on the type of EVs and the recipient cells. Once taken up, EVs 
end up in early endosomes fated for lysosomal degradation. To set free their cargo to the 
cytosol, EVs can fuse with the endosomal membrane. An alternative to endocytosis is the 
fusion of EVs with the cell membrane to set free their cargos, endocytosis however seems to 
be the predominant pathway. Adapted with permission by Springer Nature Customer Service 
Centre GmbH from van Niel, G., et al. (2018). Nature Reviews Molecular Cell Biology 19(4): 
213-228. 
After being released from the cells, exosomes and microvesicles travel to recipient cells to 
convey effects based on their cargos (34). Transfer of information to the recipient cell can 
either take place already upon binding, e.g. through antigen-presentation (67), or require the 
uptake of the vesicle and the delivery of its soluble cargo to the lumen of the cell (Figure 4). 
The initial step of binding to the cell-surface can rely on different interactions (29). For instance 
it can be based on the interaction of integrins on the vesicles that bind to their cellular 
counterparts (68), phosphatidylserine exposed on the surface of EVs that can be specifically 
recognized (69) or through mutual interactions with extracellular matrix components (70).  
After binding to the membrane, EVs can fuse with the cell membrane or be taken up by 
endocytosis (29). However, while some examples of direct fusion with the cell membrane have 
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been described (71, 72), EVs are mainly taken up by various endocytotic pathways, as 
indicated by the near abolishment of vesicle-uptake by decreasing temperature to halt energy-
dependent processes (29). Uptake can take place by clathrin coated pits (73) or independent 
from clathrin through interactions with cholesterol-rich lipid-rafts (74) and by phagocytosis (75) 
or macropinocytosis (30). Once taken up into endosomes, EVs can fuse with the endosomal 
membrane to set free their cargo into the cytosol, which has been recently demonstrated (76). 
EVs are found in all biological fluids of the body and diverse physiological functions have been 
ascribed to them (13, 77). The procoagulant activity of EVs derived from platelets is well 
documented (78, 79). Platelet EVs have also shown proangiogenic effects (80). In the immune 
system, EVs can, among other functions, present antigens on their surface (81) and in breast 
milk EVs seem to contribute to its immune modulatory properties (82). In the central nervous 
system EVs are involved in crosstalk between pre and post synapse (83, 84) and glia cells 
(85). During organ development, EVs mediate crosstalk between epithelial cells and the 
mesenchyme (86). 
In the diseased state EVs can have both beneficial and detrimental effects. In infections, EVs 
released by neutrophilic granulocytes have demonstrated antibacterial and antifungal effects 
(87, 88). Moreover EVs can act as decoy-particles for bacterial virulence factors such as the 
pore-forming toxin of S. aureus (89). On the other hand, the packaging of proteins and nucleic 
acids into EVs has also been highjacked by viruses and EVs derived from infected cells can 
infect recipient cells (90-92). EVs might also play a role in neurodegenerative diseases (93) 
and have been implicated with transferring prions between cells (94). 
A lot of research is performed into the role of EVs in cancer (95). The information contained in 
EVs can both prime distant sites in the body for metastasis (96, 97) and transform the 
phenotype of distant cancer cells (27). EVs derived from cancer cells also contribute to the 
immune suppressive effects exerted by cancers to promote their survival (98). 
Taken together the discovery of EVs and their physiological roles has been the foundation to 
an ever-expanding field of science that aims at dissecting the intricate workings of EVs in the 
human body and harnessing them in new therapeutic approaches. 
1.3. Bacterial outer membrane vesicles 
OMVs are produced through budding from the outer membrane of gram-negative bacteria. On 
their surface they retain the features of this membrane in the form of lipopolysaccharides (LPS) 
and membrane-proteins (Figure 5 A) (99). LPS makes up the outer leaflet of the outer 
membrane of gram-negative bacteria (Figure 5). It consists of lipid A, the lipophilic portion that 
forms the membrane, the core oligosaccharide and the o antigen, which is also an 
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oligosaccharide (Figure 5 B) (100). Its overall structure is well conserved, but there are 
variations between species and strains (101). The interaction of negatively charged core 
oligosaccharide and divalent metal cations forms a densely packed hydrophilic structure that 
effectively prevents the diffusion of small lipophilic compounds while lipid A prevents the 
passage of hydrophilic compounds thus making gram-negative bacteria impervious to many 
antibiotics (100, 102). LPS is recognized by the immune system and leads to strong 
inflammatory effects (103). 
 
Figure 5: A shows the schematic structure of an OMV. The outer leaflet of their lipid bilayer 
consists of LPS. Embedded into the bilayer are outer membrane proteins. In their lumen, OMVs 
can contain various cargos. LPS consists of the lipophilic lipid A and the hydrophilic anionic 
core oligosaccharide to which the O-antigen is bound, which again is a short oligosaccharide 
(B). A adapted with permission by Springer Nature Customer Service Centre GmbH from 
Kaparakis-Liaskos, M. and R. L. Ferrero (2015). “Immune modulation by bacterial outer 
membrane vesicles”, Nat Rev Immunol 15(6): 375-387. (99). B adapted with permission by 
Springer Nature Customer Service Centre GmbH from Ruiz, N., et al. (2009). “Transport of 
lipopolysaccharide across the cell envelope: the long road of discovery”, Nature Reviews 
Microbiology 7(9): 677-683. 
The production of OMVs is governed by multiple processes (104), which are directly linked to 
the structure of the gram-negative cell envelope (Figure 6). The stability of bacteria and their 
complex membrane-structure is dependent on crosslinking of its different components. The 
outer lipid-bilayer is covalently tethered to the peptidoglycan-layer in the periplasmic space by 
Braun’s lipoprotein (Lpp). In addition to that there are non-covalent interactions through the 
porin OmpA that also interacts with the peptidoglycan-layer and the Tol-Pal complex that spans 
from the inner membrane all the way to the outer membrane and plays an important role in 
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cell-division (105). By regulating the integrity of this network, bacteria are able to shed parts of 
their outer membrane without destabilizing their whole membrane and putting their viability in 
jeopardy (Figure 7). The crosslinking through Lpp has a big impact on the amount of OMVs 
produced, with a lower amount of linkage between the protein and the peptidoglycan-layer 
correlating with a higher amount of vesiculation (Figure 7 a&b) (106). Areas of lower PG-
membrane-crosslinking could also promote the accumulation of misfolded proteins and 
membrane-components that need to be expelled from the cell (Figure 7 c). These in turn can 
promote the outward bulging of the membrane to facilitate OMV-production. Finally, similar to 
mammalian EVs, the presence of lipid-microdomains and the enrichment of e.g. different types 
of LPS that encourage membrane-curvature could aid OMV-production (Figure 7 d&e). This 
was first reported for P. aeruginosa, where a charged LPS-subtype is enriched in vesicles 
(107). Elhenawy et al. saw a similar effect in in S. typhimurium, were remodeling of lipid A 
through deacetylation led to an increase in OMV-production (108). Turnbull et al. discovered 
that at least in P. aeruginosa there is also another less organized way for vesicle-production, 
explosive cell lysis (18). In biofilm settings, some bacteria rupture to set free their DNA, which 
forms an integral part of the biofilm. The remaining membrane fragments then self-organize to 
form membrane vesicles.  
 
Figure 6: The gram-negative cell envelope consists of two lipid membranes, the cytoplasmic 
and the outer membrane. Between them, there is the periplasmic space that contains a 
peptidoglycan (PG) layer and soluble proteins. The cytoplasmic membrane consist of 
phospholipids, while the outer membrane is asymmetric and its outer leaflet consists of LPS. 
The stability of the bacterial cell-envelope is based on covalent as well as non-covalent 
interactions between the outer membrane and other membrane components. Lpp forms 
covalent crosslinks, while the porin OmpA and the Tol-Pal complex mediate non-covalent 
interactions. Adapted with permission by Springer Nature Customer Service Centre GmbH 
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from Schwechheimer, C. and M. J. Kuehn (2015). “Outer-membrane vesicles from Gram-
negative bacteria: biogenesis and functions”, Nature Reviews Microbiology 13(10): 605-619. 
The process of cargo-selection for OMVs is still not comprehensively understood. 
Schwechheimer and Kuehn postulate that the recruitment of cargo or its exclusion might in 
part be governed by passive processes, in the way that cargo molecules might be more likely 
to associate with membrane-features that are located in parts of the outer membrane more 
likely to bud and form an OMV (Figure 7 f). Excluded molecules conversely might preferably 
interact with components of the periplasm that are usually not part of OMVs, such as Lpp (104). 
 
Figure 7: Multiple mechanisms are proposed for the formation of OMVs. Areas of reduced 
covalent crosslinking of PG and Lpp could lead to an increase in OMV-formation (a), while an 
increase in crosslinking would reduce vesicle-production (b). The accumulation of misfolded 
proteins and other waste-material could also lead to the outward bulging of the outer 
membrane and promote OMV-formation (c). Moreover, lipid microdomains containing 
alternative forms of LPS or other lipophilic molecules such as pseudomonas quinolone signal 
(PQS) could help vesicle formation (d and e). For cargo-recruitment into OMVs, it is theorized 
that cargos might preferentially accumulate in areas of the outer membrane more likely to form 
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OMVs, while excluded cargos would associate with areas unlikely to bud. Adapted with 
permission by Springer Nature Customer Service Centre GmbH from Schwechheimer, C. and 
M. J. Kuehn (2015). “Outer-membrane vesicles from Gram-negative bacteria: biogenesis and 
functions”, Nature Reviews Microbiology 13(10): 605-619.  
After reaching the recipient-bacterium, OMVs can be integrated into the cell-envelope (109), 
but overall it is not entirely clear if this is the main mechanism of cargo-delivery, which might 
also be accomplished by the vesicles associating with bacteria and disintegrating to set free 
their cargos in the direct vicinity of recipient cells (109). Nonetheless, there is a clear indication 
that OMVs display some degree of selectivity in their interaction with target-bacteria (110). 
Regarding OMV-uptake into mammalian cells, there is evidence that all pathways which cells 
regularly use for the uptake of outside-material can play a role in OMV uptake (see also Figure 
3) (111). The primary route of uptake can depend, among other factors, on the OMV-origin, 
their surface-makers and their size. An often-reported mechanism of entry is the uptake of 
OMVs through interaction with cholesterol-rich lipid-raft-domains (112-114). O’Donoghue et al. 
determined that uptake of OMVs through this mechanism likely depends on the presence of 
the O-antigen on the vesicle-surface (115). The O antigen is the outermost part of LPS and is 
typically more prevalent in pathogenic bacteria. This insinuates that the pathogenicity of certain 
bacteria is in some way linked to the efficient uptake of their OMVs by host cells. 
In the same way as EVs, OMVs can contain a wide array of cargoes and be important factors 
under different circumstances. For the producing bacterium itself, formation of OMVs has been 
proven an important stress-response-mechanism. OMV-production allows for the rapid 
removal of misfolded proteins and other toxic compounds (116). A reduced OMV production-
capability is hence linked to impaired growth and increased sensitivity to external stressors 
(104). Shedding of OMVs can also help bacteria adapt to changes of their environment, by 
facilitating rapid alterations of the LPS-layer facing the outside medium (117). In bacterial 
communities, OMVs can act as common goods that help not only the producing bacterium, but 
the whole community (104, 118). They improve the acquisition of nutrients through associated 
degradative enzymes (14, 119) and iron-binding molecules (12, 120). OMVs themselves can 
also be used as a nutrient-source, e.g. by heterotrophic bacteria (121). The ability of OMVs to 
carry poorly soluble molecules over great distances, enables the distribution of hydrophobic 
quorum sensing factors, such as the pseudomonas quinolone signal, which is a key factor for 
the virulence of P. aeruginosa (111).  
In host-pathogen interactions, OMVs can have both mutually beneficial effects as well as 
detrimental effect for the host. Bacteria encapsulate virulence factors in their OMVs that elicit 
cytotoxic effects in host-cells and increase the severity of the infection. Examples are outer 
membrane protein A and tissue-degrading enzymes packaged into Acinetobacter baumannii 
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OMVs (114), cytotoxic necrotizing factor type 1 in OMVs from uropathogenic E. coli (113) and 
enterotoxin found in OMVs derived from enterotoxigenic E. coli (112). Nevertheless, OMVs 
can also have beneficial effects and vesicles derived from commensal bacteria have shown 
anti-inflammatory effects (122-124). These effects are most prominent for OMVs derived from 
the gut microbiota, highlighting its importance in the prevention of inflammatory diseases (125). 
In the context of bacterial infections, OMVs have several functions that help their parent 
bacteria colonize the host and survive its countermeasures. OMVs that bind antimicrobial 
peptides and bacteriophages can act as decoy to shield their producers, similar to their 
mammalian cousins (126-128). Moreover, OMVs can be associated with beta-lactamases to 
offer further protection against antibiotics (111, 129). OMVs containing DNA can transform 
other bacteria and lead to the expression of virulence genes, such as shiga toxin (130), and 
antibiotic resistance genes, which has been studied most extensively for A. baumannii. Its 
OMVs have been implicated in the transfer of antibiotic resistance genes within the species 
(131, 132) but also across the species-barrier (133). Finally, OMVs can also trigger the 
formation of biofilms (134, 135) and vesicles contained in these bacterial communities account 
for a big portion of the LPS found there (136). Their specific role in this setting, apart from their 
biological roles previously described, however still is not completely understood (137). The 
lytic enzymes and antibiotic-binding capabilities of OMVs however, are certainly advantageous 
for shielding biofilm-dwelling bacteria from detrimental outside-influences. 
While OMVs can have many beneficial properties in bacterial communities, some bacteria also 
produce OMVs with antibacterial properties to fight off rivalling species invading their biological 
niche or to actively attack other bacteria. In several publications, the antibacterial properties of 
OMVs derived from P. aeruginosa and other gram-negative have been analyzed (138-140). 
However, of greater relevance for the work presented in this thesis and with greater potential 
for application as antibacterial nanoparticles, are OMVs produced by myxobacteria. 
1.3.1. Myxobacterial OMVs 
Myxobacteria are a group of gram-negative bacteria that possess many distinct features and 
abilities that make them a widely studied group of microorganisms (141). Myxobacteria were 
discovered in the 19th century, mostly due to their ability to form brightly colored fruiting bodies 
visible to the naked eye (Figure 8) (142). These fruiting bodies consist of endospores, the so-
called myxospores. In their vegetative state myxobacteria generally form short or long rods 
and are encountered in soil, but also grow on the bark of trees and on the feces of rabbits and 
other herbivores. The latter have also long been used for the isolation of myxobacterial species 
in the lab, as they form a relatively selective growth-medium, where other bacteria and fungi 
have difficulty growing, while myxobacteria develop their typical fruiting bodies (143). Many 
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myxobacteria sustain themselves through 
hunting and consuming of other bacteria 
(142). To this end, they have developed a 
complex cooperative lifestyle, where the 
bacteria act in unison to engulf and consume 
their prey, a behavior often compared to a 
“wolf-pack” (144). To help them lyse and 
disintegrate other bacteria, myxobacteria 
produce a wide variety of secondary 
metabolites with activity against cancer, fungi 
or bacteria (145). Especially regarding 
antibiotics, myxobacteria present researchers 
with a treasure-chest of compounds with 
novel modes of action to be optimized for their 
use as new antibiotics (146). One group of 
new antibiotics discovered in myxobacteria 
are the cystobactamids that are inhibitors of 
the bacterial type IIa topoisomerase (147). 
It was postulated that as one way of delivering 
these compounds to their prey, myxobacteria use OMVs, as there was evidence of the 
packaging of lytic enzymes and antibacterial secondary metabolites into their vesicles (141). 
Evans et al. were the first to find direct proof of the antibacterial activity of myxobacterial OMVs 
derived from Myxococcus xanthus. They could show that hydrolases packaged into the 
vesicles effectively killed E. coli bacteria (148). Schulz, Goes et al. (21, 22), evaluated OMVs 
derived from different strains of myxobacteria including strains known to produce 
cystobactamids (147). Two cystobactamids were found in OMVs derived from Cystobacter 
velatus and Cystobacter ferrugineus. Both showed antibacterial activity against planktonic 
gram-positive and –negative bacteria. Their effect was comparable to free cystobactamid and 
the established antibiotic gentamicin. Additionally, these vesicles were also taken up by 
mammalian cells and effectively killed intracellular S. aureus. In their effective concentrations 
myxobacterial OMVs were well tolerated by cells and showed virtually no cytotoxicity, while 
eliciting only a mild pro-inflammatory response. These findings make myxobacterial OMVs an 
auspicious target for further research towards their therapeutic use. Thus, one of the aims of 
this work was to evaluate the surface engineering of OMVs to introduce targeting moieties 
promoting their selective interaction with bacteria to increase their antibacterial properties. 
  
Figure 8: Fruiting bodies from different 
myxobacterial species. Adapted by 
permission of Springer Nature Customer 
Service Centre GmbH from Kaiser, D. (2013).  
“The Prokaryotes: Prokaryotic Communities 
and Ecophysiology”, Berlin, Heidelberg, 
Springer Berlin Heidelberg: 511-528. 
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1.4. Isolation and characterization of EVs 
1.4.1. EV-isolation 
EV-isolation and –purification is concerned with enriching EVs from the complex medium they 
are released into by their parent-cells. In most cases, this medium is either a bodily fluid such 
as blood or urine where EVs are found in vivo or the culture medium cells are grown in in vitro. 
Both contain many impurities that need to be removed to obtain pure EVs. These impurities 
can be dissolved in the medium, such as proteins and nutrients or be present in the form of 
nano- or microparticles, such as the producing cells themselves, their post-mortem remnants 
or other nanoparticles, e.g. viruses, lipoproteins and in case of bacteria flagella (149). These 
multiform contaminants are challenging to remove and require the use of sophisticated 
protocols for vesicle-purification (Table 1). 





The most widely used method for EV-isolation is differential ultracentrifugation (150). After 
collection of the conditioned medium, larger particles, such as cells are removed by low-speed 
centrifugation. The centrifugal force applied in this step depends on the fragility and size of the 
producing organism. Mammalian cells are sensitive to centrifugal force and comparably large, 
thus centrifugation is typically carried out in the range of 300 x g (151). For bacterial cultures, 
higher forces have to be applied due to their smaller size (152). They however also are able 
to better withstand these forces, without dying (153). After larger particles have been removed, 
typically another step of centrifugation is carried out at a higher speed to further deplete larger 
particles, such as cell debris (154). The resulting supernatant is then subjected to 
ultracentrifugation (UC) at a speed around 100000 x g to pellet EVs (154). The obtained pellet 
contains concentrated EVs, however these are still contaminated with co-precipitated proteins 
and residual supernatant. For example, miRNAs derived from medium supplements can be 
co-isolated and have been wrongly identified as EV-markers (155). Thus, another step of 
purification is needed. The simplest approach to this, is resuspension in phosphate buffered 
saline (PBS) and repetition of UC (154). The high forces exerted on EVs during UC can 
damage the vesicles or lead to their fusion (156). This problem can be somewhat mitigated by 
employing a cushion of concentrated sucrose on which the vesicles float during UC (157). 
However, residual sucrose has to be removed from the vesicles by conventional UC or another 
method. 
Due to the disadvantages of UC, alternative methods have found broad application, either 
alone or as a multistep combination. Besides UC, the method best suited for the large initial 
volumes encountered in EV-production from cell culture is tangential flow filtration (TFF). 
Compared to conventional dead-end filtration, TFF circumvents issues such as caking and 
clogging of pores by maintaining a lateral flow of the feed over the filter membrane (158). This 
reduces the strain on the vesicles and increases the volume that can be processed (159). TFF 
is typically performed in two steps. First, a membrane with a pore size large enough to let EVs 
pass is employed, to filter out any large particulate impurities. The filtered EVs can then be 
further purified and concentrated by employing a membrane with a molecular weight cutoff that 
only allows the passage of soluble impurities. While the volume of the EV-containing feed-fluid 
decreases, soluble impurities, such as proteins from the culture supernatant are filtered out 
(158). TFF can be used to process large volumes of conditioned medium (160) and compared 
to an ultracentrifuge the initial cost is much lower while upscaling can be easily implemented 
by parallelization (161). Thus, TFF is considered one of the most promising methods for future 
large-scale vesicle production (161, 162). Filtration is also used for the downstream purification 
of EVs, for example to remove non-incorporated material after surface modification. Here 
however morphology and size changes due to extrusion through small pores and particle loss 
due to adsorption to the filter need to be assessed carefully (17, 163). 
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Another method for the purification of larger volumes of EVs is precipitation of the vesicles 
using polyethylene glycol (PEG) (164). This simple method has the considerable disadvantage 
that not only EVs but also soluble proteins from the medium can be co-precipitated, leading to 
a low purity of isolated vesicles (165). This problem was mitigated by Ludwig et al. by washing 
the precipitated EVs using UC (166). They also adapted the protocol to make it applicable for 
the purification of up to 10 L of conditioned medium at once (166). 
Small volumes of EV-containing samples, for example from patient plasma or resuspended 
pellets after UC, can be purified by multiple different methods. The relatively defined size 
spectrum of EVs is utilized in their isolation by size exclusion chromatography (SEC) and the 
abovementioned filtration approaches. In SEC, the porous column material separates EVs 
from soluble impurities ranging from medium constituents to soluble proteins and small 
nanoparticles. EV are too large to diffuse into the pores of the stationary phase and thus elute 
with the void volume, while smaller impurities can interact with the column material and elute 
later (167). SEC is very effective at removing soluble impurities from EVs and the column-size 
can be scaled to the sample volume. Its main disadvantage is that it leads to the dilution of the 
samples (17). SEC is also used in a commercial kit for EV-isolation (168). 
Very high purity vesicles can be obtained using gradient UC (165). Here a gradient of sucrose 
or iodixanol is employed that leads to the flotation of EVs and other contaminants according to 
their buoyancy during UC. Sucrose is the cheaper alternative, but the hyper-osmolarity of 
concentrated sucrose solutions might damage the vesicles. Iodixanol forms iso osmolar 
solutions at all concentrations and thus potentially better preserves EV-integrity (165). After 
gradient UC a second step of purification is needed to remove residual sucrose or iodixanol 
(169). Gradient UC also separates EV-populations with different densities, which makes it 
ideally suited for in depth analysis of different vesicle populations. The need for an 
ultracentrifuge and the long centrifugation time of 16 to 18 h required for gradient UC are the 
main disadvantages compared to other EV-processing methods. 
Particularly difficult samples that contain impurities in both the same size- and density-range 
as EVs can benefit from the combination of multiple purification steps. For plasma that 
contained both very low-density lipoprotein (VLDL) overlapping with EVs in size and high-
density lipoprotein (HDL) overlapping with EVs in density, Karimi et al. designed a two-step 
process combining gradient UC with SEC (170). Gradient UC effectively removed VLDL and 




New and emerging techniques for EV-purification include enrichment of EVs through binding 
of specific surface markers (171, 172), a plethora of methods based on microfluidics (173-175) 
and asymmetric flow-field-flow-fractionation (AF4) (25, 176).  
1.4.2. EV-characterization 
EVs can be characterized regarding their physicochemical properties and regarding their 
composition and cargo. Guidelines to a comprehensive analysis of mammalian EVs are 
collected in the “Minimal information for studies of extracellular vesicles” (MISEV) document 
published by the international society for extracellular vesicles (33). According to these 
guidelines, typical protein markers, EV-size and appearance need to be analyzed and vesicles 
should be quantified, ideally combining different measurements, such protein content, particle 
number or lipid content (33). 
Physicochemical parameters can be measured using the techniques that are the standard for 
nanoparticle-characterization (177), with the caveats that EVs are generally less uniform than 
synthetic nanoparticles and that EV-samples are frequently of comparably low concentration. 
Thus, for example dynamic light scattering is of limited applicability for vesicle characterization, 
as it over represents larger particles and cannot adequately display the multimodality of EV-
samples (178). 
 
Figure 9: In nanoparticle-tracking-analysis (NTA) measurements, a laser beam travels through 
a chamber containing suspended particles. Scattered light from particles that travel into the 
laser’s light-path is collected by a microscope-assembly. A camera connected to the 
microscope captures videos of the moving particles that can be analyzed regarding particle-
number and size using software. Adapted from Dragovic, R. A., et al. (2011). Nanomedicine: 
Nanotechnology, Biology and Medicine 7(6): 780-788. Used under the Creative Commons CC-
BY 4.0 license. 
The most widely used technique to reliably assess both the size and the particle-concentration 
of EVs is nanoparticle-tracking-analysis (NTA) (179). Here particle suspensions are illuminated 
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with a laser, which is scattered when it hits a particle (Figure 9). The scattered light is collected 
by a microscope assembly set orthogonal to the light path of the laser and a camera captures 
videos of the moving particles. Through the movement per frame of the illuminated particles 
and the viscosity of the medium, the size of particles can be determined using the velocity of 
their Brownian motion. At the same time, the amount of trackable particles in the field of view 
can be used to extrapolate the particle concentration. After staining the vesicles e.g. through 
the binding of a fluorescently labeled antibody, NTA can also be employed to discriminate 
between different EV-populations by fluorescence (180). 
While light scattering based methods can measure the size-distribution and concentration of 
nanoparticles, their identity as vesicles is best determined by electron microscopy (181). In 
transmission electron microscopy (TEM) the membrane and lumen of EVs is visible and thus 
they can be discriminated from other particulates in the medium. While regular TEM with 
negative staining of EVs using heavy metal ions is relatively easily realized, only cryo TEM can 
show the vesicles in their native state, as here no staining or drying are necessary to visualize 
the vesicles. In cryo TEM, thin films of EV-containing samples are vitrified by flash-freezing 
and then imaged using a special cooled sample holder (182). Scanning electron microscopy 
has also been employed for the visualization of EVs. Here the vesicles are visible as small 
spheres. The drying of the sample during sample preparation however often leads to the 
formation of aggregates (183). Electron microscopy of EVs can be combined with immunogold 
labeling to also obtain information about surface markers of EVs (181). 
Physical characterization of EVs can also be performed by atomic force microscopy, which 
offers information about their mechanical properties (184), and tunable resistive pulse sensing 
that measures particle size and concentration (185) and can also be used for the evaluation of 
the zeta potential of nanoparticles (186). However both techniques are less widely used than 
NTA and TEM (181). 
The protein content of EVs can be assessed on the bulk level, using typical assays such as 
BCA- and Bradford-assay. A caveat is that these assays usually can only reliably assess 
proteins on the surface of the vesicles. To measure proteins present in the lumen of EVs, they 
first need to be lysed. This can be done using Radioimmunoprecipitation assay (RIPA) buffer 
(187), however compatibility problems with the protein-quantification assay of choice may 
arise. Even without lysis, the protein-content of EV samples combined with their particle 
number can be used for an easy assessment of their purity for the comparison of different EV-
isolation protocols (187). Specific proteins can be assessed using western blotting or LC/MS, 
the latter is also used to analyze the lipid-content of EVs. Another technique that is popular for 
assessing EV-markers is flow cytometry (FACS). 
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Compared with Western blotting, where EVs can be processed in the same way as cells (188), 
FACS-based analysis of EVs is considerably more complex than the analysis of mammalian 
cells. The small size of EVs is near or below the resolution limit of most conventional flow 
cytometers (189). Thus, the cytometer settings need to be optimized to reliably detect single 
EVs and distinguish EVs from similar background events (190, 191). A more sensitive 
detection of EVs can be realized by employing imaging flow cytometry (189). Here, scattered 
light is captured by a microscope and measured by a camera with much higher resolutions 
than conventional photodiodes or photomultiplier tubes. This allows for the direct visual 
detection of single EVs (189). Specialized flow cytometers for EV-detection are not 
ubiquitously available and if a semi-quantitative assessment of the presence or absence of 
e.g. a tetraspanin on the vesicle surface is the sole concern of the measurement, EVs can also 
be chemically linked to beads sized in the range of few micrometers (192). These beads give 
similar signals to cells and can thus be measured with standard flow cytometers. 
1.5. EVs in biomedical applications 
EVs are currently evaluated in many therapeutic and diagnostic applications and there are 233 
clinical trials that focus among other aims on the use of EVs as biomarkers and therapeutics 
(ClinicalTrials.gov was searched for “exosome OR (extracellular vesicle)”, last visited 
09.10.2020 at 13:19). 
In EV-based diagnostics, researchers utilize the specific effects diseases can have on the 
composition of EVs and their easy availability from all bodily fluids. EVs are being developed 
as biomarkers for,  among others, the detection and monitoring of various cancers such as 
lung cancer (193), prostate cancer (194) or breast cancer (195), Parkinson’s disease (196) 
and liver diseases (197). To this end, liquid biopsies containing EVs carrying the relevant 
information have been obtained from blood (195-197), synovial fluid (198), urine (194, 199), 
saliva (200) and tears (201). The latter three can be obtained without any invasive procedures, 
thus minimizing risks and unpleasantness for the patient. 
For therapeutic use, EVs exhibit some general advantages that prompted researchers to 
further evaluate them. Their intrinsic pharmacological activity, the selective enrichment of 
active cargoes, their ability to cross biological barriers and transfer sensitive cargoes over long 
distances (see 1.2 and 1.3 for a closer evaluation) and their good safety profile (21, 124, 202, 
203) all contribute to the potential of EVs in therapeutic applications. Moreover, methods have 
been developed to engineer EVs to encapsulate the cargoes of choice (see 1.5.1) and 
introduce new moieties to their surface (see 1.7). 
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In therapeutic approaches, EVs can either themselves act as the therapeutic agent or be 
utilized as drug delivery vehicles. The main fields of therapeutic application of native 
mammalian EVs are tissue regeneration and wound healing (204, 205), where especially EVs 
derived from mesenchymal stem cells have shown broad activity (206, 207). These results 
however have been put under suspicion by the recent finding that a large portion of the 
observed activity might be caused by co-purified soluble proteins instead of EVs (208). Another 
source for EVs with regenerative activity are cardiosphere-derived cells, whose EVs improve 
the healing of myocardial injuries (209). 
One more important application aimed at the native activity of EVs and especially OMVs, is 
vaccination (210). Bacterial vesicles carry antigens on their surface and as their cargo that can 
elicit a specific immune response (211). Additionally the immunogenic LPS found on OMVs 
can act as an adjuvant (212, 213). The potentially excessive toxicity of LPS however (103), 
can require the modification of this membrane component to produce OMVs with an 
acceptable safety profile (see 1.8.1). One OMV-containing vaccine against Neisseria 
meningitidis serogroup B has been authorized in 2013 and 2015 in the EU and US respectively 
and today is in use for all age groups (214). An OMV-based vaccine against Shigella sonnei 
is currently in development and has completed phase 1 clinical trials (215). 
Despite the promising results of EVs as therapeutics and drug delivery vehicles, their broad 
clinical translation has not been realized yet, due to a multitude of hindrances that still need to 
be addressed (see 1.6). 
1.5.1. EVs as drug delivery vehicles 
In the context of this work, the applicability of EVs as drug delivery vehicles is of special 
concern, as the surface-engineering techniques presented herein are mainly aimed at 
developing a method for the efficient decoration of EVs with targeting moieties to facilitate EV-
based drug delivery. 
The first step to successful drug delivery using nanoparticles is the encapsulation of drugs. 
Here the endogenous loading of EVs with therapeutically active compounds by the parent cells 
and the exogenous encapsulation of drugs after EV-isolation can be differentiated. 
Endogenous loading is carried out either naturally by the parent cells themselves (see 1.2 and 
1.3) or by genetic engineering. Loading through genetic engineering has been achieved, by 
the overexpression of the cargo-molecules of choice, as exemplified by Mizrak et al., who 
produced EVs loaded with enzymes and the corresponding mRNA that once transferred to 
target cells made them susceptible to treatment with 5-fluorocytosin (216). Overexpression 
however can lead to overall changes in gene-expression that might also influence EV-
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production and –components (217). Thus, more specific ways methods to target cargoes to 
EVs have been developed. Cells have been engineered to express fusion-proteins consisting 
of an EV-enriched membrane protein and an RNA-binding domain that selectively binds the 
cargo-RNA resulting in effective RNA-enrichment into EVs (218, 219). It has also been 
discovered that certain RNA-sequences can convey loading into EVs by the cellular machinery 
(57, 58), which could be utilized to encapsulate therapeutic RNAs. Drugs can also be 
encapsulated into EVs by adding them to the growth-medium of their parent cells. This way, 
gentamicin loaded OMVs (220) and mammalian EVs loaded with paclitaxel have been 
obtained (221). 
For exogenous encapsulation after EV-isolation, the approach depends on the structure of the 
prospective cargo. Hydrophobic drugs are easily encapsulated, as they embed themselves 
into the phospholipid bilayer, as demonstrated for hydrophobic porphyrins and curcumin (222, 
223). Encapsulation into the EV-membrane increased the bioavailability of curcumin in vivo 
and protected mice from septic shock induced by LPS-injection (222). 
While the lipid membrane of EVs helps them protect sensitive molecules in their lumen, it also 
forms a natural barrier for the encapsulation of hydrophilic drugs. Multiple techniques have 
been evaluated for the encapsulation of hydrophilic molecules in EVs. 
Haney et al. compared sonication, freeze-thaw cycles, saponin incubation and incubation at 
RT for the loading of mammalian EVs with the enzyme catalase (224). They found that 
sonication, extrusion and saponin-treatment led to the highest encapsulation of active enzyme. 
However, sonication and extrusion, as well as freeze-thaw cycles, also affected the size and 
shape of EVs of the vesicles and might affect their therapeutic efficiency (224). Nonetheless, 
both EVs loaded by saponin-incubation and sonication showed antioxidant and 
neuroprotective effects in mice. Saponin incubation was also evaluated for the encapsulation 
of hydrophilic porphyrins into EVs by Fuhrmann et al., who tested it alongside hypotonic 
dialysis, extrusion and electroporation (223). They found that both dialysis and saponin-
incubation led to a significant improved loading efficacy, however dialysis compromised the 
ability of EVs to transfer their cargo into cells. Electroporation, which was not effective for the 
hydrophilic model-porphyrin, significantly enhanced loading with a porphyrin of intermediate 
hydrophilicity (223). Indeed, electroporation seems to be a suitable method for small molecules 
such as doxorubicin (225), for larger and more complex molecules however, encapsulation by 
electroporation has been associated with problems, regarding OMV-stability (226) and the 
precipitation of RNA-cargos (227). Nevertheless, electroporation remains a popular method for 
exogenous drug-loading of EVs (217). An alternative to encapsulating cargos in the lumen of 
EVs is anchoring them on their surface (228-230), which is discussed in more detail in 1.9.1.2. 
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Successful examples of EV-based drug delivery include the abovementioned catalase-loaded 
EVs to convey neuroprotection in Parkinson-models (224), the loading of EVs with a 
photosensitizer by incubation of their parent cells leading to loaded vesicles that significantly 
outperformed liposomes in drug delivery to tumor organoids (231) and the delivery of siRNA 
to the brain of mice using EVs engineered with brain specific viral protein on their surface 
(232). The last study is also an example for the introduction of targeting moieties to the EV 
surface. EV surface engineering and its objectives are evaluated in more detail in 1.7, 1.8 and 
1.9. 
1.6. Challenges towards clinical translation of EVs 
To reach the market, potential EV-based therapeutics need to successfully pass through pre-
clinical and clinical evaluation and gain approval from the respective governing body. In context 
of the rules and regulations that apply to EVs, they are best categorized as biological medicinal 
products (233, 234).  
 
Figure 10: Multiple hurdles currently hinder the transition from therapeutically active EVs to 
approved EV-therapeutics. The safety and efficacy of EVs need further evaluation to determine 
unwanted off-target effects and the mode of action of the vesicles. The identity and purity as 
well as other quality criteria of EVs still need to be defined also in light of the limitations of 
current methods for EV-isolation and characterization. Quality criteria of EVs are also important 
to derive from them release criteria for the industrial production of EVs. Here moreover, the 
scalability of EV-production processes needs to be assessed. Finally, the storage stability of 
EV-formulations needs to be evaluated with the aim of establishing alternatives to frozen 
storage of EVs to make the storage and distribution of EV-formulations more feasible. 
Besides the positive example of OMVs as part of a clinically approved meningococcal vaccine 
(214), clinical translation of EV-based therapeutics has not been realized yet. The journey of 
EVs from bench to bedside is still held back by challenges during the translation-process (162). 
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The most difficult of these hurdles mainly relate to the safety and efficacy of EVs, the 
specifications of EV formulations and their industrial scale production (Figure 10). 
Regarding safety, the cargos of EVs and their pleiotropic effects in the body are under 
investigation. The possible pro-metastatic and tumorigenic effects of EVs derived from cancer 
cell lines are already discussed (95-97), but also the procoagulant or proangiogenic activity of 
some EVs could prove problematic (78-80). Additionally, the heterogeneous populations of 
EVs produced by cells make it difficult to anticipate possible unwanted off-target effects (235). 
The heterogeneity is also problematic for assessing the efficacy of EV formulations and 
determining a mode of action (236), knowledge of which is required as part for the 
documentation required for the initiation of clinical trials (237). Due to the presence of multiple 
active molecules in EVs evaluation of their pharmacodynamics is complicated (238).  
Regarding the specifications of EV formulations, the main question is how to define identity 
and purity of EVs (162). The methods for EV purification are limited and the higher throughput 
required for their upscaled production further limits applicable methods (see 1.4.1). While the 
differentiation between different subsets of EVs cannot be realized with current methods (33), 
they also always carry over some non-EV components of the cellular secretome (162). Thus 
instead of defining the final product as "exosomes" or "EVs", Gimona et al. proposed to rather 
define the formulations as vesicle enriched secretome fractions (162). Fortuitously the inherent 
heterogeneity of biological products is also acknowledged in the ICH guidelines concerning 
biological medicinal product (239), making this a viable approach.  
To define the quality of EV formulations, also a higher degree of standardization in their 
production and evaluation is needed, as seemingly small changes in culture- and isolation-
conditions can have a big impact on their functionality, affecting the comparability of different 
studies. For EVs derived from mesenchymal stem cells, the number of passages in culture 
altered their pharmaceutical activity (240) and different isolation methods might not only affect 
the purity of isolated EVs but also their activity (241). Another important aspect in this regard 
are the cells used for EV-production. As in other human-derived medicinal products, inclusion 
criteria for donors must be defined (233), as diseases and other parameters can affect the 
safety and activity of EVs. In a recent study, the influence of donor-age on vesicle-activity was 
demonstrated (242). Some cell-types, such as mesenchymal stem cells can also be isolated 
from different tissues such as the umbilical cord, bone marrow or adipose tissue (236). Studies 
have shown that there are differences in the composition and pharmaceutical activity of MSC-
EVs based on the tissue of origin (243, 244). The international society for extracellular vesicles 
is thus focusing on generating universal guidelines for the production, evaluation and 
application of EVs. Examples of the fruits of these efforts are the MISEV guidelines discussed 
above (33), MIFlowCyt-EV (245), which deals with the reporting of FACS-experiments and the 
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recently published comprehensive discussion of reference materials for EV-measurements 
(246).  
As the purification process has great influence on the final EV-product, as it is the case for 
most biologicals (247), another important aspect of the EV production process is its scalability. 
Increasing the production volume without changing the process, could greatly speed up the 
transition from laboratory scale production of EVs to the larger batches needed for preclinical 
evaluation and clinical trails to the potentially even larger batches after successful approval 
(162). For OMVs the GMP-conform production has already been realized (248), for 
mammalian cells only the isolation of the complete secretome without EV-enrichment has been 
demonstrated (249). 
The quality of EV formulations, i.e. identity, purity, potency and quantity also need throughout 
evaluation to derive from it robust parameters for release criteria for industrial production (239). 
Here especially in vitro potency assays are needed (234). An assay for the evaluation of MSC-
derived EVs are currently investigated (250) 
The final hurdle in EV translation refers to the storage stability of EV-based products and their 
distribution, which is discussed in detail in the following chapter. 
In conclusion, a lot of work is still needed to generate the knowledge required for the clinical 
translation of EV-based therapeutics. Nevertheless, especially for MSC-EVs, substantial 
progress has already been made and the knowledge gained from this endeavor will be the 
basis for the future translation of EVs derived from other cell-types. 
1.6.1. EV storage 
The complexity of EV-samples makes it important to very thoroughly monitor their storage 
stability. Especially for the large-scale industrial production, EV-containing therapeutics need 
to be stable over longer periods of time and during distribution to the patients. However, also 
EV-containing patient samples for biomarker determination and EVs isolated in laboratory 
settings for basic research often need to be stored before their analysis without being 
compromised. Thus, methods for the optimal storage of EVs are under investigation. EV-
samples can be stored either in liquid form, frozen or in dried form after lyophilisation or spray-
drying. 
For storage in liquid form at 4 °C, there is evidence that at least for a short period of a few days 
EVs derived from various biological fluids and cell culture were sufficiently stable (251, 252). 
For longer term storage however, there was generally a decline in vesicle-stability for liquid 
storage of EVs (251). These findings have important implications especially for EV isolation 
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and characterization, as the time required for some steps can make it impractical to carry out 
all steps in one day without overnight storage. In this context also another parameter important 
for EV-storage and -processing needs to be considered, the choice of the vials the samples 
are stored in. Some materials might lead to the unspecific and irreversible adsorption of EVs 
(233). Thus, the effect of the vials should be evaluated (253). 
Freezing EVs at -80 °C is currently considered as the gold standard for their storage (162). 
Even after 30 years of storage at this temperature intact vesicles showing typical markers could 
be obtained from seminal fluid, however a lowered acetylcholine esterase activity and a 
decreased inhibition of HIV-1 were found in stored samples (254). -80 °C was shown to be 
better at stabilizing EVs than storage at 4 °C or -20 °C  (252). It was also demonstrated that 
EV-samples benefit from the addition of cryoprotectants in the same way as other complex 
biological samples, such as proteins (255). Cryoprotecting agents are generally hydrophilic 
molecules that can promote the formation of amorphous rather than crystalline ice, thus 
reducing potential damage to EVs through ice crystals. Moreover, through the formation of 
hydrogen-bonds to macromolecules they can help stabilize their structure (256). Typical 
molecules employed in this role are amino acids, polymers, non-reducing sugars, sugar-
alcohols and di-saccharides such as sucrose and trehalose (257). Trehalose was employed 
by Bosch et al. and greatly reduced the aggregation of EVs during frozen storage (255). 
The main disadvantage of EV-storage at -80 °C are the expense of the required freezers and 
upholding the cold-chain. Especially the latter would be an important factor once EVs see 
broad use as therapeutics and EV-containing proprietary medicinal products become 
available. Thus, another storage-method would be desirable that can successfully preserve 
EVs at RT or 4 °C. For therapeutic proteins, the method of choice to stabilize them is storing 
them in the dry state (257). This can be achieved by lyophilisation or spray drying. While spray-
drying of EVs has been proposed (256) and tested with OMVs for the production of vaccines 
(258), it has not been applied widely yet and the influence the spraying process has on the 
vesicles and their cargo needs to be evaluated. For lyophilisation on the other hand, there are 




Figure 11: The process of lyophilisation has two main steps. First samples are frozen at low 
temperature at atmospheric pressure. Then, samples are dried under high vacuum. In the 
primary drying stage, samples are maintained at a low temperature while the ice sublimates. 
Then the shelf temperature is increased in the secondary drying stage to promote the 
desorption of water bound to the lyophilizates. Adapted from Kawasaki, H., et al. (2019). 
Journal of Chemistry 2019: 9502856. Used under the Creative Commons CC-BY 4.0 license. 
In the process of lyophilisation or freeze-drying, samples are frozen and under low pressure 
the water contained in the sample is sublimated, leaving a dry solid (Figure 11) (257). The 
lyophilisation process can generally be divided into three parts, the freezing of the sample, the 
primary drying step that leads to the sublimation of ice and the secondary drying step, where 
the desorption of bound water takes place (259). As the removal of their hydration shell puts 
great strain on the conformation of biomolecules, excipients, so-called lyoprotectants, are 
needed to maintain the native structure of the dried molecules during and after lyophilisation 
(260). The most important lyoprotectants in practical application are the two disaccharides 
trehalose and sucrose, which also show cryoprotective properties (260).  There are two main 
hypotheses that try to explain the effect of lyoprotectants during lyophilisation (261). One 
explanation is that lyoprotective agents can, through their multiple hydroxyl groups, replace 
the hydrogen bonds that would be lost by the removal of water. This keeps the native 
conformation of biomolecules as the thermodynamically more favorable state and thus 
prevents conformation-changes. The other hypothesis depends on the ability of lyoprotectants 
to form an amorphous solid that forms a rigid matrix for lyophilized biomolecules, which 
prevents their unfolding and other degradation processes that depend on molecular mobility. 
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It seems likely that both hypotheses play a role in the stability of lyophilized formulations, but 
further evaluations are needed to completely understand these processes (262). 
El Baradie et al. and Charoenviriyakul et al. determined that EVs could indeed be lyophilized 
and stabilized by the addition of lyoprotectants such as trehalose and PVP (263, 264). A 
comprehensive assessment of different buffers, lyoprotectants and lyophilisation-conditions 
has not been performed so far and the long-term stability of lyophilized EVs has not been 
measured. Thus, one of the objectives of this study was optimizing the freeze-drying of EVs 
from various sources for their future application as therapeutics. 
1.7. EV surface engineering and targeting 
Decoration of the surface of EVs with new moieties is employed to achieve different goals 
(Figure 12). The most basic of which is fluorescent labeling of EVs to make it possible to follow 
their fate in vitro and in vivo. Covalent labeling of EVs by chemical or genetic means can 
circumvent some disadvantages of lipophilic dyes that are widely employed (265, 266). These 
lipophilic dyes penetrate into the lipid-membrane of the vesicles and are retained there. Their 
corresponding low solubility in aqueous media can however also lead to the formation of 
particles that are difficult to remove (267). Moreover, high concentrations of lipophilic dyes in 
EV-membranes can lead to quenching of fluorescence and thus the overestimation of EV-
uptake into cells, once the dye is diluted in the recipient cell membrane and the fluorescent 
read-out increases (268). Finally lipophilic dyes can be transferred to other plasma 
membranes, where they may lead to false assumptions about EV-uptake and –distribution 
(269). 
As mentioned above the structure of LPS on the surface of OMVs can be modified to reduce 
their toxicity and improve their applicability as vaccines (210). Intervening in the interaction of 
host cells and EVs is also the aim of PEGylation, which is widely used to increase the 
circulation time of synthetic nanoparticles by reducing their uptake by the reticulo-endothelial 
system (270). As EVs, despite their ability to transfer cargoes throughout the body, tend to 
rapidly accumulate in the liver and spleen after their administration (266), PEGylation could 
potentially help increase their circulation time. In this case however, the potential adverse 




Figure 12: There are multiple aims of EV surface engineering. Cell-specific targeting and 
uptake can be promoted through surface-bound targeting moieties (A). Meanwhile shielding 
EVs from unspecific uptake by phagocytic cells could also be achieved through surface 
modification (B). For OMVs, an important step towards their clinical application is the 
modification of their lipopolysaccharides to reduce their toxicity (E). Finally, exogenous cargos 
(C) and fluorescent dyes (D) can be introduced by tethering them to the vesicle surface. This 
figure was adapted from Richter, Maximilian; Vader, Pieter; Fuhrmann, Gregor (2020). 
“Approaches to surface engineering of extracellular vesicles”. Submitted to Advanced drug 
delivery reviews. The figure was partially prepared using Biorender. 
The main aim of engineering the surface of EVs however is equipping them with targeting 
moieties to achieve their enrichment in the tissue of choice (272). While some studies have 
revealed specific tropisms of EVs depending on their origin (96, 266), a deeper understanding 
of the underlying mechanisms is missing for most EV-types and it is not a given that EVs would 
exist with natural high affinity to every target of interest. Additionally evidence that EVs would 
demonstrate any strong tropism after administration in vivo is thin, as some researchers 
reported little to no accumulation at the site of interest for native EVs (273, 274). Thus, 
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increasing the targeting-capabilities of EVs by introducing new moieties to their surface is of 
great interest. 
1.7.1. Targeting of pathogenic bacteria 
One of the aims of this work is to produce OMVs with enhanced bacterial binding. There are 
diverse advantages to specifically targeting bacteria using antibacterial nanoparticles, also 
called nanoantibiotics. By efficiently delivering antibacterial agents to their intended target, 
higher concentrations can be reached, where they are needed, while off-target sites are less 
affected. This refers not only to human cells and tissues that would be less affected by adverse 
reactions such as the nephron- and ototoxic effects of vancomycin and aminoglycosides (275, 
276), but also to the human microbiota. By ideally tailoring targeting of the nanoantibiotic 
selectively to pathogenic bacteria, common side effects that are linked to the unselective killing 
of bacteria, could be circumvented. While in some cases this can already partially be achieved 
by using local drug-administration at the site of infection, in many cases there is a natural and 
beneficial microbiome present that could be affected, e.g. on the skin (277) and in the lung 
(278). Direct delivery of antibiotics to the bacteria via nanoantibiotics can also help overcome 
resistance mechanisms by increasing the uptake and saturating efflux pumps (279). 
While the field of nanoantibioitcs is expanding with a constant stream of new sophisticated 
strategies, focused especially on particles composed of various metals, such as gold, silver 
and copper (280), not much has been published regarding the active targeting of bacteria. This 
is possibly linked to the increased variability of bacteria compared to the cells of the human 
body. While research of antibacterial monoclonal antibodies is ongoing, so far there have been 
few examples of antibody-targeted antibacterial nanoparticles. Al-Sharqi et al. used a two step-
method to selectively bind their photoactivatable silver-nanoparticles to S. aureus (281). 
Nanoparticles were decorated with a goat anti-mouse antibody that recognized mouse 
antibodies against protein A that were adsorbed to the bacterial surface. In another study, 
Kang et al. addressed intracellular bacteria using gadoliniumoxide-chrome-nanoparticles 




Most approaches for active targeting of bacterial infections however have been conducted 
using small molecules. These bind to surface-features of bacteria or help the particles reach 
intracellular bacteria. The most popular 
example so far has been the glycopeptide 
antibiotic vancomycin. Its ability to strongly 
bind to the cell-wall of gram-positive 
bacteria (283) has been successfully 
employed in several publications. In a first 
application, Gu et al. modified gold 
nanoparticles with vancomycin that, 
through multivalency, successfully bound 
vancomycin resistant enterococci and 
inhibited their growth (284). Surprisingly the 
same effect was observed for the gram-
negative bacterium E. coli that is highly 
resistant to treatment using monovalent 
vancomycin. 
In an interesting approach, Kell et al. modified magnetic nanoparticles with vancomycin and 
used them for the magnetic isolation of various bacteria from solutions (285). They also 
evaluated the influence of the architecture of vancomycin on the particles (286). The 
vancomycin molecule possesses two distinct functional groups that can be easily addressed, 
and lead to two different conformations of the vancomycin molecules on the nanoparticle 
surface (Figure 13). The amine can be modified using activated esters and the carboxylic acid 
can be activated and subsequently coupled to an amine. The latter however holds the caveat 
that cross-reactivity with the amino groups of other vancomycin molecules is possible. This 
could lead to the dimerization of vancomycin, which could potentially even increase its binding 
activity (287, 288) and thus lead to artificially inflated binding of the respective nanoparticles.  
In their study, Kell and coworkers found out that linking vancomycin using the carboxylic acid 
led to a higher capture efficiency compared to the amino group, especially also for gram-
negative bacteria, in line with the earlier findings of Gu et al.. They however do not comment 
on the issues described above and thus it remains unclear, to what extend di- or 
oligomerization of vancomycin played a role in their results (286). 
In more recent publications, vancomycin has acted as the targeting moiety for micelles with 
lipase-triggered release of ciprofloxacin (289), fluorescent polymeric nanoparticles for in-vivo 
imaging of infection with S. aureus (290) and photoactivatable polypyrrole nanoparticles for 
the photothermal killing of S. aureus (291).  
Figure 13: The structure of vancomycin contains 
a carboxylic acid and amino function (highlighted 
in circles). Both have been employed for 
tethering of vancomycin to nanoparticles. 
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Another class of small molecules that hold great promise for bacterial targeting are short 
peptides with high binding affinity to bacterial surface epitopes. Through phage-display 
Hussian et al. developed a cyclic 9-amino acid peptide that, through specific targeting of S. 
aureus, could increase the antibacterial efficacy of their drug-loaded nanoparticles (292). 
An alternative approach that is directed at bacteria that persist inside macrophages to escape 
the immune system and antibiotic therapy is functionalization with mannose. Mannose 
receptors on the surface of macrophages lead to the uptake of mannosylated particles that 
thus can reach intracellular bacteria (293). To this end, Xiong and coworkers developed a 
mannose presenting nanogel that, once taken up, gets degraded by bacteria present in the 
macrophages to set free its vancomycin-cargo (294). Mannose functionalization has also been 
realized for EVs to increase uptake into dendritic cells, albeit not with the prospect of 
antibacterial therapy (295). 
Due to the success of vancomycin as a targeting moiety for antibacterial drug delivery and its 
straightforward chemical modification, it was chosen as a model targeting ligand to be 
introduced to OMVs by chemical surface engineering.  
1.8. Pre-isolation surface-engineering of EVs 
Pre-isolation surface engineering of EVs is performed by manipulation of the parent cell to 
obtain modified EVs. This can be achieved either by genetic engineering, by metabolic labeling 




Figure 14: Surface modification of EVs can take place either before or after their isolation. The 
latter can be achieved by physical or chemical means. The most prominent method for pre-
isolation engineering is the expression of fusion proteins of integral EV-surface-proteins and 
the protein of interest (A). Alternatively, azide-labeled EVs for subsequent chemical labeling 
can be generated through feeding the parent cells with azide-labeled sugars or amino acids 
(metabolic labeling, B) or fusing them with azide-labeled liposomes (parent-cell membrane 
labeling, C). Physical methods for EV surface engineering encompass fusing them with 
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liposomes D, specifically or unspecifically adsorbing molecules to their surface (E) or inserting 
modified lipids into their membrane (F). Chemical engineering approaches can take place in 
one step for simple molecules lacking functional groups with cross-reactivity (G). More 
complex molecules benefit from a two-step approach, were in the first step azide groups are 
introduced to the EV-surface, which subsequently are coupled to the molecules of interest in 
bioorthogonal reactions (F). This figure was adapted from Richter, Maximilian; Vader, Pieter; 
Fuhrmann, Gregor (2020). “Approaches to surface engineering of extracellular vesicles”. 
Submitted to Advanced drug delivery reviews. The figure was partially prepared using 
Biorender. 
1.8.1. Genetic engineering 
The generation of modified EVs through genetic engineering is by far the best-characterized 
method for EV surface modification. Through the expression of fusion proteins of the 
transmembrane domains of known EV surface-proteins coupled with the epitope of interest, a 
wide variety of different targeting moieties have been expressed on the vesicle-surface.  
In one of the first examples of endowing 
EVs with targeting moieties through genetic 
modification, the rabies viral glycoprotein 
(RVG) was expressed on the surface of 
EVs through fusion with Lysosome-
associated membrane protein 2 (Lamp2b) 
derived from immature murine dendritic 
cells (Figure 15) (232). This protein has 
previously been shown to mediate the 
uptake of RVG-modified siRNA into the 
central nervous system of mice (296). 
Alvarez et al. encapsulated various siRNAs 
into the RVG-EVs and could prove that the 
use of targeted EVs significantly increased 
gene-silencing in the central nervous system 
after systemic injection (232). These results 
could later be replicated by Liu et al. and 
Yang et al., who used RVG-targeted EVs to 
convey neuroprotection after stroke (297) 
and counteract morphine relapse 
respectively (298). In another example 
fusion with the tetraspanin CD63 was used 
to label EVs with green and red fluorescent 
Figure 15: Genetic engineering was used to 
produce EVs targeted to the brain of mice. Bone 
marrow was harvested from mice and the cells 
were differentiated to immature dendritic cells. 
These cells were transfected with a plasmid 
expressing a fusion peptide of rabies viral 
glycoprotein, which promotes targeting, and 
Lysosome-associated membrane protein 2 
(Lamp2b), which mediates transfer to the EV-
membrane. After their isolation, vesicles were 
loaded with a siRNA and administered to mice. 
Adapted by permission of Springer Nature 
Customer Service Centre GmbH from Alvarez-
Erviti, L., et al. (2011). “Delivery of siRNA to the 
mouse brain by systemic injection of targeted 
exosomes”, Nat Biotech 29(4): 341-345. 
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protein (299). The Her2 receptor that is overexpressed in certain types of breast cancer has 
been the target of a study exploring the delivery of siRNA using OMVs derived from E. coli 
(300). Utilizing these engineered OMVs Gujrati et al. delivered siRNA to xenograft mouse 
models, effectively reducing tumor-growth. Besides targeting, genetic modification of parent 
cells can be employed to display antigens on the surface of EVs. For mammalian EVs, fusion 
with the C1C2 domain of lactadherin was used to generate EVs decorated with tumor-antigens 
to elicit a tumor-specific immune response (301, 302). Cytolysin A on the surface of E. coli 
OMVs was also used for antigen-display to protect mice from A. baumannii and influenza 
infections respectively (303, 304). 
Instead of displaying new moieties on the vesicle-surface, genetic engineering can also be 
used to alter the molecules that are naturally present on EVs. This is an important strategy in 
the development of OMV-based therapeutics, as LPS on the vesicle surface can lead to strong 
inflammatory responses in parenteral application (103) and the application of OMVs has been 
hindered by its presence (210). Thus, efforts have been made to remove LPS or reduce its 
toxicity. In a prove of concept study, Kim et al. generated an E. coli strain that produced LPS 
of reduced toxicity and expressed a model-peptide on the surface of its OMVs (305). In another 
study, antigens from Mycobacterium tuberculosis and Chlamydia trachomatis were 
successfully expressed on the surface on OMVs derived from E. coli and S. enterica serovar 
Typhimurium (306). The native immunogenicity of these detoxified OMVs also makes them 
useful as adjuvants (210), for example to improve the efficacy of a vaccine against influenza 
(212). 
In general, genetic engineering of parent cells is a very powerful technique, but it completely 
depends on a good understanding of vesicle surface-proteins. While EVs derived from 
mammalian cells have been thoroughly evaluated in this regard, knowledge is lacking for EVs 
of other provenance and in. Thus, especially in case of bacterial vesicles, where the vesicles 
from only a few species have been characterized well enough to allow for their surface 
modification by genetic engineering (307-311), more research is needed. Thus, instead of 
genetic manipulation, the development of a general method to engineer OMVs after their 
isolation was the central subject of this work. 
1.8.2. Other methods for pre-isolation surface engineering 
Two very similar methods to obtain already modified EVs from cells are metabolic labeling and 
the enrichment of modified lipids in the membrane of parent cells.  
In metabolic labeling, azide-analogues of natural nutrients such as sugars and amino acids 
are added to the culture medium. They are taken up by cells and incorporated into 
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biomolecules. Stochastically some of these molecules will be present on the surface of EVs 
produced by the cells, where they are accessible to chemical reactions after EV-isolation (see 
1.9.2). Lee et al. explored the applicability of different azido-sugar derivatives for fluorescent 
labeling of EVs and determined that the azide-labeled mannose derivate led to the best 
surface-availability of azide groups (312). The same azido mannose derivative was also used 
earlier by Wang et al. (313). They could also show that azido homoalanine can be employed 
in the same way. 
Azide groups can also be introduced to the surface of parent cells by fusing them with 
fusogenic liposomes that contain azide-labeled phospholipids (314). Shedding of azide-lipids 
as part of EVs thus works similarly to metabolic labeling and presents the opportunity for 
downstream chemical modification. 
1.9. Post-isolation surface engineering of EVs 
Post isolation surface engineering can be achieved either by direct chemical labeling of the 
vesicle surface or by physical interactions with surface features of EVs or their lipid membrane 
(Figure 14 D-H). 
The main disadvantage of modifying EVs after their isolation, compared to genetic engineering, 
is the reduced control over the extent and the site of modification. This could affect the 
efficiency of such approaches and potentially negatively influence vesicle-activity. Moreover, 
incubation and or reaction conditions might have adverse effects on vesicle integrity and the 
removal of non-incorporated material requires the use of a suitable method for purification that 
leaves the vesicles intact while guaranteeing their purity. There are however also advantages 
that make the exploration of post-isolation surface engineering of EVs a worthwhile pursuit. In 
contrast to genetic engineering, where researchers are limited to peptides, post-isolation 
modification allows displaying all kinds of molecules such as fluorescent dyes and small 
synthetic molecules on the vesicle surface, but also larger molecules such as aptamers (315, 
316). As no engineering of the parent cell is required, the methods described in the following 
chapters can also be employed to engineer autologous EVs derived from a patient’s plasma 
or harvested cells, circumventing possible adverse effects due to the administration of 
exogenous EVs. Without the requirement of extensive knowledge of surface proteins of the 
EVs to be modified, post-isolation modification can also be employed in cases where 
knowledge about suitable targets for the generation of fusion proteins is sparse. This is 
especially important in the field of OMV-research. The surface proteins of bacterial vesicles 
can vary by species and strain (317) and proteomic analysis of OMVs derived from the 
myxobacteria employed in this work has not been carried out yet. 
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1.9.1. Physical modification of EVs 
1.9.1.1. Fusion with liposomes 
Liposomes have been extensively studied and their easy and reproducible production and drug 
loading are big advantages for their use in EV-modification. Moreover, förster resonance 
energy transfer (FRET) based assays to study the fusion of liposomes are already established 
(318). These assays are based on the presence of two lipophilic dyes in the liposome 
membrane that form a FRET-pair (Figure 16). Once the liposome fuses with another 
phospholipid membrane, its lipids and the lipophilic dye are diluted in the membrane of the 
newly formed hybrid particle reducing the FRET effect. However, for FRET to give reliable 
information about the actual full fusion of the particles, hemifusion, i.e. interaction of only the 
outer leaflet of the lipid bilayers, needs to be precluded, as it does not necessarily lead to full 
fusion  (319, 320). To only assess full fusion, one of the FRET-partners in the outer leaflet  can 
be inactivated by oxidation, to assess only mixing of the inner leaflet, which does not occur by 
hemifusion (321). Alternatively the mixing of encapsulated contents in the respective particle-
populations can be assessed (322). With suitable assays to quantify the fusion of liposomes 
and EVs, two main questions remain how to achieve the fusion of EVs and liposomes and how 
to remove non-fused liposomes and ideally EVs from the mixture. 
So far, few studies have examined the fusion of EVs with liposomes using different 
approaches. Sato et al. evaluated the fusion of EVs derived from two cell lines with liposomes 
of differing compositions (323). To achieve fusion, they subjected mixtures of EVs and 
liposomes to ten cycles of freeze thawing, however without differentiation of hemifusion and 
full fusion. The results of Sato et al. regarding cell-uptake of their hybrid EVs are in 
disagreement to established knowledge, e.g. cationic lipids decreasing uptake instead of 
increasing it and PEGylation increasing uptake instead of decreasing it. Moreover they did not 
address the removal of non-fused particles and stress of freezing and thawing of EVs might 




Figure 16: The PEG-mediated fusion of EVs and liposomes can be monitored using FRET. To 
this end, liposomes were labeled with NBD-PS, which is excited at 460 nm and emits light at 
535 nm, and rhodamine-PE, which is excited at 535 nm and emits light at 580 nm. When native 
liposomes were excited at 460 nm, due to FRET, only the emission of rhodamine at 580 nm 
was visible. Once liposomes and EVs had fused and the dyes were diluted, the fluorescence 
of NBD became visible. Adapted with permission from Piffoux, M., et al. (2018). “Modification 
of Extracellular Vesicles by Fusion with Liposomes for the Design of Personalized Biogenic 
Drug Delivery Systems”, ACS Nano 12(7): 6830-6842. Copyright (2018) American Chemical 
Society. 
Piffoux et al. used another approach to achieve fusion with less implications for EV-integrity 
and also demonstrated the removal of unfused liposomes (320). Their method was based on 
the co-incubation of EVs and liposomes with PEG8000, which mediated the formation of hybrid 
particles (Figure 16). To prove that PEG8000 led to full fusion of EVs and liposomes, they used 
the oxidation-based method described above. Non-fused liposomes were removed by gradient 
UC. With their method, they achieved a fusion of up to 62% of added liposomes with EVs and 
the PEGylated hybrid particles they created showed a greatly decreased uptake into cells. 
They also assessed the fate of liposome- and EV-cargoes upon fusion and showed that there 
was no leakage of native EV cargoes, while liposome cargoes were efficiently carried over into 
the newly formed hybrid particles. Thus, the simultaneous surface modification and drug-
loading of EVs could be achieved. 
While PEG-mediated fusion with liposomes has great potential for the engineering of 
mammalian cell derived EVs, it is unclear as of yet, whether this technique would also work 




1.9.1.2. Lipid insertion into the EV-membrane 
The phospholipid bilayer of EVs also plays an important role in methods based on the insertion 
of phospholipids or cholesterol into their membrane. Phospholipid- and cholesterol-post-
insertion are two established methods for the post-production modification of liposomes (324, 
325). In the development of liposomal formulations, these techniques are employed, when the 
molecule of choice would be sensitive to the organic solvents employed in the conventional 
production of liposomes. In EV-research, they can be used for the post-isolation surface 
modification of EVs. 
Phospholipid- or cholesterol-labeled hydrophilic molecules can insert into target membranes 
upon co-incubation, but they differ in the incubation temperature needed to achieve efficient 
insertion. Phospholipid insertion is typically taking place at 60 °C, while cholesterol insertion 
already can take place at 17 °C, depending on the inserting molecule (326). While the 
temperature requirement of the latter variant is more suitable for EV-engineering, both 
methods have been employed to produce modified vesicles. 
 
Figure 17: Co-incubation of micelles containing the lipids of choice and EVs under increased 
temperature leads to the insertion of these lipids into the EV membrane. Adapted with 
permission from Elsevier from Kooijmans, S. A. A., et al. (2016). “PEGylated and targeted 
extracellular vesicles display enhanced cell specificity and circulation time”, Journal of 
Controlled Release 224: 77-85. 
Phospholipid-post-insertion was employed for the PEGylation and introduction of a targeting  
moiety to EVs by insertion of lipids modified with PEG and an EGFR-binding nanobody (Figure 
17) (327). As expected insertion at 60 °C, while most effective in terms of the amount of 
inserted molecules, led to damaging of the vesicles reducing their activity in in vitro assays. 
The authors determined that 40 °C was better suited for EVs, balancing insertion efficiency 
and vesicle-stability. Targeting of EVs with the nanobody was successful in vitro, in vivo 
however, only an increased circulation time of EVs was visible with no measurable targeting 
of EGFR-expressing cells. Choi et al. also used lipid post-insertion to generate mannose-
functionalized EVs (295). They incubated their vesicles for 3 h at 37 °C and found that insertion 
was proportional to the number of phospholipid-PEG-mannose molecules per EV. In in vivo 
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experiments, they could show a higher accumulation of their mannose-targeted EVs in lymph 
nodes close to the injection site compared to native EVs.  
Cholesterol insertion has so far not been used to equip EVs with targeting moieties. Instead, it 
was employed to load EVs with a cargo of cholesteryl-modified siRNA. Three groups have 
used this approach to deliver siRNA to silence the cancer-related human antigen R (228), the 
huntingtin gene (229) and CD45 or eGFP (230). The optimization of cholesterol-post-insertion 
was exhaustively evaluated by O’Loughlin and coworkers, who got some important insights 
into the optimization this method. They optimized the incubation-time, -temperature 
and -volume and determined that 1 h at 37 °C in a volume of 100 µl would lead to the best 
results. They also looked at the insertion efficiency as a function of the ratio of cholesteryl-
siRNA molecules to EVs. A lower ratio led to a higher encapsulation efficiency, while increasing 
the ratio decreased the percentage of inserted siRNA. The amount of inserted molecules per 
EV however increased. Thus, the ratio of vesicle and cholesteryl-modified molecule depends 
on the aim of the study. In case of O’Loughlin and coworkers, the aim was to achieve a high 
encapsulation efficiency of the expensive modified siRNA, while the natural targeting ability of 
EVs was used to deliver the molecule to its target, thus they used a very low ratio. A high ratio 
could be employed, if the foremost aim was achieving the insertion of as many molecules per 
particle, for example to produce targeted EVs. 
Both lipid- and cholesterol-post-insertion have the disadvantage that inserted molecules can 
potentially leak from the vesicle membrane in the presence of acceptor membranes and serum 
proteins (326, 328). Especially cholesterol-anchored molecules might easily dissociate from 
the vesicles, which makes the throughout evaluation of insertion stability a crucial step in 
developing methods for EV surface engineering by post-insertion techniques. Nonetheless, 
the simple experimental conditions and molecules employed for cholesterol post-insertion 
prompted its investigation as a method for the surface engineering of myxobacterial OMVs. 
1.9.1.3. Adsorption to the EV-surface  
Adsorption to the surface of EVs can either be multivalent and rely on the general negative 
surface charge of EVs or highly specific and tailored to EV surface markers. 
Sawada et al. modified EVs by adsorbing an amphiphilic cationic nanogel to their surface, to 
increase their uptake in recipient cells (329). In another example, cationized pullulan was 
adsorbed to EVs , which led to their selective uptake into liver cells both in vitro and in vivo 
(330). 
Specific interaction with the tetraspanin CD63, which is a typical surface marker of EVs (49), 
was employed by Gao and coworkers (331). They coupled a morpholino oligomer with activity 
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against Duchenne muscle dystrophy and a muscle-targeting peptide to a short peptide with 
high binding affinity to CD63. EVs modified with these molecules displayed efficient muscle 
targeting and showed activity in vivo in a muscle dystrophy mouse model. 
1.9.2. Chemical modification of EVs  
In general, the approach for the chemical surface-modification of EVs depends on the 
complexity of the introduced molecules. For simple molecules such as fluorescent dyes or 
PEG-derivatives (295), without functional groups that could lead to side-reactions, one-step-
processes often suffice. Here functional groups present on the EV-surface are targeted. The 
most accessible of these are amino groups, found in lysine side-chains and N-termini of EV-
surface-proteins (332, 333). These amines can be coupled with carboxylic acids to form a 
stable amide-bond. The most practical variant is using an activated ester such as N-
hydroxysuccinimide (NHS) or its sulfonated analogue, as this strategy allows for the 
preparation of the ligand in advance. Moreover, in many cases NHS esters of dyes and PEG-
derivatives are commercially available. However, this approach only works, as long as the 
molecule to be installed on the EV-surface contains no amines itself. Otherwise side products 
consisting of di- or oligomers might be formed. This reduces the amount of available molecules 
for the reaction with EVs and may also lead to vesicles modified with a heterologous mixture 
of molecules, with potentially reduced activity. 
In these cases, a two-step-process is needed. In the first step, a suitable functional group is 
installed on the EV-surface. This can be done through NHS esters, but also, as described 
above through metabolic labeling or through physical processes, e.g. lipid-insertion as 
described by Di et al. (334). Another method to achieve this -using diazotransfer- is one of the 
subjects of this work. In the second step, this group is then coupled to the molecule to be 
displayed on the vesicles. To work well in this set-up, the reaction performed in the second 
step must fulfill certain requirements. It must be orthogonal to the functional groups 
encountered in both the EVs and the ligand. It should work under tolerable conditions for the 
vesicle, in the best case under physiological conditions without the addition of organic solvents. 
Moreover, as EV-concentrations are oftentimes low and the ligands used expensive, the 
reaction should work well also in diluted solutions. Finally fast kinetics are desirable, to limit 
the exposure of EVs to potentially detrimental conditions and to streamline the process of EV-
modification. All these requirements are satisfied very well by reactions subsumed under the 




1.9.2.1. Click-chemistry and bioorthogonal chemistry 
The term “click-chemistry” was devised by Sharpless and coworkers in 2001 (335). Per its 
definition it refers to reactions that can me modularly employed to generate a wide variety of 
compounds with high yields and fast kinetics from simple starting materials (335). These 
reactions should ideally work in water or without the addition of solvents and only generate 
unproblematic byproducts (335).  While they describe multiple reaction types in their paper that 
fulfill click-chemistry-criteria, the term click-chemistry has become almost synonymous with the 
copper-catalyzed Huisgen-type [2+3] alkyne-azide cycloaddition (CuAAC, Figure 18), 
published independently by two groups in 2002 (336, 337). The reaction is often referred to as 
“copper-catalyzed click-chemistry”. Indeed, CuAAC is one of the quintessential click-reactions. 
It works very well in aqueous media, with fast kinetics, stereoselectivity and little unspecific 
side-reactions. The mechanism of this reaction was elucidated by Worrell et al. who 
determined that different from earlier assumptions, two chemically equivalent copper-ions take 
part in the reaction (338). The copper(I)-ions required for CuAAC are typically generated in situ 
through reduction of copper(II) by ascorbic acid. Copper(I) however is unstable and prone to 
generate reactive oxygen species that can damage biomolecules (339). Thus, it needs to be 
stabilized by ligands (340). Especially ligands based on tris(triazolmethyl)amine are popular 
as their solubility can be tuned through the substitution of the triazoles and they increase the 




Figure 18: This figure shows examples of the click-chemistry reactions employed in this work. 
In CuAAC, a terminal alkyne and an azide form a triazole under catalysis by Cu(I). A catalyzer 
can be omitted in SPAAC, were the alkyne is incorporated into a strained cyclooctane ring, 
e.g. into dibenzocyclooctyne (DBCO). In inverse electron-demand Diels-Alder reactions 
(IEDDA), tetrazines, e.g. methyltetrazine, react with suitable dienophiles, such as trans-
cyclooctene. 
In 2004 Carolyn Bertozzi and coworkers presented a modified version of the [2+3] alkyne-
azide cycloaddition that did away with the copper-catalyst by incorporating the alkyne group 
into a strained cyclooctane ring (341), based on earlier findings of Wittig and Krebs (342). 
While this strain-promoted alkyne-azide-cycloaddition (SPAAC, Figure 18), loses its 
stereoselectivity and has slower kinetics than CuAAC, it is still fast and selective and the 
absence of a toxic catalyst make it more benign for application in biological systems (341). 
While the initially synthesized cyclooctyne-derivatives had slow reaction kinetics with azide, 
they were improved by the introduction of electron-withdrawing fluorine atoms next to the 
alkyne (343) and by increasing the ring-strain through the addition of two aryl rings to the 
cyclooctyne and the introduction of an endo- or exocyclic amide (344, 345). 
Even faster kinetics than in CuAAC can be reached in inverse electron-demand Diels-Alder 
reactions (IEDDA, Figure 18) between 1,2,4,5-tetrazines and strained alkenes or alkynes. Here 
the fastest variants approach the rate constant of enzyme-catalyzed reactions (346). 
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Thalhammer et al. evaluated the reactions of varying dienophiles with tetrazines and in some 
cases found very fast kinetics, especially for trans-cyclooctene (TCO) (347). Blackman et al. 
later adapted this reaction for the modification of biomolecules in aqueous media (348) and 
since then  IEDDA has been intensely investigated and found wide application (332, 349). Both 
the tetrazine as well as the dienophile can be tuned in regards to reactivity and stability. The 
highest reaction rates are reached with TCO-derivatives (350) and monophenyl-substituted 
tetrazines (351). 
Besides organic synthesis, were especially CuAAC is a versatile tool, click-chemistry reactions 
are quintessential tools of bioorthogonal chemistry (346). Bioorthogonal chemistry strives to 
achieve the selective labeling of biomolecules by employing reactants that show no cross-
reactivity with the functional groups encountered in biological systems (332, 352). With their 
fast kinetics in aqueous media and the absence of a toxic catalyst, both SPAAC and IEDDA 
are ideal for the modification of biomolecules. Azide-groups are quite inert in vivo and can be 
introduced to biomolecules both chemically using e.g. activated esters (332) or diazotransfer 
(see 0) as well as through metabolic labeling (353, 354) and genetic code expansion (355). 
Using this approach, Chang et al. successfully labeled azido-sugars in living mice with a model 
peptide (354). SPAAC has however some limitations for in vivo application as the strained 
alkynes employed in these reactions show some reactivity towards nucleophiles encountered 
in the lumen of cells (356, 357). This issue is not present for IEDDA reactions that exhibit high 
selectivity in in vivo conditions (349). IEDDA has been employed for intracellular fluorescent 
labeling, for example for super-resolution imaging of actin filaments (358) and its high 
selectivity and fast reaction rate even at very low concentrations make it ideally suited for 
pretargeting (349, 359). Pretargeting is mainly utilized in targeted radionuclide-therapy and -
imaging. First, a TCO-labeled antibody against a tumor-antigen is injected and allowed to bind, 
while unbound antibody is eliminated. Then the tetrazine-labeled radionuclide is injected and 
selectively accumulates at the target site through IEDDA reaction with the antibody. Thus, off-
target-labeling and radiotoxicity can be significantly reduced (359). IEDDA and SPAAC or 
CuAAC can also be employed orthogonally to each other, for example for dual labeling of cells 
(360). To achieve this however the right cyclooctynes need to be chosen that do not show 
reactivity towards tetrazines. One such example is the dibenzocyclooctyne derivative (DBCO, 





Besides their use in click-chemistry, azide groups also 
find application in organic synthesis. They can form 
protection groups for amines that can be removed 
under mild conditions, e.g. using the Staudinger 
reduction (361), they can be used to generate amides 
and carbamates (362) and they are utilized in pro-
drug strategies (363). While azide groups can be 
introduced to biomolecules through reactions with 
azide-containing molecules, such as 2-azidoacetic 
acid, they can be also directly generated from primary 
amines using diazotransfer (Figure 19 B). 
In diazotransfer, the azide is generated by transfer of 
a diazo group from an azide-containing donor molecule (364). The main advantage of 
diazotransfer is that unlike approaches employing sodium azide as the nucleophile in a 
nucleophilic substitution reaction, the stereochemistry of the molecule is retained and no 
elimination products are formed (365). Pandiakumar and coworkers evaluated the mechanism 
of the diazotransfer reaction and determined that the amine attacks the terminal nitrogen of 
the azide group of the donor molecule, which leads to the formation of the azide-containing 
product and leaves one nitrogen attached to the donor molecule (364). 
Diazotransfer was typically performed in organic media using triflyl azide (Figure 19 A) (366). 
While this method works well and has been widely applied, triflyl azide has several drawbacks. 
Trifluoromethanesulfonic anhydride is expensive and the triflyl azide has a poor shelf life. It 
can only be stored in solution and its reported explosiveness make its handling difficult (367). 
These disadvantages where addressed by Goddard-Borger and Stick, who developed 
imidazole-1-sulfonyl azide (ISA) HCl as a shelf-stable and cheap alternative to triflyl azide 
(Figure 19 A) (365). ISA HCl was successfully used to convert various amines into the 
respective azides and has also been applied by other researchers (365, 368, 369). In later 
studies it was discovered that ISA HCl was not as inert as initially assumed and the sulfate 
and mesylate salts of ISA were confirmed to be more stable and less prone to explosive 
decomposition (370). The discovery of van Dongen et al. that diazotransfer with ISA can also 
be performed in aqueous media (371), opened up its application in the modification of peptides 
and other biomolecules (372). Based on these results, diazotransfer with ISA was evaluated 
in this work as a method to generate azide-labeled OMVs (AzideOMVs) that could be 
subsequently modified using CuAAC and SPAAC. 
Figure 19: Triflyl azide and imidazole-
1-sulfonyl azide (ISA) HCl are the most 
widely employed diazotransfer agents 
(A). Diazotransfer can, under basic 
conditions and with Cu(II) as a 




1.9.2.3. Examples of chemical surface modification 
So far, only few publications have explored the chemical surface modification of EVs. Choi and 
coworkers employed a simple one-step process, using an NHS ester to introduce biotin-
modified PEG to EVs derived from bovine serum albumin (295). While biotin was successfully 
introduced to the vesicles, they observed the formation of EV-aggregates, which was absent 
in their alternative approach, where biotin and mannose were introduced by phospholipid-post-
insertion. In another study EVs derived from red blood cells were labeled with AlexaFluor 488 
NHS ester to evaluate their association with  Neuro2A cells and A431 cells after the 
introduction of targeting moieties by genetic engineering (373). Di et al. performed a two-step 
modification, by first introducing maleimide groups through lipid insertion that were 
subsequently coupled with either a fluorescent dye, magnetic nanoparticles or gold 
nanoparticles (334). 
 
Figure 20: In this figure, a two-step approach to the chemical surface modification of EVs is 
demonstrated. First DBCO-groups are introduced to the vesicle surface through reaction with 
DBCO sulfo-NHS ester. These groups subsequently take part in a SPAAC reaction with an 
azide-modified c(RGDyK)-peptide to obtain targeted EVs. Adapted with permission from 
Elsevier from Tian, T., et al. (2018). “Surface functionalized exosomes as targeted drug 
delivery vehicles for cerebral ischemia therapy”, Biomaterials 150: 137-149. 
A two-step approach based on click-chemistry was first realized by Smyth and coworkers 
(333). First they introduced an alkyne to the EV-surface using pentinoic acid NHS ester, then 
using bathophenantroline as the copper-ligand, they introduced an azide-labeled fluorescent 
dye to the vesicles to track their uptake into cells. In their publication, they show that CuAAC 
did not have an impact on EV-size, however they do not comment on recovery rate of EVs 
after modification. SPAAC has been employed for the surface modification of EVs both after 
metabolic labeling and after reaction with a DBCO NHS ester. As detailed above, different 
azide-modified sugars and amino acids can be used to generate azide-labeled EVs by 
metabolic labeling (see 1.8.2). Wang et al. used the azide groups on their EVs to prepare 
biotinylated EVs by reaction with DBCO coupled biotin (313). These vesicles were 
subsequently further functionalized with streptavidin-Horseradish peroxidase. This allowed for 
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the intracellular delivery of this enzyme through EV-uptake by recipient cells. Tian et al. first 
modified their EVs using the sulfo-NHS ester of DBCO (Figure 20) (225). By using the 
sulfonated form of NHS, they greatly increased the solubility of the molecule, circumventing 
the issue of precipitation in aqueous media, caused by the lipophilicity of DBCO. In the next 
step, they introduced an azide-modified cyclic RGD-peptide to selectively target the EVs to 
ischemic lesions in the brain of mice. They also analyzed the degree of surface-modification 
by SPAAC using a fluorescent derivative of their peptide and estimated a modification with 
approx. 260 molecules per vesicle. 
While chemical surface engineering of EVs has great potential for the introduction of targeting 
moieties to the vesicles, so far it has not been utilized extensively. Especially for myxobacterial 
OMVs, were surface-proteins suitable for the expression of fusion-proteins have not been 
identified yet, and for the targeting of bacteria, were typical targeting moieties cannot be easily 
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3.1. Bacterial Culture 
3.1.1. Culture of SBCy050 myxobacteria and production of 
conditioned medium 
SBCy050 bacteria were used as a production organism for the isolation of OMVs. To cultivate 
the bacteria, first a pre-culture was prepared by adding 1ml of a cryostock containing 25% 
glycerol to 50 ml of 2SWC-medium. After 48 h of growth, the preculture with an OD600 of 
approx. 1.0 was used to inoculate the cultures for OMV-isolation. 150 ml of 2SWC-medium per 
500 ml conical culture-flask were inoculated with a starting OD600 of 0.04±0.01. After 96 h of 
cultivation and reaching of the late stationary phase, the vesicle-containing culture-supernatant 
was harvested. 
First bacteria and large debris were pelleted by centrifugation at 9500*g for 10 min. Then the 
supernatant was either filtered or subjected to another round of centrifugation at 9500*g for 15 
min to remove residual bacteria. Filtration was carried out using a 0.45 µm pore-size bottle top 
filter. The resulting cell-free conditioned medium was then typically directly subjected to 
ultracentrifugation as described below. 
3.2. Cell culture 
3.2.1. A549 lung cancer cells 
A549 cells were cultured in RPMI 1640 medium supplemented with 10% FBS. T75 flasks were 
used for maintaining the culture, while T225 flasks were used to generate sufficient amounts 
of conditioned medium for EV-isolation. After passaging new T75 flasks were seeded with 
0.2*10^6 cells in 12 ml medium and T225 flasks with 0.6*10^6 cells in 30 ml of medium. Flasks 
were maintained for 120 h, with a medium exchange after 48 h. After 120 h, flasks to be used 
for EV-isolation were washed once with PBS, then RPMI 1640 without FBS was added, while 
for T75 flaks used for maintaining the culture, the medium was exchanged with FBS-containing 
medium. After another 48 h, the cells in T75 flasks were trypsinized, counted using a CASY 
cell counter and seeded into new flasks. The medium from T225 flasks was harvested and 
centrifuged 4 min at 300*g to pellet detached cells and the supernatant was typically stored at 
-80 °C for up to three weeks. After thawing and before UC conditioned medium was centrifuged 




3.2.2. Human umbilical cord endothelial cells (HUVEC) 
HUVEC cells were cultured in EGM-2 medium containing 2% FBS. Passages 5-9 after thawing 
were used for EV-isolation. During passaging, cells obtained from one T225 flask were split 
into four new T225 flasks. Cells were cultivated with 25 ml of EGM-2 medium per flask for 120 
h, with feeding after 48 h. After 120 h cells were washed once with PBS and cultured for 48 h 
with serum-free EBM-2 medium. Conditioned medium was harvested and centrifuged at 300*g 
for 4 min and typically stored at -80 °C for up to three weeks After thawing and before UC 
conditioned medium was centrifuged for 15 min at 9500*g. Cells from flasks used for passaging 
were washed twice with PBS, trypsinized and split into four new T225 flasks. 
3.2.3. RO cells 
RO cells (DSMZ, ACC 452) were cultured by Eilien Heinrich as described previously (374). 
RPMI medium supplemented with 1% (v/v) insulin-transferrin-selenium-ethanolamine was 
used to culture the cells. Generally, 0.75 × 106 cells/mL were seeded in 45 ml of medium in a 
T75 flask. After 3 days, 25 ml of medium were replaced with 50 ml of fresh medium. After 7 
days, conditioned medium was harvested. Cells were pelleted at 300*g for 8 min, then the 
supernatant was centrifuged at 9500*g for 15 min and subsequently filtered through a 0.45 µm 
pore-size bottle top filter. 
3.3. Liposome preparation 
Liposomes were prepared using the lipid-film hydration method followed by extrusion (375). 
To produce lipid films a solution of 2 mM DMPP and 3 mM DPPC in chloroform was prepared 
and 1 ml aliquots of it air-dried in glass-HPLC vials. Lipid-films were rehydrated with 1 ml of 
PBS at 42 °C, vortexed and then extruded eleven times through a 200 nm polycarbonate 
membrane. Liposomes were then directly used in experiments or diluted as necessary. 
3.4. EV-isolation 
3.4.1. Ultracentrifugation 
To obtain concentrated EVs from conditioned medium, particles were pelleted using 
ultracentrifugation. Typically samples were subjected to 2 h of centrifugation at 100000*g and 
4 °C using an SW32 Ti rotor with thick-wall PC-tubes. This allowed for the simultaneous 
processing of approx. 180 ml conditioned medium. 
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After UC, the supernatant was decanted. EVs were either resuspended in residual supernatant 
or PBS was added to the pellet for resuspension. Pellets were typically used directly or stored 
up to 24 h at 4 °C. 
3.4.2. Size exclusion chromatography 
SEC was generally performed using Kimble Flex-columns filled with Sepharose Cl-2b as the 
stationary phase and filtered PBS as the mobile phase. Purification of samples was conducted 
using either gravity-driven elution or partially automated using an ÄKTA start chromatography 
system equipped with a fraction collector. The use of a differing setup is indicated in the 
respective method section. For SEC-purification using the ÄKTA start instrument, columns 
were equilibrated to be used with a flow of 1 ml/min. Fractions of either 0.5 or 1 ml were 
collected. Between runs, columns were cleaned with at least 1.5 column volumes of buffer to 
ensure the removal of residual contaminants from the previous run. 
3.5. Characterization of extracellular vesicles 
3.5.1. EV-size and concentration 
EV-size and concentration were mainly measured by NTA. Moreover, the size of EVs was also 
assessed using Cryo-TEM. 
NTA was performed using Nanosight-instruments in varying setups, due to maintenance and 
failure of components of the system. Differences in sensitivity of the setups led to different 
results regarding the apparent particle-concentration of EV-samples. This made the 
comparison of some of the results, especially for the assessment of bound molecules per 
particle difficult. This problem however was mitigated, by normalizing results to control or 
standard samples measured in parallel. 
Cryo-TEM measurements were performed by Marcus Koch as previously described (21). 3 µl 
of EV-pellet or purified EVs were pipetted onto a holey carbon film and after blotting for 2 s, 
the sample was frozen rapidly by plunging into liquid ethane at 108 K using a cryoplunger. 
Frozen samples were transferred to a cryo-TEM sample holder and imaged in bright field TEM 




3.5.2. Protein content 
The protein content of EVs and other samples was measured using a bicinchoninic acid assay 
according to the manufacturer’s instructions. A calibration curve was prepared freshly for each 
experiment and samples were diluted to a protein concentration between 0.5 and 30 µg/ml to 
conform to the linear range of the kit. Samples were measured using a plate reader. 
3.5.3. SBCy050 autofluorescence 
The autofluorescence of SBCy050 OMVs was measured with an excitation wavelengths of 410 
nm and an emission wavelength of 629 nm, as described in the master thesis of Eilien Heinrich. 
3.6. Surface functionalization of EVs 
3.6.1. Chemical synthesis and analysis of synthesized 
compounds 
All reagents were obtained from commercial suppliers and used as received. Liquid 
chromatography-coupled mass spectrometry (LC/MS) analysis was generally performed using 
a Dionex UltiMate 3000 system equipped with a MSQ Plus ESI Quadropol mass spectrometer. 
Samples were typically analyzed using a gradient from 5% ACN and 95% H2O to 100% ACN 
over the course of 5 min. High-resolution mass spectrometry (HRMS) was performed using a 
Dionex Ultimate 3000 RSLC equipped with a Q Exactive Focus mass spectrometer and a 
Acquity UPLC® BEH C8 column. Preparative HPLC (prepHPLC) was generally performed 
using an Ultimate 3000 UHPLC+ focused system with a C18 column. 
NMR spectra were recorded using a Bruker AV 500 or Bruker Ascend 700. Chemical shifts are 
reported as part per million (ppm). Coupling constants of reported signals are given in Hertz 
(Hz). Data was reported as chemical shift, multiplicity of the signal (singulet (s), doublet (d), 
triplet (t), quartet (q), doublet of doublets (dd), doublet of triplets (dt), multiplet (m) and broad 
(br)), coupling constants and integration. 
3.6.2. General approach 
The surface of SBCy050 OMVs was modified after their isolation with various methods. 
Vesicles were generally modified with fluorescent molecules to allow for the assessment of the 




3.6.3. Cholesterol insertion 
For cholesterol insertion, purified SBCy050 OMVs, A549 EVs or freshly prepared liposomes, 
diluted to the same concentration range as EVs, were incubated with 1000 molecules per 
particle of cholesterol PEG 2000 FITC for 1 h at 30 °C and 300 rpm. SBCy050 OMVs and 
liposomes were incubated with or without the addition of 0.1 mg/ml of saponin. 
After the incubation period, samples were purified by gravity-flow-driven SEC using a 10 ml 
Sephadex G75 column for SBCy050 OMVs and A549 EVs and a 25 ml Sepharose Cl-2b 
column for liposomes. Collected fractions were analyzed by NTA and regarding their FITC 
fluorescence (excitation: 490 nm, emission: 525 nm). From this, the number of inserted 
cholesterol PEG 2000 FITC-molecules per particle was calculated. 
3.6.4. Functionalization with activated esters 
SBCy050 UC-pellets were purified by SEC using a 35 ml column before introduction of the 
activated ester. The protein-content of vesicle-containing fractions was measured by BCA-
assay and adjusted to a concentration of 48.8 µg/ml. The sample was then mixed with either 
sulfo-cyanin-7 NHS ester in different concentrations or with sulfo-cyanin-7 carboxylic acid at 
9.8 µM. Both compounds were dissolved in dry DMSO at 8 mg/ml and stored in -80 °C in 
single-use aliquots. Samples were incubated for 1 h at RT. Then they were purified using a 30 
ml SEC column covered with aluminum foil. Fractions were analyzed by NTA and regarding 
their fluorescence (excitation: 750 nm, emission: 781 nm) and the amount of dye-molecules 
per particle was calculated. 
3.6.5. Diazotransfer 
Diazotransfer was performed by mixing 400 or 1000 µl of the resuspended vesicle-pellet with 
0.32 mM CuSO4, 0.81 mM ISA and varying concentrations of NaOH. After incubation for 30 
min to 20 h, the sample was purified using the same 35 ml SEC-column that was employed 
for pellet-purification in NHS ester-experiments. The obtained AzideOMVs were typically 




3.6.5.1. Synthesis of imidazole-1-sulfonyl azide (ISA) HCl 
 
Figure 21: Reaction scheme of the synthesis of ISA HCl. 
ISA was synthesized based on the protocol of Goddard-Borger and Stick (365). 
500 mg of NaN3 (7.7 mmol) were weighed into a 100 ml two-necked RBF (Figure 21). After the 
introduction of a nitrogen-atmosphere, NaN3 was suspended in 7.7 ml of dry acetonitrile. The 
stirred suspension was cooled to 0 °C and 0.63 ml (7.7 mmol) sulfuryl chloride were added 
dropwise over 10 min. The mixture was allowed to slowly reach RT and stirred overnight. Then, 
after re-cooling to 0 °C, 1 g of imidazole (14.69 mmol) dissolved in 15 ml of dry acetonitrile was 
added slowly to the mixture. After stirring for 5 h, approx. 25 ml of ethyl acetate were added to 
the reaction mix. The organic phase was washed with saturated NaHCO3 and dried over 
MgSO4. Approx. 4 ml of 4 M HCl in dioxane were added to the organic layer. After 2 h, the 
HCl-salt of ISA was isolated as colorless crystals. ISA HCl was stored at -20 °C under an argon 
atmosphere. 
3.6.6. Chemical modification of AzideOMVs by SPAAC 
Typically, 500 µl of AzideOMVs were mixed with 4.9 µM of DBCO AF594 or SPAAC-based 
linker and incubated for 20 h at RT and 300 rpm. To this end, DBCO AF594 and the SPAAC-
based linker were dissolved in DMSO and aliquoted in 1 µl aliquots containing 2.45 nmol per 
aliquot, enough to prepare 500 µl of a 4.9 µM solution. Samples were purified by SEC with the 
same 30 ml SEC-column that that was employed for purification after incubation with activated 
esters. Fractions were analyzed by NTA and regarding their fluorescence (DBCO AF594: 





3.6.6.1. Synthesis of the SPAAC-based linker 
 
Figure 22: Reaction scheme for the synthesis of the SPAAC-based linker. 
2 mg (2.23 µmol) of azide-PEG3-cyanine5-PEG4-amine were dissolved in 250 µl of a mixture 
of water/DMF 1:1 (v/v) (Figure 22). To this solution 1.66 mg (2.45 µmol) of TCO-PEG4-DBCO 
dissolved in 250 µl of 1:1 water/DMF were added. The mixture was stirred overnight until 
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completion of the first reaction-step, as indicated by LC-MS analysis. The mixture was 
concentrated under a stream of nitrogen and stored at -80 °C. 
In the next step, 0.45 mg (2.45 µmol) of DBCO NHS ester were dissolved in 250 µl of dry DMF 
and added to the intermediate, together with 3.5 µl of trimethylamine diluted 1:10 (v/v) in dry 
DMF (2.23 µmol). The mixture was stirred for 48 h at RT until the presence of the desired 
product was confirmed. The reaction mixture was purified by prepHPLC.  
3.6.6.2. Synthesis of methyltetrazine vancomycin 
 
Figure 23: Reaction scheme for the synthesis of methyltetrazine vancomycin. 
37.8 mg of vancomycin HCl (25.46 µmol) were dissolved in 4730 µl of dry DMSO and 7.06 µl 
trimethylamine (50.92 µmol) were added (Figure 23). To this, 10 mg of methyltetrazine NHS 
ester (30.55 µmol) were added and the mixture was stirred at RT for 4 h until completion as 
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indicated by LC/MS. Cold ethyl acetate was added to the reaction mixture and the solution was 
stored overnight at 4 °C. On the next day, a pink precipitate was isolated by filtration and 
lyophilized. The lyophilized precipitate was further purified by prepHPLC. 
3.6.6.3. IEDDA reaction conditions 
The respective TCO-group containing molecule (either SPAAC-based linker, TCO-PEG4-
DBCO, PEG8 CuAAC-linker or PEG6 CuAAC-linker) was reacted with a methyltetrazine 
containing molecule (either methyltetrazine vancomycin or methyltetrazine-PEG4-biotin), by 
mixing equal amounts of both compounds dissolved in DMSO in a volume of 2 to 6 µl. After 1 
h incubation at RT, the product was used in OMV modification without further purification. 
3.6.7. Chemical modification of AzideOMVs by CuAAC 
To perform CuAAC, Na ascorbate was freshly dissolved in either water or 40 mg/ml NaOH at 
a concentration of 200 mg/ml. 14.11 µl of this solution were mixed with 20 µl of 10 mg/ml 
CuSO4 in water. Of this 5.53 µl were added to a mixture of 14.1 µl of 20 mg/ml Tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA) and the respective alkyne (either alkyne Af594, 
the CuAAC-linker or the product of the reaction of a linker and methyltetrazine-vancomycin or 
methyltetrazine-PEG4-biotin). The resulting solution was quantitatively added to 500 µl of 
AzideOMVs. After typically 4 h of incubation at RT and 300 rpm, purification using the 30 ml 
SEC-column was performed as described above. Fractions were analyzed by NTA and 
regarding their fluorescence (Alkyne AF594: excitation: 590 nm, emission: 627 nm; CuAAC 




3.6.7.1. Synthesis of the PEG8 CuAAC-linker 
 
Figure 24: Reaction scheme for the synthesis of the PEG8 CuAAC-linker. 
23.0 mg Boc propargyl glycine (0.108 mmol) were dissolved in 830 µl of dry DMF and solution 
was cooled to 0 °C on ice. 45.5 mg of COMU (0.106 mmol) and 39.1 µl DIPEA (0.230 mmol) 
were added (Figure 24). Then 50.0 mg of TCO-PEG8-amine (0.089 mmol) dissolved in 250 µl 
of dry DMF were added slowly. The reaction was left to warm up to RT overnight. The product 
of this reaction was purified by prepHPLC to obtain the Boc-protected intermediate. Boc-
deprotection was carried out by dissolving the lyophilized Boc-protected intermediate in 
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approx. 200 µl of dioxane, cooling it to 0 °C and adding 2 ml of 4 M HCl in dioxane. The mixture 
was warmed to RT over the course of 2 h. Deprotection of the intermediate was confirmed by 
LC/MS and HCl, dioxane and the bi-products of the Boc deprotection were removed under 
vacuum. 26 mg of the deprotected intermediate (0.039 mmol) were dissolved in 100 µl of dry 
DMSO and 11.2 µl DIPEA (0.066 mmol) were added. To this, 25 mg of sulfo-cyanine 5 NHS 
ester (0.033 mmol) dissolved in 400 µl of DMSO were added. The reaction was stirred 
overnight at RT. The product was purified by prepHPLC and lyophilized. 
3.6.7.2. Synthesis of the PEG6 CuAAC-linker 
 
Figure 25: Reaction scheme for the synthesis of the PEG6 CuAAC-linker. 
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The whole synthesis was executed protected from light as far as possible. 42.9 mg of Fmoc 
propargyl glycine (0.128 mmol) were dissolved in 830 µl of dry DMF and the solution was 
cooled to 0 °C on ice. Then 53.9 mg of COMU (0.126 mmol) and 46.0 µl DIPEA (0.273 mmol) 
were added (Figure 25). Then 50.0 mg of TCO-PEG6-amine (0.105 mmol) dissolved in 250 µl 
of dry DMF were added slowly. The reaction was left to warm up to RT overnight. The product 
of this reaction was purified by prepHPLC to obtain the Fmoc-protected intermediate. Fmoc-
deprotection was carried out based on the protocol of Hoffmann et al. (376). The purified 
intermediate was dissolved in 2 ml of 20% piperidine in DMF (v/v) and incubated at RT for 30 
min. After confirmation of complete deprotection, DMF and piperidine were removed under 
high vacuum and the product was purified by prepHPLC. 17 mg of the deprotected 
intermediate (0.030 mmol) were dissolved in 100 µl of dry DMSO and 9.0 µl DIPEA (0.052 
mmol) were added. To this, 22.7 mg of sulfo-cyanine 5 NHS ester (0.030 mmol) dissolved in 
400 µl of DMSO were added. The reaction was stirred overnight at RT. The product was 
purified by prepHPLC and lyophilized.  
3.6.8. Assessment of residual copper after diazotransfer 
and CuAAC 
The amount of residual copper in SBCy050 OMVs after diazotransfer and after subsequent 
CuAAC was assessed using inductively coupled plasma mass spectrometry (ICP-MS). ICP-
MS measurements were performed by Ralf Kautenburger and Kristina Brix. 
Samples were treated with 0.3% triton X-100 to lyse vesicles, filtered through a 0.2 µM syringe 
filter and 2 ml per sample were diluted 1 in 5 and measured by ICP-MS. To assess residual 
copper-content for diazotransfer, 2.5 ml each of OMVs subjected to diazotransfer under 
optimized conditions, untreated OMVs and a control containing SEC fractions obtained from 
the injection of pure PBS were used for analysis. CuAAC was assessed using OMVs subjected 
to CuAAC with alkyne AF594 under optimized conditions, untreated OMVs and a control 
containing SEC fractions obtained from the injection of pure PBS. 
3.6.9. Testing of biotinylated OMVs 
500 µl of biotinylated OMVs or controls were incubated with 2.5 µg/ml streptavidin-FITC for 1 h 
and purified by SEC using a 10 ml sepharose column. Fractions of 0.5 ml were collected and 





3.7. Storage-stability of EVs  
3.7.1. General protocol for β-glucuronidase encapsulation 
β-glucuronidase was encapsulated in EVs by co-incubation with saponin. EV-pellets after UC 
were mixed with 0.1 mg/ml saponin and 1.5 mg/ml β-glucuronidase, vortexed briefly and then 
incubated for 10 min at RT with intermitted mixing by gentle flicking of the tube to limit the 
generation of foam. Directly after the end of the incubation period, samples were purified by 
SEC to remove non-encapsulated enzyme, saponin and soluble impurities carried over from 
UC. 
3.7.2. β-glucuronidase assay 
The activity of β-glucuronidase encapsulated in EVs was assessed by the enzymatic 
conversion of non-fluorescent fluorescein di-β-D-glucuronide into fluorescent fluorescein. 
125 µl of EVs were mixed with 25 µl of fluorescein di-β-D-glucuronide in a well of a black 
96-well plate to obtain a final concentration of 8.3 µg/ml fluorescein di-β-D-glucuronide. The 
initial fluorescence was measured directly after the sample preparation at an excitation 
wavelength of 480 nm and an emission wavelength of 516 nm. Then the plate was covered 
with adhesive film to counteract evaporation and incubated in the dark for 18 h at 37 °C. Then 
the fluorescence at t18 h was acquired. The enzyme activity was calculated by subtraction of 
t0 from t18 and subsequent subtraction of the blank consisting of pure buffer.  
3.7.3. Initial experiments with A549- and HUVEC-EVs 
Storage of A549- and HUVEC-EV-samples was assessed as part of the publications of Frank, 
Richter et al. (377, 378). EVs were purified by gravity-flow SEC using 15 ml Sepharose Cl-2b 
in a 1.0 cm diameter column. A sample volume of up to 400 µl was purified in one SEC run 
and fractions of 1 ml were collected. Vesicle-containing fractions were pooled for storage. 
Samples were either stored at 4 °C, -80 °C or samples were lyophilized with or without the 
addition of 4% (w/v) trehalose in a Lyophilizer ALPHA 2-4 LSC. For lyophilisation, samples 
were frozen at -80 °C for 1 h and then lyophilized with the following parameters. The main-
drying step lasted for 46 h at a pressure of 0.180 mbar, with the shelf temperature set to 15 
°C. Then pressure was reduced to 0.0035 mbar and the shelf temperature increased to 25 °C 
for the final drying step lasting two hours. After lyophilisation, samples were stored at 4 °C. 
Lyophilized samples were re-dispersed in water for 30 min before further analysis. 
Purified A549-EVs were stored for 48 h at 4 °C, -80 °C or they were lyophilized without the 
addition of 4% trehalose and stored at 4 °C. After storage, particle-size and concentration were 
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assessed by NTA. HUVEC-EVs were initially stored for 14 d at RT, 4 °C, -80 °C or lyophilized 
without the addition of 4% trehalose and stored at 4 °C. Then particle-size and concentration 
were assessed by NTA.  
In a subsequent experiment, β-glucuronidase was encapsulated into HUVEC-EVs and they 
were stored for 7 d at 4 °C, -80 °C or lyophilized with the addition of 4% (w/v) trehalose.  After 
storage potentially leaked enzyme was removed using asymmetric flow-field-flow-fractionation 
(AF4), performed by Kathrin Fuhrmann. EV-purification was carried out using a small channel 
equipped with a 30 kDa molecular weight cut-off cellulose membrane and a 350 µm spacer. 
PBS filtered through a 0.1 µm filter was used as the mobile phase. 300 µl of EVs were injected 
at a rate of 0.2 ml/min and focused for 10 min. Then, the sample was eluted at a rate of 1 
ml/min with a cross-flow that decreased from 2 ml/min to 0.1 ml/min in 8 minutes. Elution was 
continued for another 10 min without cross-flow. Eluting proteins were detected using UV-
absorption at 280 nm. Particles were detected by multi-angle light scattering at 658 nm. 
Fractions of 1 ml of the eluate were collected between 12.5 and 27 min. EV-containing fractions 
were assessed regarding particle-size and –concentration by NTA and enzyme activity was 
measured using the β-glucuronidase assay and compared to unstored samples that were 
treated in the same way. 
3.7.4. Long-term storage of optimized RO-EV-formulations 
The parameters for EV-lyophilisation were optimized in cooperation with the group of Prof. 
Wolfgang Frieß, LMU Munich.  
After initial freeze-thaw and lyophilisation experiments (Trenkenschuh E., Richter, M. et al. 
(2020). “Formulation development of lyophilized extracellular vesicles with long-term stability”, 
manuscript submitted to Advanced Healthcare Materials), RO-EVs were subjected to long-
term storage in lyophilized form. Eilien Heinrich cultured RO-cells and performed UC. M. 
Richter encapsulated β-glucuronidase in the vesicles, purified them by SEC and assessed 
enzyme activity before and after storage and lyophilisation. E. Trenkenschuh prepared the EV-
formulations from purified EVs, performed lyophilisation and the analysis of the colloidal 
stability of EVs. 
The buffer of purified RO-EVs with encapsulated β-glucuronidase was exchanged with Na- or 
K-phosphate using Slide-A-Lyzer MINI dialysis devices (20K MWCO), samples were filtered 
through a 0.02 µm pore-size filter and four formulations were prepared: 
1. 10 mM Na-phosphate with 5% sucrose and 0.02% poloxamer-188 (P188) 
2. 10 mM K-phosphate with 5% sucrose and 0.02% P188 
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3. 10 mM Na-phosphate with 5% sucrose and 0.02% polyvinylpyrrolidone (PVP) 
4. 10 mM Na-phosphate with 5% PVP and 0.02% P188 
Samples of 190 µl were lyophilized using a LyoStar TM 3 pilot-scale freeze-dryer. Samples 
were frozen at -50 °C for 2 h, then primary drying was performed at -20 °C and 53 mbar. Final 
drying was carried out at 20 °C and 53 mbar. Samples were stoppered under nitrogen at 600 
mbar. Samples were stored at 2-8, 25 and 40 °C for one month and six months. Enzyme 
activity and colloidal stability of RO-EVs was assessed before lyophilisation, directly after 
lyophilisation, after one month and after six months.  
Colloidal stability was measured using tunable resistive pulse sensing. EV-recovery was 
assessed using a NP100 nanopore with a measurement size-range of 50-330 nm. Formation 
of larger aggregates was assessed using a NP600 nanopore with a measurement size-range 
of 275-1570 nm. 
For the measurement of enzyme activity potentially leaked enzyme was removed by SEC. 
SEC was performed using a 10 ml volume, 1.0 cm diameter Sepharose Cl-2b column with 10 
mM Na-Phosphate as the mobile phase, to match the osmolarity of the buffer of the EV-
samples. Fractions of 0.5 ml were collected. Vesicle-containing fractions were assessed using 
the β-glucuronidase assay. 
3.8. Plotting of data and statistical analysis 
All data is plotted as mean ± SD if not explicitly stated otherwise. The number of independent 
experiments is stated in the text. Statistical analysis was performed using Sigmaplot 14.0. 
Pairwise comparison of samples was performed using one-way analysis of variance (ANOVA) 
followed by a Tukey post hoc test. Differences between samples were considered significant 
at p ≤ 0.05. In graphs, symbols above bars indicate that the respective sample shows 
significant difference to all other samples bearing the same symbol. Groups of samples that 
share a significant difference with another sample or group of samples are indicated by a 





4.1. Characterization of SBCy050 bacteria and OMVs 
 
 
Figure 26: Panels A-C show light microscopy pictures of SBCy050 bacteria after 96 h in culture. 
Aggregates as seen in B started to appear when the bacteria were close to reaching the 
stationary phase. As visible in the growth curve (D), SBCy050 reached the stationary after 
approx. 72 h (mean values of n=3 cultures). Black bars represent 20 µm. 
The growth of SBCy050 bacteria was assessed by measuring OD600. It was determined that 
the stationary phase was reached after approx. 72 h (Figure 26 D). OMVs were harvested after 
96 h. Comparing the OD600 at isolation over the course of one year a mean OD600 of 1.33±0.12 
was reached by the bacteria (n=30). Under the microscope, SBCy050 bacteria were rod-
shaped and started to form small aggregates once they approached the stationary phase 
(Figure 26 A&C). After 72-96 hours of culture, red clumps started to appear on the sides of the 





Figure 27: Representative chromatogram of the purification of a SBCy050 pellet using the 
ÄKTA instrument. OMVs eluted in the first larger peak after around 18 to 20 ml, while soluble 
impurities and proteins aggregates eluted later around 45 ml. Both peaks were well separated. 
After UC, the OMV-pellet appeared dark red. Pellets after UC and OMVs purified by SEC were 
analyzed by cryo TEM. While the pellet (Figure 28 C) showed more vesicular structures, a lot 
of non-vesicular material was visible, which was not the case for purified OMVs (Figure 28 D). 
The removal of soluble impurities was also well visible in the UV-chromatogram of OMVs 
purified by SEC (Figure 27). OMVs eluted after around 20 ml, while the elution of soluble 
impurities started at approx. 32 ml. NTA-analysis of purified OMVs showed a reproducible 
mean size of around 100 nm (Figure 29). OMVs further showed a characteristic 




Figure 28: SBCy050 OMVs showed a characteristic autofluorescence. Excitation (A) and 
emission scans (B) revealed an optimal excitation wavelength of 410 nm with an emission 
maximum at 629 nm. Panels C and D show cryo TEM pictures of the SBCy050 pellet after UC 
and purified OMVs after an additional step of SEC. While in the pellet (C) more vesicular 
structures were visible, it also contained much more non-vesicular material than SEC-purified 
samples (D). 
4.1.1. Optimization of OMV-purification 
600 ml of SBCy050 cultures were pooled and processed by either two-time centrifugation or 
filtration. After UC and SEC of the samples, the particle-yield, the size-distribution and the 
protein-content per particle were compared. Filtration using the Merck Steritop filter system led 
to particle-recovery of 114.1±5.6% (n=3), while the protein content per particle was 96.8% of 
the filtered OMVs (n=2). The size distributions of the obtained vesicles were very similar 
(Figure 29). Subsequently the Merck Steritop filter was compared with another model produced 
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by Neolab with the same membrane material and pore size. Using the Neolab filter, the particle 
yield was reduced to 33.4% (n=2). Thus, filtration using the Steritop 0.45 µm pore size filter 
subsequently replaced the second centrifugation step in OMV-isolation. 
 
Figure 29: Size distribution after UC and SEC-purification of SBCy050 OMVs, where the 
bacterial cultures were processed by either two-time centrifugation (black) or centrifugation 
and filtration through a Steritop 0.45 µm filter (red) (mean values from n=3). 
4.2. Cholesterol insertion 
SBCy050 OMVs, liposomes and A549 EVs were subjected to cholesterol insertion (for 
characterization of A549 cells and EVs and liposomes see Supp. figure 1 & Supp. figure 2). 
To this end, the particle concentration of the purified vesicles or diluted liposomes was first 
measured, then they were incubated with 1000 cholesteryl-PEG200-FITC molecules per 
particle. For OMVs and liposomes, also the addition of 0.1 mg/ml saponin during incubation 
was tested. After purification the particle concentration and fluorescence intensity were 
measured (Figure 30). On average 100.9±22.9 molecules inserted into liposomes and 
114.5±69.8 molecules inserted into A549 EVs. Only 4.3±1.4 molecules inserted into SBCy050 
OMVs. The addition of 0.1 mg/ml saponin during incubation decreased the insertion into 
liposomes to 48.7±17.3, while increasing the insertion into OMVs to 7.6±8.1 molecules per 
particle (all cholesterol insertion experiments were performed as n=3). The results described 
here were obtained using the first, less sensitive nanosight setup, thus they can only be directly 





Figure 30: Inserted cholesteryl-PEG2000-FITC molecules per particle for SBCy050 OMVs, 
liposomes and A549 OMVs. Black bars represent samples modified by 1 h incubation at 30 °C 
(performed for all three), grey bars represent samples modified by 10 min incubation with 0.1 
mg/ml saponin (performed for OMVs and liposomes). 30 °C 1 h: SBCy050 OMVs were 
significantly different from A549 EVs (p=0.044); Saponin incubation: SBCy050 OMVs were 
significantly different from Liposomes (p=0.020). 
4.3. OMV surface-modification with activated esters 
Purified SBCy050 OMVs were modified with different concentrations of sulfo-cyanine 7 NHS 
ester (Figure 31). With the addition of 9.80 µM of the NHS ester, 571.7±151.7 dye molecules 
per particle were found on the OMVs (n=9). 546.8±163.1 dye molecules per particle were found 
for 4.90 µM (n=8), 470.3±135.9 for 2.45 µM (n=3) and 196.4±35.8 for 0.98 µM (n=3). The 
negative control containing 9.80 µM of sulfo-cyanine 7 carboxylic acid led to the recovery of 
17.8±0.8 dye molecules per particle (n=3). The results described here were obtained using the 
first, less sensitive nanosight setup, thus they can only be directly compared to the results 




Figure 31: Dye molecules per particle for SBCy050 OMVs modified with differing 
concentrations of sulfo-cyanine 7 NHS ester, compared to the negative control treated with 
sulfo-cyanine 7 carboxylic acid (9.8 µM free acid). 9.8 µM and 4.9 µM were significantly 
different from 0.98 µM and 9.8 µM free acid (p≤0.010); 2.45 µM was significantly different from 
9.8 µM free acid (p=0.006). 
4.4. EV surface-modification by diazotransfer 
4.4.1. Preliminary experiments 
In preliminary experiments the conditions for aqueous diazotransfer described by van Dongen 
and coworkers were tested with SBCy050 OMV pellets (371). SBCy050 pellets were incubated 
with 0.588 mg/ml K2CO3 and 0.073 mg/ml CuSO4 for 20 h. After incubation and purification 
82.4% of particles were recovered compared to untreated controls (n=2). Microscopic 
assessment of treated samples revealed the formation of aggregates that were not present in 
control samples (Figure 32 A&B). Subsequently, it was assessed whether aggregates were 
caused by soluble proteins in the pellet or magnesium and calcium ions carried over from the 
2SWC medium. Thus, either 150 µg/ml BSA, a solution of 0.125 mg/ml CaCl2 and 0.25 mg/ml 
MgSO4 or a combination of BSA, CaCl2 and MgSO4 were incubated for 20 h with either K2CO3 
and CuSO4 or the same amount of water. While all negative controls did not contain any 
aggregates, all samples containing K2CO3 and CuSO4 contained small but morphologically 
similar aggregates to the SBCy050 pellet (Figure 32 C-E). After replacement of K2CO3 with 






Figure 32: Light microscopy pictures of the untreated SBCy050 pellet (A) and  the mixture of 
pellet, K2CO3 and CuSO4 (B). The aggregates found in B were compared to aggregates 
formed in samples containing K2CO3, CuSO4 and either BSA (C) or CaCl2 and MgSO4 (D) or 
BSA, CaCl2 and MgSO4 (E). White arrows point at aggregates of similar morphology, black bar 
represent 20 µM. 
4.4.2. Synthesis of ISA HCl 
The synthesis was carried out as planned until the ultimate step of ISA-precipitation. With part 
of the solution precipitation as ISA hydrogen sulfate was attempted according to Potter et al. 
(379), however, no precipitation was observed. Thus, the remaining solution was precipitated 
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using 4 M HCl in dioxane and ISA HCl was successfully isolated as clear crystals. In total, 355 
mg of ISA HCl were obtained (22.0%). The identity of ISA was confirmed by NMR and FTIR. 
FTIR revealed a characteristic band for azide at 2125 cm-1. 1H NMR (500 MHz, D2O): 9.17 (s, 
1H), 8.06 – 7.92 (m, 1H), 7.57 – 7.51 (m, 1H).  
4.4.3. Diazotransfer optimization 
Different diazotransfer conditions were evaluated using DBCO AF594 to assess the amount 
of introduced azide groups. The suitability of DBCO AF594 was tested by injecting the dye 
dissolved in PBS at 4.9 µM onto the SEC column. No elution of the dye in the fractions usually 
containing OMVs was measured (Supp. figure 3 A&B). To allow the determination of reacted 
dye molecules per particle, a calibration curve of DBCO AF594 was created (Supp. figure 4 
A).  
Preliminary experiments showed an increase in dye-molecules per particle of 140% for 
increasing the pH from 7.3 to 9.4 (n=3-4) and an increase of 28% for reducing incubation time 
from 20 h to 4 h (n=2-4). Thus, the effect of pH and incubation time on modification efficiency 
and OMV stability were systematically evaluated with 30 min incubation time and varying pH 
and pH 9.5 and varying incubation times respectively. 
 
Figure 33: SBCy050 pellets were subjected to diazotransfer for 30 min at different pH values. 
The modification efficiency was plotted relative to pH9.5 (A) and OMV-stability was evaluated 
by NTA and ÄKTA AUC and compared to untreated control OMVs (B). A: pH 7.5 was 
significantly different from pH 11.0 (p<0.001); B: NTA RR: pH 7.5 was significantly different 
from pH 11.0 (p=0.027); ÄKTA RR: pH 7.5 was significantly different from pH 11.0 (p=0.016). 
Increasing of the incubation pH led to a higher modification efficiency (Figure 33). Compared 
to pH 9.5 (n=4) only 25.7±3.2% of the surface modification was reached at pH 7.5 (n=3), while 
the modification efficiency was increased to 204.0±46.6% at pH 11.0 (n=3). Regarding OMV 
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stability, increasing the pH led to a decrease in recovery rates compared to untreated OMVs. 
At pH 7.5 97.4±11.9% of particles and 100.1±15.5% of the ÄKTA AUC were recovered (n=3). 
This decreased to 86.7±7.7% particle and 79.8±5.7% AUC recovery at pH 9.5 (n=4) and 
71.8±7.8% particle and 65.1±4.4% AUC recovery at pH 11 (n=3). 
 
Figure 34: Representative frames from NTA-videos of SBCy050 OMVs treated with 
diazotransfer at pH 7.5 (A) or pH 9.5 (B) followed by SPAAC with DBCO AF594. Samples were 
measured in the fluorescence mode of the NTA instrument. 
Differences in modification efficiency were also qualitatively visible in the fluorescence mode 
of the NTA. Figure 34 shows the comparison between representative frames taken from videos 
captured of diazotransfer followed by SPAAC at either pH 7.5 (A) or pH 9.5 (B). To increase 
visibility, these measurements were taken using the highest camera level. Injection of the pure 
AF594 dye dissolved in PBS did not show particles (data not shown). 
 
Figure 35: SBCy050 pellets were subjected to diazotransfer at pH 9.5 with differing incubation 
times. The modification efficiency was compared for 30 min, 2 h and 20 h incubation (A). OMV-
stability was evaluated by NTA and ÄKTA AUC relative to untreated control OMVs (B). 
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Decreasing the incubation time from 20 h to 2 h and to 30 min did not lead to a decrease in 
modification efficiency and slightly increased recovery rates (Figure 35). At 30 min incubation 
time 129.2±50.6 dye molecules per particle reacted with OMVs (n=5), 2 h incubation resulted 
in 134.1±44.2 dye molecules per particle (n=3) and 20 h incubation led to 109.6±13.8 dye 
molecules per particle (n=3). With 30 min incubation, 99.1±15.1% of particles and 85.3±5.0% 
of the ÄKTA AUC were recovered compared to untreated control OMVs (n=6). These values 
decreased to 81.8±11.6% particle and 79.3±3.8% AUC recovery with 2 h incubation time (n=3) 
and 95.4±24.4% particle and 74.5±4.7% AUC recovery with 20 h incubation time (n=3). 
 
Figure 36: The autofluorescence of SBCy050 OMVs modified by diazotransfer at pH 9.5 for 30 
min and purified by SEC was compared to purified untreated control OMVs. Diazotransfer was 
significantly different from Control (p=0.025). 
The effect of diazotransfer conditions was further evaluated by comparing the 
autofluorescence of OMVs subjected to diazotransfer for 30 min at pH 9.5 with untreated 





Figure 37: Unspecific binding of DBCO AF594 (SPAAC) and Alkyne AF594 (CuAAC) to control 
OMVs (grey bars) compared to the reaction with AzideOMVs (black bars). Respective control 
values were significantly different from AzideOMV samples (p≤0.003). 
To rule out that the observed bound dye per particle was solely or to a large degree caused 
by unspecific interaction of the dye with the vesicles, the labeling of untreated OMVs was 
compared to azide OMVs (Figure 37). For DBCO AF594 an unspecific labeling of 12.2±4.5 
molecules per particle was found (n=3), compared to 84.7±27.4 molecules per particle for 
AzideOMVs (n=5). 
As copper has cytotoxic effects and its divalent cations might be able to intercalate into the 
LPS of OMVs, the copper-content of OMVs subjected to diazotransfer was measured. OMVs 
subjected to diazotransfer for 30 min at pH 9.5, untreated OMVs and a control containing SEC 
fractions obtained from the injection of pure PBS were treated with 0.3% triton X, then filtered 
through a 0.2 µM filter and the copper content was measured by ICP-MS. The treated sample 
contained 6.2 ng/ml copper, untreated OMVs contained 3.5 ng/ml and the PBS control 




Figure 38: Comparison of the modification efficiency of diazotransfer performed using fresh 
ISA solution or ISA solution stored at -80 °C for up to 3 months. 
Finally, the difference between freshly prepared aqueous solutions of ISA and aliquots that 
were prepared in advance and stored at -80 °C for up to 3 months was evaluated (Figure 38). 
Fresh ISA solutions led to 123.8±30.1 dye molecules per particle, while frozen ISA aliquots led 
to 133.0± 22.2 dye molecules per particle, no significant difference was found between both 
groups (n=6). 
4.4.4. Comparison of modification with activated ester and 
diazotransfer 
The modification efficiency achieved by diazotransfer and SPAAC was directly compared with 
surface modification with sulfo-cyanine 7 NHS ester (Figure 39). While treating purified OMVs 
with 4.9 µM sulfo-cyanine 7 NHS ester led to 206.5±20.2 dye molecules per particle, treating 
the pellet directly after UC with 4.9 µM sulfo-cyanine 7 NHS ester only led to 40.4±13.3 dye 
molecules per particle. Increasing the sulfo-cyanine 7 NHS ester concentration to 49 µM 
increased the surface modification to 103.2±12.2 dye molecules per particle. Diazotransfer and 
SPAAC led to 142.0±11.2 dye molecules per particle (all experiments n=3). 





























Figure 39: Modification efficiency for the SBCy050 pellet modified with either 4.9 or 49 µM 
sulfo-cyanine 7 NHS ester, purified OMVs modified with 4.9 µM sulfo-cyanine 7 NHS ester or 
OMVs treated with diazotransfer and modified by SPAAC. All values showed statistically 
significant differences from all other values (p≤0.003). 
4.5. Introduction of targeting moieties by SPAAC 
4.5.1. Synthesis of methyltetrazine vancomycin 
The synthesis of methyltetrazine vancomycin was carried out as described in 3.6.6.2. The 
reaction yielded 2.96 mg of a deeply magenta colored solid (7.0%). During prepHPLC, 
methyltetrazine vancomycin eluted between 19.7 and 20.9 min corresponding to a 
concentration of 23-24% ACN. The purified molecule was characterized by LC/MS (Supp. 
figure 6) and HRMS, dissolved in dry DMSO at 2.45 nmol/µl and aliquoted in 1 µl aliquots. 
HRMS (ESI) calculated for C77H84Cl2N13O25 [M+H]+: 1660.5073, found: 1660.5072. 
4.5.2. Synthesis and implementation of the SPAAC-based 
linker 
The synthesis of the SPAAC-based linker was carried out as described in 0. In the crude 
product, there were two major peaks with absorption at 646 nm (Supp. figure 7). The peak at 
3.69 min was identified as the SPAAC-based linker according to the detected masses of 912.0 
and 608.4 m/z that corresponded to the [M+H]2+ and [M+2H]3+ ions respectively (calculated 
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from C104H132N11O18+). The peak at 3.36 min showed masses of  818.3 and 546.2 m/z 
corresponding to the [M+H]2+ and [M+2H]3+ ions of the putative degradation-product without 
the DBCO-group (calculated from C89H122N10O19+) (Figure 40). 
 
 
Figure 40: Structure of the SPAAC-based linker and the putative degradation-product lacking 
the DBCO-group. 
The crude mixture was purified by prepHPLC. The SPAAC-based linker eluted between 32 
and 34 min corresponding to a concentration of 62-66% ACN. Analysis of the prepHPLC-
fractions indicated the presence of this side product in all fractions that contained the linker 
molecule. Thus, the fractions with the highest ratio of SPAAC-based linker to side-product were 
collected and lyophilized. A yield of 0.31 mg (7.7%) of the SPAAC-based linker was obtained, 
LC/MS-analysis however indicated the presence of the beforehand identified side-product in a 
higher ratio than suggested by the prepHPLC-fractions. To assess the effect LC/MS-analysis 
had on the molecule, the duration of the LC/MS method was increased to 25 min with 
proportional adjustment of the solvent-gradient (Supp. figure 8). The longer method led to an 
increase of the peak-area of the degradation product and the ratio of SPAAC-based linker to 
degradation product decreased from 0.84 to 0.30. The purified compound was dissolved in at 
2.45 nmol/µl and aliquoted in 1 µl aliquots. The SPAAC-based linker was characterized by 




Figure 41: Elution profile of the SPAAC-based linker either dissolved in PBS (black) or mixed 
with AzideOMVs (red) or control OMVs (green) and incubated for 20 h. The y-axis displays the 
fluorescence of cyanine 5. 
The pure linker molecule was mixed with a final concentration of 4.9 µM with 500 µl of either 
PBS, AzideOMVs or untreated ctrl OMVs and after 20 h incubation samples were subjected to 
SEC-purification. As Figure 41 shows, there was a high elution of free linker at the same time 
as OMVs eluted, thus affecting the determination of bound molecules per particle. 
The linker molecule was reacted with methyltetrazine-vancomycin by mixing of one aliquot 
linker and one aliquot of methyltetrazine vancomycin as described in 3.6.6.3. LC-MS indicated 
that both the SPAAC-based linker as well as the side-product reacted with methyltetrazine 
vancomycin and formed two products with 3454.47 da ([M+3H]4+ ion identified at 861.3 m/z, 
calculated from: C181H215Cl2N22O43+) and 3267.39 da ([M+3H]4+ ion identified at 817.8 m/z, 
calculated from: C166H206Cl2N21O44+) (Supp. figure 9 & Supp. figure 10). The UV absorption at 
649 nm indicated the formation of three peaks per compound with the same mass that were 
not differentiated in the mass-chromatogram. The IEDDA-product of the linker was confirmed 




Figure 42: Elution profile of the conjugate of the SPAAC-based linker with methyltetrazine-
vancomycin dissolved in PBS. The y-axis displays the fluorescence of cyanine 5. 
The effect of the conjugation of vancomycin was tested by dissolving the conjugate at 4.9 µM 
in PBS and subjecting it to SEC. As Figure 42 shows, there was again an early elution of the 
linker, indicating its insufficient solubility. Thus, it was decided to develop a new linker molecule 
based on CuAAC. 
4.6. CuAAC with SBCy050 OMVs 
To allow the determination of reacted dye molecules per particle, a calibration curve of alkyne 
AF594 was created (Supp. figure 4 B).  
In preliminary experiments, CuAAC was performed according to the protocol of Hong et al. by 
first mixing CuSO4 with THPTA (340). This was added to a mixture of alkyne AF594 and 
AzideOMVs and the CuAAC reaction was initiated by addition of sodium ascorbate (340). 
Using 4.9 µM of alkyne AF594, 11.5% of the modification efficiency of SPAAC with 4.9 µM 
DBCO AF594 was reached (n=2). Increasing the alkyne Af594 concentration to 19.6 µM 
increased the modification efficiency to 32.4% (n=2). 
In following experiments 19.6 µM of alkyne were used and the protocol was changed to the 
protocol described in 3.6.7. The suitability of alkyne AF594 for SEC-purification at this 
concentration was tested by injecting the dye dissolved in PBS at 19.6 µM to the SEC column. 
No elution of the dye in the fractions usually containing OMVs was measured (Supp. figure 3 
C&D). Cu(I) ions were generated by mixing of CuSO4 and sodium ascorbate. This solution 
was added to the mixture of THPTA and alkyne AF594. The resulting mixture was added to 
AzideOMVs. Different conditions for CuAAC were tested and compared to SPAAC (Figure 43). 
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Sodium ascorbate was either dissolved in water or in 40 mg/ml NaOH. In the latter case the 
incubation time was either 2 h or 4 h. SPAAC led to 84.7±27.4 dye molecules per particle 
(n=5), 2 h incubation with addition of NaOH to 60.1±13.2 (n=3), 4 h incubation with addition of 
NaOH to 77.9±20.1 (n=5) and 4 h incubation without NaOH to 41.1±4.9 (n=4). Compared to 
SPAAC, CuAAC for 2 h with the addition of NaOH led to a particle recovery of 92.8±19.0% 
(n=3) and an AUC of 98.4% (n=2), 4 h incubation with NaOH-addition led to a particle recovery 
of 79.1±12.3% (n=4) and an AUC of 90.8±5.1% (n=3). 4 h incubation without the addition of 
NaOH led to the recovery to 95.4±4.0% of particles (n=4) and an AUC of 99.9±10.9% (n=3). 
Following these results, CuAAC was performed with 4 h incubation and sodium ascorbate 
dissolved in 40 mg/ml NaOH. 
 
Figure 43: Evaluation of CuAAC-modification of SBCy050 OMVs. In panel A, the modification 
efficiency of CuAAC performed with ascorbic acid dissolved in 40 mg/ml NaOH (either 2 h or 
4 h CuAAC-reaction time) or dissolved in water was compared with SPAAC. In Panel B, the 
OMV-stability during CuAAC was evaluated relative to SPAAC. A: No NaOH was significantly 
different from SPAAC (p=0.026). 
The copper-content after SEC of OMVs subjected to CuAAC was assessed by ICP-MS. OMVs 
subjected to CuAAC, untreated OMVs and a control containing SEC fractions obtained from 
the injection of pure PBS were treated with 0.3% triton X, then filtered through a 0.2 µM filter 
and the copper content was measured. The treated sample contained 1.6 ng/ml copper, 
untreated OMVs contained 3.6 ng/ml and the PBS control contained 1.9 ng/ml. For the 
calibration curve of the measurement, see Supp. figure 5. 
The effect of CuAAC on the autofluorescence of SBCy050 OMVs was evaluated by comparing 
SPAAC to CuAAC with the respective AF594 derivative. CuAAC led to the reduction of the 
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autofluorescence to 7.8±3.5% of the fluorescence intensity measured for OMVs treated with 
SPAAC (n=4). Omitting NaOH, as it was later tried for the modification with the IEDDA-product 
of the PEG6-linker and methyltetrazine-vancomycin, approximately doubled the remaining 
fluorescence after CuAAC compared to the standard protocol (increase by a factor of 1.9±0.6, 
n=3). 
The unspecific labeling of untreated control OMVs was evaluated in the same manner as for 
DBCO AF594 (see 4.4.3). An unspecific labeling of control OMVs with 5.3±2.8 molecules per 
particle was measured (n=3), compared to 77.9±20.1 molecules per particle for AzideOMVs 
treated in the same way (n=5) (Figure 37). 
4.6.1. Synthesis and testing of the PEG8-linker for CuAAC 
The synthesis of the PEG8-linker was carried out according to 0. The Boc-protected 
intermediate was obtained by prepHPLC with a yield of 120.8 mg (89.8%), it eluted between 
18.0 and 20.8 min corresponding to a concentration of 63-73% ACN. Its purity was confirmed 
by LC/MS (Supp. figure 11) and the molecule was characterized by NMR. 1H NMR (500 MHz, 
DMSO-d6): 5.72-5.51 (m, 1H), 5.45-5.36 (m, 1H), 4.17 (dd, J=11.73, 5.53, 1H), 4.05 (dt, 
J=12.49, 5.62, 2H), 3.49-3.44 (m, 28H), 3.41-3.32 (m, 6H), 3.26-3.11 (m, 3H), 3.11-3.01 (m, 
2H), 2.77 (t, J=2.25, 1H), 2.48 (dd, J=5.31, 2.54, 1H), 2.38 (ddd, 16.79, 8.46, 2.5, 1H), 2.31-
2.16 (m, 3H), 1.92-1.82 (m, 3H), 1.65-1.40 (m, 5H), 1.36 (s, 12H) (Supp. figure 12). 13C NMR 
(126 MHz DMSO-d6): 170.8, 156.3, 156.3, 155.5, 135.3, 132.9, 130.0, 129.9, 81.1, 79.6, 78.9, 
74.9, 73.1, 70.1, 70.0, 69.9, 69.8, 69.4, 69.1, 53.4, 41.0, 40.3, 38.5, 34.1, 34.0, 32.5, 30.9, 
28.4, 25.5, 24.9, 22.3, 22.2 (Supp. figure 13). 
Some problems were encountered during Boc-deprotection. While in the test-experiment for 
the Boc-deprotection only a small amount of a side-product was generated, the deprotection 
of the main amount of the Boc-protected intermediate led to the generation of significant 
amounts of a side-product (Supp. figure 14 & Supp. figure 15). In LC/MS-analysis a molecule 
with a mass of 254.9 eluting at 1.36 min was detected, corresponding with the [M+2H]2+ ion of 
the putative byproduct 1 lacking the TCO group (calculated from C23H45N3O9) (Figure 44 A). 
The side product however was only identified later and it was not removed from the 
deprotected intermediate before the next reaction step. 
According to 0, 26 mg of the deprotected intermediate were reacted with 25 mg of sulfo-
cyanine 5 NHS ester and LC/MS analysis of the crude product of the reaction with sulfo cyanine 
5 NHS ester revealed the presence of multiple compounds with absorbance at 646 nm (Supp. 
figure 16 & Supp. figure 17). The compound eluting at 2.84 min was identified as the PEG8-
linker with a mass of 640.9 corresponding to its [M+ACN-2H]2- ion (calculated from 
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C62H89N5O17S2). The compound eluting at 2.13 min showed a mass of 564.7 corresponding to 
the [M-2H]2- ion of putative byproduct 2.1 (calculated from C55H81N5O16S2), the compound 
eluting at 2.49 min showed a mass of 877.0, corresponding to the [M-2H]2- ion of putative 
byproduct 2.2 (calculated from C87H117N7O23S4) (Figure 44 B). 
The crude product was purified by prepHPLC and eluted between 15 and 19.2 min 
corresponding to a concentration of 53-68% ACN. Lyophilisation yielded 11.5 mg (26.8%) of a 
dark blue powder, part of which was dissolved in dry DMSO at 9.78 nmol/µl and aliquoted in 
1 µl aliquots. The purified product was characterized by HRMS and NMR and its purity 
confirmed by LC/MS (Supp. figure 18) The HRMS-measurement of the PEG8-linker was 
inconclusive and the compound could not be identified. 1H NMR (500 MHz, DMSO-d6): 8.36 (t, 
J=13.06, 2H), 8.09-8.03 (m, 2H), 7.81 (s, 2H), 7.63 (ddd, J=8.16, 5.18, 1.53, 2H), 7.31 (dd, 
J=8.31, 2.60, 2H), 7.04-6.97 (m, 1H), 6.57 (t, J=12.24, 1H), 6.29 (dd, J=24.73, 13.81, 2H), 
5.74-5.53 (m, 2H), 4.62-4.52 (m, 1H), 4.39 (dd, J=14.14, 8.08, 1H), 4.07 (t, J=6.56, 2H), 3.75-
3.63 (m, 4H), 3.63-3.56 (m, 5H), 3.42-3.30 (m, 30H), 3.27-3.13 (m, 3H), 3.12-3.05 (m, 2H), 
2.83 (t, J=2.56, 1H), 2.39 (ddd, J=16.23, 8.00, 2.45, 1H), 2.34-2.23 (m, 1H), 2.21-2.07 (m, 4H), 
2.07-1.93 (m, 2H), 1.91-1.73 (m, 3H), 1.69 (s, 12H), 1.64-1.40 (m, 7H), 1.39-1.28 (m, 3H), 
1.28-1.19 (m, 5H), 0.90-0.78 (m, 1H) (Supp. figure 19). 13C NMR (126 MHz DMSO-d6): 173.6, 
172.8, 172.0, 170.0, 154.2, 145.3, 145.2, 142.7, 142.0, 140.5, 140.4, 129.6, 129.5, 126.0, 
126.0, 125.9, 125.63, 119.95, 119.9, 110.1, 110.0, 103.6, 103.3, 101.3, 94.7, 80.7, 74.4, 73.5, 
72.8, 72.3, 70.5, 69.8, 69.6, 69.5, 69.1, 68.8, 66.3, 65.6, 60.2, 51.3, 48.9, 43.6, 43.4, 38.6, 
34.8, 33.8, 33.7, 31.2, 29.0, 28.7, 27.1, 26.9, 26.6, 25.6, 25.1, 24.8, 24.6, 22.1, 22.0, 21.9, 





Figure 44: A shows the deprotected intermediate of the PEG8-linker and the putative byproduct 
that lost the TCO-group. B displays the finished PEG8-linker compared to putative byproducts 
that would result from the reaction of sulfo-cyanine 5 NHS ester with putative byproduct 1. 
After the synthesis of the PEG8 CuAAC linker, its solubility was tested by dissolving the linker 
at 19.6 µM in PBS and performing an SEC. The solubility of the molecule was deemed 
sufficient as only little early elution of the PEG8-linker was visible (Supp. figure 21 A&B). 
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Next the PEG8-linker was coupled to AzideOMVs by CuAAC. To assess unspecific labeling, 
control OMVs were treated in the same way. AzideOMVs reacted with 356.0 molecules per 
particle, while 47.8 molecules did bind unspecifically in control experiments (n=2) (For the 
calibration curve of the PEG8-linker see Supp. figure 4 C). Due to the inactivity of the PEG8-
linker in IEDDA experiments, no further experiments were conducted. 
 
Figure 45: Zoomed view of the 1H-NMR spectra containing the signals of the protons belonging 
to the alkene-group of cyclooctene. Boc-protected intermediate (A, blue) and the PEG8-linker 
(B, red).  
The PEG8-linker did not show any reactivity towards methyltetrazine-vancomycin, as only the 
educts were visible, even after leaving both compounds to react overnight (Supp. figure 22). 
In comparison, the Boc-protected intermediate clearly showed reactivity towards 
methyltetrazine-vancomycin as indicated by the disappearance of the peak at 2.24 min and 
the emergence of three new peaks at 2.56, 2.80 and 2.85 min (Supp. figure 23). Comparison 
of the region of the respective 1H-NMR spectra containing the two alkene-protons revealed a 
change in the spectra that might coincide with the inactivation of the TCO-group (Figure 45). 
Due to these results, it was decided to change the protection group of the amine and employ 
Fmoc propargyl glycine in the next synthesis attempt. 
4.6.2. Synthesis of the PEG6-linker for CuAAC 
The synthesis of the PEG6-linker was carried out according to 3.6.7.2. Complete conversion of 
the starting material to the Fmoc-protected intermediate and its purification were confirmed by 
LC/MS (Supp. figure 24) and the molecule was characterized by HRMS and NMR. During 
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prepHPLC-purification, the Fmoc-protected intermediate eluted between 22.1 and 23.9 min 
corresponding with a concentration of 78-84% ACN. The yield was 62.7 mg (75.3%). HRMS 
(ESI): Calculated for C43H60N3O11 [M+H]+: 794.4223, found: 794.4219. 1H NMR (700 MHz, 
CDCl3): 7.75 (d, J=7.56, 2H), 7.58 (d, J=7.07, 2H), 7.38 (t, J=7.46, 2H), 7.30 (dt, J=7.42, 0.91, 
2H), 6.86 (br, 1H), 5.82 (br, 1H), 5.62-5.51 (m, 1H), 5.50-5.44 (m, 1H), 5.14 (br, 1H), 4.43 (dd, 
J=10.65, 7.07, 1H), 4.38-4.28 (m, 3H), 4.21 (t, J=7.00, 1H), 3.65-3.53 (m, 20H), 3.52-3.44 (m, 
5H), 3.31 (s, 2H), 2.76 (d, J=15.06, 1H), 2.62 (dd, J=16.11, 4.97, 1H), 2.36-2.26 (m, 3H), 2.15 
(t, J=2.52, 1H), 1.99 (d, J=12.21, 1H), 1.94-1.85 (m, 5H), 1.77-1.66 (m, 2H), 1.55-1.47 (m, 1H) 
(Supp. figure 25). 13C NMR (176 MHz CDCl3): 169.7, 156.3, 155.8, 143.8, 141.3, 134.9, 133.0, 
127.8, 127.1, 125.1, 125.1, 120.03, 80.50, 79.4, 77.2, 77.0, 76.9, 72.0, 70.5, 70.4, 70.2, 70.2, 
69.7, 67.11, 53.37, 47.1, 41.2, 40.7, 39.6, 38.7, 34.3, 32.5, 31.0, 23.0 (Supp. figure 26). 
Fmoc-deprotection and purification of the deprotected intermediate was carried out according 
to plan and complete deprotection and purification by prepHPLC were confirmed by LC/MS 
(Supp. figure 27). The molecule was further characterized by HRMS and NMR. During 
prepHPLC-purification, the deprotected intermediate eluted between 18.8 and 23.3 min 
corresponding with a concentration of 28-35% ACN. The yield was 20.3 mg (48.8%). HRMS 
(ESI): Calculated for C28H50N3O9 [M+H]+: 572.3520, found: 572.3534. 1H NMR (500 MHz, 
CDCl3): 7.65 (br, 1H), 5.73-5.43 (m, 2H), 5.18 (br, 1H), 4.31 (dd, J=10.1, 6.0, 1H), 3.67-3.57 
(m, 20H), 3.56-3.40 (m, 7H), 3.32 (t, J=4.96, 2H). 2.72 (ddd, J=16.86, 4.47, 2.67, 1H), 2.53 
(ddd, J=16.86, 7.86, 2.60, 1H), 2.38-2.25 (m, 2H), 2.18-2.06 (m, 1H), 2.05 (t, J=2.60, 1H), 1.99 
(d, J=11.82, 1H), 1.95-1.85 (m, 2H), 1.83-1.65 (m, 6H), 1.61-1.46 (m, 2H) (Supp. figure 28). 
13C NMR (126 MHz CDCl3): 173.0, 134.9, 133.0, 129.8, 129.7, 80.7, 80.5, 71.1, 70.6, 70.54, 
70.52, 70.4, 70.3, 70.2, 69.9, 53.8, 41.2, 40.7, 39.0, 38.7, 34.3, 34.1, 32.6, 31.0, 25.6, 25.3, 
24.8, 22.4 (Supp. figure 29). 
The deprotected intermediate was reacted with sulfo-cyanine 5 NHS ester. LC/MS-analysis of 
the crude product revealed that the obtained PEG6-linker consisted of two molecules with the 
same signal at 597.0 m/z (corresponding to the [M-2H]2- ion of the PEG6-linker, calculated from 
C60H83N5O16S2) but slightly different retention times as indicated by the UV-absorption at 254 
nm (Supp. figure 31). Reacting a prepHPLC-fraction from a test-purification that contained both 
compounds with methyltetrazine vancomycin revealed that the peak at 2.77 min preferably 
reacted, while the second peak at 2.79 min remained (Supp. figure 32). The prepHPLC-method 
was thus designed to separate both peaks and they were collected separately. The active 
linker eluted between 34.5 and 36.5 min corresponding to 38-40% ACN. The inactive linker 
eluted directly afterwards without a clean separation of both peaks. LC/MS-analysis confirmed 
the purity of the collected fractions containing the active PEG6-linker (Supp. figure 33). 
However, after lyophilisation, a new peak appeared at 2.09 min and the PEG6-linker peak 
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showed a shoulder (Supp. figure 34). HRMS analysis of the PEG6-linker was inconclusive with 
the appearance of multiple unidentified peaks and low detection of the mass corresponding to 
the linker molecule. In LC/MS the peak of the PEG6-linker showed a signal at 597.0 m/z 
corresponding to the [M-2H]2- ion (Calculated from C60H83N5O16S2). The yield of the active 
PEG6-linker was 12.85 mg (32,8%). The PEG6-linker was dissolved in dry DMSO at 9.78 
nmol/µl and aliquoted in 1 µl aliquots. The inactive PEG6-linker isolated from the second peak 
was lyophilized as well and analyzed by LC/MS and NMR. LC/MS revealed that it indeed 
contained material exhibiting the same mass as the active linker (Supp. figure 44), however 
with a slightly later elution. Active PEG6-linker: 1H NMR (500 MHz, DMSO-d6): 8.36 (t, J=13.14, 
2H), 8.07 (d, J=7.20, 2H), 7.82 (s, 2H), 7.63 (dd, J=7.41, 5.61, 2H), 7.31 (dd, J=8.26, 1.71, 
2H), 7.03-6.92 (m, 1H), 6.57 (t, J=12.36, 1H), 6.31 (d, J=13.76, 1H), 6.25 (d, J=13.76, 1H), 
5.63-5.52 (m, 1H), 5.47-5.37 (m, 1H), 4.38 (dd, J=14.07, 7.76, 1H), 4.19 (dd, J=11.48, 5.25, 
1H), 4.07 (t, J=6.88, 2H), 3.59 (s, 3H), 3.49 (s, 21H), 3.39-3.32 (m, 5H), 3.26-3.13 (m, 3H), 
3.12-3.01 (m, 2H), 2.97 (dd, J=10.79, 5.36, 1H), 2.83 (s, 1H), 2.39 (dd, J=16.79, 7.80, 1H). 
2.31-2.18, (m, 2H), 2.17-2.06 (m, 3H), 1.93-1.79 (m, 3H), 1.69 (s, 12H), 1.60-.146 (m, 5H), 
1.40-1.29 (m, 2H), 1.28-1.19 (m, 1H), 0.94-0.80 (m, 1H) (Supp. figure 35). 13C NMR (126 MHz 
DMSO-d6): 173.6, 172.9, 172.0, 170.0, 155.8, 154.2, 145.3, 145.2, 142.7, 142.0, 140.5, 140.4, 
134.9, 132.5, 126.1, 126.0, 125.7, 120.0, 119.9, 110.13, 110.06, 103.6, 103.4, 80.8, 79.1, 72.8, 
69.8, 69.7, 69.66, 69.63, 69.5, 69.2, 68.9, 51.3, 48.9, 40.7, 38.7, 38.2, 34.8, 33.8, 32.2, 30.6, 
27.1, 26.9, 26.6, 25.6, 24.9 (Supp. figure 36). COSY (Supp. figure 37), HSQC (Supp. figure 
38), HMBC (Supp. figure 39).  
Inactive PEG6-linker: 1H NMR (500 MHz, DMSO-d6): 8.36 (t, J=13.11, 2H), 8.09-8.03 (m, 2H), 
7.81 (s, 2H), 7.63 (ddd, J=8.56, 5.30, 1.25, 2H), 7.31 (dd, J=8.28, 2.58, 2H), 7.02-6.92 (m, 1H), 
6.57 (t, J=12.19, 2H), 6.31 (d, J=13.82, 1H), 6.25 (d, 13.82, 1H), 5.69-5.54 (m, 2H), 4.55 (m, 
1H), 4.39 (dd, J=14.24, 8.13, 1H), 4.07 (t, J=6.96, 2H), 3.59 (s, 3H), 3.49 (s, 20H), 3.40-3.24 
(m, 6H), 3.26-3.13 (m, 3H), 3.08 (dd, J=11.79, 5.83, 2H), 2.83 (t, J=2.43, 1H), 2.39 (ddd, 16.68, 
8.05, 2.51, 2H), 2.33-2.22 (m, 2H), 2.17 (s, 1H), 2.16-2.07 (m, 4H), 2.06-1.97 (m, 1H), 1.84-
1.72 (m, 2H), 1.69 (s, 12H), 1.65-1.58 (m, 1H), 1.58-1.51 (m, 3H), 1.51-1.40 (m, 3H), 1.39-1.29 
(m, 3H), 1.28-1.11 (m, 5H), 0.87-0.79 (m, 1H) (Supp. figure 40). 13C NMR (126 MHz DMSO-
d6): 173.6, 172.9, 172.0, 170.0, 155.9, 155.1, 154.2, 145.4, 145.2, 142.7, 142.0, 140.5, 140.4, 
129.8, 129.7, 129.5, 126.1, 126.0, 125.6, 120.0, 119.9, 118.2, 110.1, 110.0, 103.6, 103.4, 80.8, 
74.4, 72.8, 69.8, 69.7, 69.6, 69.5, 69.1, 68.9, 51.3, 48.9, 38.7, 34.8, 33.8, 33.7, 29.2, 27.1, 
26.9, 26.6, 25.6, 25.2, 24.9, 24.6, 22.0, 21.9, 19.5 (Supp. figure 41). COSY (Supp. figure 42), 




Figure 46: Zoomed view of the 1H-NMR spectra containing the signals of the protons belonging 
to the alkene-group of cyclooctene. Active PEG6-linker (A) and inactive PEG6-linker (B).  
Both active and inactive PEG6-linker were analyzed by NMR to evaluate structural differences 
between both compounds. To this end, the region of their respective 1H-NMR spectra relevant 
to the alkene in the TCO-group was compared (Figure 46) and the protons and carbons making 
up their respective cyclooctene rings were assigned using 2D-NMR (Table 2). Both analyses 
revealed differences between the compounds. 
Table 2: Assignment of the protons and carbons belonging to the cyclooctene ring of the active 
and inactive PEG6-linker. 
 
The purified PEG6-linker was reacted with methyltetrazine-vancomycin and methyltetrazine-
PEG4-biotin. LC/MS analysis revealed that the unidentified degradation product did not 
participate in the reaction and some PEG6-linker remained corresponding to the shoulder found 
in the starting material (Supp. figure 45 & Supp. figure 46). The correct mass of the IEDDA 
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product of PEG6-linker and methyltetrazine-vancomycin was found in HRMS. LC/MS revealed 
three peaks at 2.26, 2.48 and 2.52 min that all showed a signal at 943 m/z corresponding with 
the [M+3H]3+ ion of the reaction product (calculated from C137H168Cl2N6O41S2) (Supp. figure 45) 
HRMS (ESI): IEDDA PEG6-linker and methyltetrazine-vancomycin: Calculated for 
C137H169Cl2N6O41S2 [M+H]+: 2828.0444, found: 2828.0442. 
Similar results were obtained for the IEDDA reaction with methyltetrazine-PEG4-biotin. The 
corresponding mass of the product was confirmed by HRMS and again three peaks of the 
product were visible at 2.41, 2.68 and 2.75 min in LC/MS (Supp. figure 47 & Supp. figure 48). 
The latter two co-eluting with unreacted methyltetrazine biotin. HRMS (ESI): IEDDA PEG6-
linker and methyltetrazine-PEG4-biotin: Calculated for C87H125N10O22S3 [M+H]+: 1757.8127, 
found: 1757.8110. 
4.6.3. OMV modification with the PEG6-linker and OMV-
biotinylation 
The solubility of the PEG6-linker was tested as described before by dissolving it at 19.6 µM in 
PBS and injecting it on the SEC column (Supp. figure 21 C&D). While the overall picture was 
the same as for the PEG8-linker, with most of the fluorescence eluting late, the amount of dye 
that eluted at the same time as OMVs would was notably higher than for the PEG6-linker. Thus, 
this early elution of PEG6-linker would need to be taken into consideration for the interpretation 
of surface-modification using this molecule. The product of the IEDDA reaction of the PEG6-
linker with methyltetrazine-PEG4-biotin (biotinlinker) was tested in the same way. Here the 
early elution was in the same range as the PEG8-linker, much lower than for the native PEG6-
linker (Supp. figure 21 E&F). 
AzideOMVs were reacted with either the PEG6-linker or the biotinlinker and the modification 
efficiency was measured. The results were compared to CuAAC and SPAAC using the 
respective AF594 derivatives and the unspecific labeling of the vesicles was assessed using 
untreated control OMVs (Figure 47). Calibration curves both for the PEG6-linker and the 
biotinlinker were constructed (Supp. figure 4 D&E). Modification with the PEG6-linker led to the 
recovery of 269.1±51.4 molecules linked to OMVs (n=6), compared to 46.8±18.7 for the control 
(n=3). Application of the biotinlinker led to 393.3±52.0 molecules per particle (n=3), compared 
to 105.3±9.1 for the control (n=3). CuAAC and SPAAC with AF594 led to 87.4±35.7 and 




Figure 47: Modification efficiency of the modification of AzideOMVs with the PEG6-linker, the 
biotinlinker, alkyne AF594 or DBCO AF594 and unspecific labeling of control OMVs with the 
PEG6-linker or the biotinlinker. Linker was significantly different from biotinlinker and both linker 
and biotinlinker were significantly different from all other samples (p≤0.005). 
The extent of unspecific labeling of OMVs was further evaluated by normalizing the dye 
molecules per particle of control samples to the results of the modification of AzideOMVs under 
the same conditions (Figure 48). The highest unspecific labeling was observed for the 
biotinlinker with 26.8±2.3%. With the PEG6-linker molecule, an unspecific labeling of 
17.4±6.9% was observed. DBCO AF594 led to a similar value of 14.4±5.4%. The lowest 
unspecific labeling was measured for alkyne AF594 at 6.8±3.6% (all experiments n=3). 
 
Figure 48: Comparison of the unspecific labeling of control OMVs with the PEG6-linker, 
biotinlinker, alkyne AF594 or DBCO AF594. Values are relative to the modification efficiency 
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achieved with AzideOMVs with the same compounds. Biotinlinker was significantly different 
from Alkyne AF594 (p=0.005). 
4.6.4. Evaluation of biotinylated OMVs 
The presence of biotin on the surface of OMVs was evaluated using FITC-labeled streptavidin 
(Figure 49). To have a further comparison to OMVs biotinylated with the PEG6-linker, 
AzideOMVs were also biotinylated using SPAAC with the reaction product of TCO-PEG4-
DBCO and methyltetrazine-PEG4-biotin (SPAAC-biotinlinker). Both types of biotinylated OMVs 
showed a clear increase above the negative controls. The SPAAC-biotinlinker however, led to 
by far the highest recovery of streptavidin-FITC in the vesicle-containing fractions and the other 
results were normalized to reduce the variability introduced by differences in vesicle-
concentration between the independent experiments. To confirm that the high degree of 
labeling was not based on insufficient solubility of the SPAAC-biotinlinker, the pure molecule 
at 4.9 µM was subjected to SEC and no early elution of the molecule was visible according to 
the 280 nm UV-cell of the ÄKTA instrument (Supp. figure 49). The control containing only PBS 
led to a recovery of 1.5±2.0%, the control containing untreated OMVs to 3.2±3.9%. Biotinlinker 
OMVs led to a recovery of 25.8±8.0%, while control OMVs incubated with the biotinlinker gave 
a value of 11.7±0.9% and OMVs modified with the PEG6-linker (linker OMVs) gave a value of 
2.4±1.9%. The pure biotinlinker dissolved in PBS at 4.9 nM and the SPAAC-biotinlinker at 4.9 
nM led to values of 3.0±1.4% and 1.9±1.0% respectively (all experiments performed as n=3). 
The IEDDA reaction between TCO-PEG4-DBCO and methyltetrazine-PEG4-biotin was 





Figure 49: Fluorescence of the OMV-containing fractions after labeling with streptavidin-FITC 
and SEC-purification. Values are relative to SPAAC-biotinlinker modified OMVs. The 
“biotinlinker control” refers to untreated OMVs subjected to CuAAC with the biotinlinker. 
Biotinlinker OMVs were significantly different from all other samples (p≤0.002), Biotinlinker 
control was significantly different from PBS control (p=0.029) and pure SPAAC-biotinlinker 
(p=0.039). 
4.6.5. OMV modification with the Vancomycin-linker 
Initial experiments indicated that the vancomycin-linker led to an unspecific labeling of control 
OMVs. This was further evaluated by comparing control OMVs that were either incubated with 
the vancomycin-linker under standard CuAAC conditions, CuAAC conditions, were sodium 
ascorbate was dissolved in water instead of NaOH and control OMVs incubated with just the 
vancomycin-linker and no copper, THPTA and sodium ascorbate (Figure 50). These three 
conditions were compared to controls that were incubated with the unmodified linker or the 
biotinlinker (see 4.6.3). The results indicated a significant increase in fluorescent labeling of 
OMVs in the presence of the excipients used in CuAAC. The controls showed a fluorescence 
intensity of 741.3±314.3 units (n=6). OMVs incubated with the vancomycin-linker showed an 
increase to 11893.0±4207.8 units (n=3). This value decreased to 8186.5±5902.9 units for 
samples incubated without NaOH (n=3) and to 1155.8±118.9 units for samples just incubated 




Figure 50: The unspecific labeling of untreated SBCy050 OMVs with the vancomycinlinker 
under different conditions was compared to the background labeling obtained with the PEG6-
linker or the biotinlinker (control). Control OMVs were subjected to CuAAC with the 
vancomycin-linker either under standard-conditions, without the usage of NaOH to dissolve 
sodium ascorbate, or by simple co-incubation without addition of CuAAC-excipients. Both 
vancomycinlinker and vancomycinlinker no NaOH were significantly different from Control 
(p≤0.026), Vancomycinlinker was significantly different from vancomycinlinker no excipients 
(p=0.007). 
4.7. EV storage-stability evaluation 
4.7.1. Preliminary short-term storage of A549 EVs 
Data presented in this chapter was published as part of Frank, J., et al. (2018). "Extracellular 
vesicles protect glucuronidase model enzymes during freeze-drying." Scientific Reports 8(1): 
12377. 
In a preliminary experiment, EVs derived from A549 cells were stored for 2 d at 4 °C, -80 °C 
or in lyophilized form without the addition of a cryoprotectant (Figure 51). The recovered 
particle number relative to samples before storage showed a slight increase at 4 °C and -80 °C 
to 123.2±38.4% and 108.9±16.0% respectively, while the particle recovery was reduced to 
65.0±12.0% in lyophilized samples. At the same time, the mean particle size of lyophilized EVs 
increased to 259.0±20.9 nm compared to 183.9±26.7 nm for samples before storage. Storage 
at 4 °C and -80 °C did not elicit a change in particle size with mean sizes of 178.6±17.5 nm 
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and 180.2±14.2 nm respectively. These results are also well visible in the particle size-
distribution. While samples before storage and ones stored at 4 or -80 °C show a very similar 
size distribution, the distribution of lyophilized samples is much broader with a shift to higher 
diameters (Figure 51 C, for the full size-distribution see Supp. figure 50 A). 
 
Figure 51: Panel A shows the mean size of A549 EVs stored for 2 d at 4 °C, -80 °C or after 
lyophilisation compared to samples before storage. In panel B, the particle recovery rate of 
samples after storage relative to untreated samples is presented. Panel C contains the size 
distribution of particles in the range from 0 to 300 nm as measured by NTA, mean values from 
three measurements are plotted. A: The mean size of lyophilized A549 EVs was significantly 
higher than both the size of EVs before storage (p=0.009) and the size of EVs stored at 4 




4.7.2. Storage stability of HUVEC-EVs 
Data presented in this chapter was published as part of Frank, J., Richter, M., et al. (2018). 
"Extracellular vesicles protect glucuronidase model enzymes during freeze-drying." Scientific 
Reports 8(1): 12377. Data from the seven day storage experiment was also part of Richter, 
M., et al. (2019). "Evaluation of the Storage Stability of Extracellular Vesicles." JoVE(147): 
e59584. 
HUVEC cells were cultured until passage 9, for pictures of HUVEC cultures, see Supp. figure 
51. In a first evaluation of their storage stability, HUVEC EVs were stored for 14 d at RT, 4 °C, 
-80 °C and in lyophilized form without the addition of a cryoprotectant (Figure 52). The particle 
recovery was assessed compared to the particle concentration before storage. At RT 
78.1±4.4% of particles were recovered, at 4 °C 66.0±13.0%, at -80 °C 51.7±10.4% and after 
lyophilized storage 34.7±8.4% of the starting particles were recovered. The particle size 
increased for all samples during storage. EVs before storage had a mean particle size of 
155.3±9.3 nm. After 14 d at RT the mean size was 171.0±4.8 nm, at 4 °C it was 181.3±4.2 nm, 
at -80 °C it was 193.4±8.5 nm and after lyophilized storage it was 213.5±9.9 (all data n=3). 
These changes were also observed in the size-distribution of EVs before and after storage, 
especially in case of -80 °C and lyophilisation (Figure 52 C, for full size-distribution, see Supp. 




Figure 52: Panel A shows the mean size of HUVEC-EVs after 14 d of storage compared to 
vesicles before storage. Panel B shows the particle recovery rate of stored samples relative to 
the initial concentration. Panel C contains the size distribution of particles in the range from 0 
to 300 nm as measured by NTA, mean values from three independent experiments are plotted. 
A: The mean size of EVs stored at 4 °C, -80 °C and lyophilized was significantly higher than 
before storage (p≤0.014). Both EVs stored at -80 °C and lyophilized were significantly larger 
than EVs stored at RT (p≤0.033). B: RT led to significantly higher recovery than both -80 °C 
and lyophilized storage (p≤0.040). Storage at 4 °C led to a significantly higher recovery rate 
than lyophilized storage (p=0.017). 
Next, the effect of trehalose as a cryoprotectant on the stability of HUVEC EVs was tested. As 
an additional parameter, β-glucuronidase was encapsulated into the vesicles. EVs were 
subjected to 7 d of storage at 4 °C, -80 °C and in lyophilized form with the addition of 4% (w/v) 
trehalose (Figure 53). To make sure that no leaked beta glucuronidase would influence the 
enzyme-activity assessment, samples were subjected to purification by AF4 before the beta 
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glucuronidase assay was performed. At 4 °C there was no reduction in particle concentration 
after storage, with a recovery of 103.3±23.7% of the starting concentration. The recovery rate 
was reduced to 84.9±5.9% at -80 °C and to 57.7±10.2% after lyophilisation. Compared to the 
previous experiment no changes in particle size were visible. Before storage, the mean particle 
size of HUVEC EVs was 152.9±25.4 nm. This changed to 142.9±23.7 nm at 4 °C, 
154.1±22.7 nm at -80 °C and 149.0±26.6 nm after lyophilisation. The small changes in EV-size 
were also observed in the size distributions of fresh and stored EVs, where compared to 14 d 
of storage only small changes were visible (Figure 54, for full size distribution see Supp. figure 
50). The recovery of active beta glucuronidase per particle was the highest in lyophilized 
samples at 58.5±36.8% of the starting material. In samples stored at 4 °C recovery was 




Figure 53: Panel A shows the mean size of HUVEC EVs after 7 d of storage compared to EVs 
before storage. Panel B shows the particle recovery rate of stored samples relative to the initial 
concentration. In panel C the enzyme activity per particle, normalized to samples before 
storage is displayed. B: The particle recovery rate for 4 °C was significantly higher than for 
lyophilized storage (p=0.025). C: The Enzyme activity per particle in samples stored at -80 °C 




Figure 54: Size distribution of fresh and stored HUVEC EVs in the range from 0 to 300 nm as 
measured by NTA. Mean values from three independent experiments are plotted. 
4.7.3. Optimization of RO EV storage and long term 
stability of encapsulated beta glucuronidase 
Data presented in this chapter was part of the publication by Trenkenschuh E., Richter, M. et 
al. (2020). “Formulation development of lyophilized extracellular vesicles with long-term 
stability”, manuscript submitted to Advanced Healthcare Materials. 
Four formulations of RO-EVs were evaluated for long-term storage (n=3): 
1. 10 mM Na-phosphate with 5% sucrose and 0.02% P188 
2. 10 mM K-phosphate with 5% sucrose and 0.02% P188 
3. 10 mM Na-phosphate with 5% sucrose and 0.02% PVP 
4. 10 mM Na-phosphate with 5% PVP and 0.02% P188 
While the evaluation of colloidal stability was carried out by Eduard Trenkenschuh at LMU 
Munich, the measuring of β-glucuronidase stability was carried out in Saarbrücken by 
Maximilian Richter. After redispersion, if applicable, samples were purified by SEC and the EV-
containing fractions were evaluated regarding their active enzyme content (Figure 55 & Table 
3). Before lyophilisation, the PVP-containing samples of conditions 3&4 exhibited almost twice 
the fluorescence intensity of the conditions 1&2, while no enzyme activity was found in these 
samples directly after lyophilisation. In samples of conditions 1&2, enzyme activity was 




Figure 55: Stability of β-glucuronidase encapsulated in RO EVs stored for 6 months expressed 
as the fluorescence-intensity of fluorescein generated through the enzymatic conversion of 
fluorescein-di-β-D-glucuronide. Samples contained either 10 mM sodium or potassium 
phosphate as a buffer and either 5% sucrose + 0.02% P188, 5% sucrose + 0.02% PVP or 5% 
PVP + 0.02% P188 as cryo- and lyoprotectants. Placebo samples contained just the respective 
excipients and no EVs. 
After one month of storage enzyme activities generally recovered compared to directly after 
lyophilisation. For all samples but condition 4, enzyme activity was reduced with higher storage 
temperature. Condition 1 led to the highest recovery of active enzyme between 106.7 and 
65.7%. For condition 2, 66.6 to 52.4% were recovered and 71.2 to 62.1% were recovered for 
condition 3. Condition 4 exhibited the highest reduction in enzyme activity to 40.1 to 48.5%. 
After 6 months of storage, enzyme activity was greatly reduced in all samples. Samples 
containing PVP showed a very high variability in the measured enzyme activity, fluctuating 
around zero fluorescence. For condition 1, enzyme activity was reduced to 26.3 and 18.2% at 
2-8 and 25 °C respectively, while no active enzyme was recovered at 40 °C. Condition 2 led 
to the recovery of 19.9 to 22.0%. Samples of condition 3 showed a recovery of 14.5 and 5.2% 
at 2-8 and 25 °C respectively, while no active enzyme was recovered at 40 °C. In condition 4, 
no active enzyme was recovered at all temperatures. Placebo samples revealed no 
background fluorescence for conditions 1&2, while conditions 3&4 exhibited a background 




Table 3: Remaining enzyme activity in lyophilized and stored RO EV samples. Recovered 
enzyme activity is expressed as the percentage of fluorescein fluorescence found relative to 







5.1. Cultivation of SBCy050 bacteria and Isolation of their 
OMVs 
Compared to other gram-negative bacteria, SBCy050 myxobacteria exhibited a very slow 
growth. The cultivation conditions for SBCy050 were based on the work Eilien Heinrich 
performed in her master thesis. As the bacteria did not grow in single colonies once plated on 
agar, it was not possible to get an assessment of the number of bacteria that gave rise to the 
OMVs isolated. The data gathered over the course of this project for their OD600 at isolation at 
nonetheless demonstrate the reproducibility of their culture. 
While the initial protocol for differential centrifugation was based on centrifuging the bacterial 
culture twice at 9500 g to pellet bacteria and their debris, the protocol was successfully 
optimized by replacing the second step of centrifugation with filtration. Analysis of the vesicles 
obtained with the optimized protocol suggested no changes compared to the original protocol 
(Figure 29). Filtration not only was faster than the second 15 min centrifugation step, but also 
led to a higher yield of conditioned medium, as in centrifugation the last 10 ml of supernatant 
had to be discarded to prevent the disturbance of the bacterial pellet. Thus, for the original 
protocol the yield of supernatant was only 60%, while the yield approached 100% for the 
filtration-based protocol. Therefore, despite the increased amount of consumable used, 
filtration made the process of OMV-production more economical by reducing the consumption 
of medium, the incubator shelf-space needed for cultivation and the time needed to obtain cell-
free conditioned medium. The Steritop filter employed in this protocol was shown to be suitable 
to filter out bacteria in a recent publication (380). Interestingly, replacing it with another bottle 
top filter of a competitor that supposedly employed the same material for the filter-membrane 
greatly reduced the OMV-yield, emphasizing the need for thorough evaluation of every step of 
vesicle production. 
Once conditioned medium has been produced there are multiple methods to obtain purified 
and concentrated EVs, as discussed above (1.4.1). Since an ultracentrifuge and suitable rotors 
for the volumes of medium that required processing were available at the institute, UC was the 
method of choice to concentrate EVs from conditioned medium. With a processing time of 
approx. 2.5 h to obtain a vesicle-pellet from up to 360 ml of conditioned medium, it was much 
faster than PEG-precipitation, which requires overnight incubation. On the other hand, TFF, 
which would reduce the strain on the vesicles during purification and potentially lead to higher 
yields, would have required a considerable investment into the required instruments and the 
running costs of the required filter cassettes. Additionally, the early stages of the optimization 
of OMV surface engineering required many replicates with relatively low volume of conditioned 
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medium, which for TFF would result in the use of a high amount of consumables. Thus, with 
the investments into an ultracentrifuge and rotors already done, UC was the more economical 
variant. Still, a later scale-up of EV-production to larger batches might benefit from TFF as 
opposed to UC. 
The main drawback of the co-isolation of many impurities derived from the conditioned medium 
was addressed by an additional step of purification using the pellet obtained by UC. Here the 
choice was between SEC and density gradient UC. While the latter would allow for the isolation 
of highly purified subsets of EVs and not dilute the samples, as it occurs in SEC, its requirement 
for long ultracentrifugation steps made it considerably less useful in the present setting. As 
multiple people depended on the availability of the ultracentrifuge for EV-purification, wide use 
of density gradient UC would slow down progress for the whole group. Additionally, the main 
draw of this method, the potential isolation of EV-subsets based on their density was of little 
importance for the optimization of OMV surface engineering and the evaluation of EV storage 
stability that were the main subjects of this work. Thus, SEC using cheap self-prepared 
columns was the method of choice. Especially after partial automation using the ÄKTA start, 
SEC presented an easy and highly reproducible method that was moreover ideally suited to 
remove soluble impurities carried over from UC. Its main drawback, the dilution of purified 
samples, however necessitated the evaluation of methods for EV surface engineering based 
on the number of purification-steps they would require, favoring methods that could already be 
used with the pellet after UC. 
5.2. Surface functionalization of EVs 
The first of the main objectives of this work was the development of an efficient method for the 
surface modification of myxobacterial OMVs (Box 2). As described in the introduction, there 
are three general pathways to EV surface modification: genetic engineering, physical 
modification and chemical functionalization. As the aim of this project was the introduction of 
small molecules as targeting moieties against bacteria and they were to be installed on the 
surface of myxobacterial OMVs, genetic engineering was not a suitable method. Neither could 
molecules such as vancomycin be expressed easily, nor have the proteomics of SBCy050 
OMVs been investigated to determine surface-proteins suitable for the expression of fusion 
proteins. Thus, only physical and chemical engineering remained. 
As described above, the isolation-protocol for OMVs employed in this work influenced the 
applicability of methods for OMV surface functionalization. SEC excels at removing soluble 
impurities from the particles, which makes it particularly well suited for the modification of EVs 
with soluble molecules. Thus, it is favorable for post-insertion, adsorption and chemical 
modification. On the other hand, SEC is unable to separate particles that are in a similar size-
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range, which would be required for approaches based on the fusion of OMVs with liposomes, 
where unfused liposomes would require removal. Moreover the PEG-based fusion with 
liposomes had not been published yet at the start of the project (320) and the freeze-thaw 
based fusion of EVs and liposomes (323) was questionable due to potential negative effects 
of freezing and thawing on EV-integrity (224) and the lack of removal of unfused particles. 
In regards to physical modification, especially lipid-insertion based methods seemed attractive 
as they combined a relatively straightforward synthesis-task with an easily implemented 
protocol that would allow for the one-step introduction of targeting moieties to OMVs, 
potentially even directly after UC. Thus, lipid-insertion was chosen to be investigated first.  
To facilitate the quantification of EV-labeling and the optimization of the protocol a fluorescent 
cholesteryl-PEG-derivative was used. The same was also done in the later labeling-
approaches. Based on the fluorescence readout, calibration curves and the particle- 
concentration as measured by NTA, the amount of dye molecules per particle could be 
approximated. Due to a change in the NTA-hardware during the course of this project, the 
sensitivity of particle-detection changed. Thus, the early experiments conducted for cholesterol 
insertion and NHS ester modification underestimated the amount of particles, which resulted 
in an overestimation of the modification efficiency compared to later experiments and a direct 
comparison of absolute values cannot be made. 
5.2.1. Cholesterol insertion  
Compared to phospholipid-insertion, the insertion of cholesterol-modified molecules seems to 
be better suited for the modification of EVs due to the lower incubation temperatures required 
for optimal insertion (0). Additionally, while it was clear from the start that the different 
membrane structure of OMVs could be problematic for cholesterol post-insertion, some 
findings made it seem probable that cholesterol insertion in particular might work with OMVs. 
Hopanoids, bacterial sterols, are membrane components of the outer membrane of various 
gram-negative bacteria and they were also identified in myxobacteria (381). Moreover, 
cholesterol was found to interact with lipid A and sphingomyelin in the same way as its bacterial 
analogue diplopterol (382). The results of the conducted experiments however clearly 
indicated that cholesterol insertion does not work with SBCy050 OMVs (4.2). The attempt of 
transiently disrupting the membrane-integrity with saponin to promote the insertion also was 
unsuccessful and even led to a decrease in the insertion into liposomes (Figure 30), which 
were used as a positive control alongside A549 cell derived mammalian EVs. The results were 
either caused by a badly optimized protocol or the differences in membrane structure between 
mammalian EVs and OMVs 
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The protocol was based on the findings of O’Loughlin et al., who determined that a high ratio 
of cholesterol-modified molecules to EV led to a higher per particle insertion (228). Thus, a 
ratio of 1000 cholesteryl-PEG-FITC molecules per particle was employed. The insertion of 
around 100 molecules per particle is well in line with their findings of approx. 165 siRNA 
molecules per particle for a ratio of 1500:1. Taking this into consideration, it seems unlikely 
that optimization of the protocol alone could mitigate the low insertion efficiency into SBCy050 
OMVs compared to A549 EVs or liposomes. 
Looking closer at the structure of the outer membrane the high density of negatively charged 
LPS becomes apparent (383). The repulsive force of these negative charges is bridged by 
divalent cations that lead to a tightly knit supramolecular structure that is important for the 
stability of the gram-negative cell-envelope (383). This structure could be the critical hindrance 
for the insertion of cholesterol into the membrane. While chelating agents such as EDTA can 
be used to destabilize the supramolecular structure of LPS, doing so can lead to the overall 
disintegration of OMVs (384). Thus, cholesterol post-insertion was not pursued further. 
Interestingly, in a recent publication Jiang et al. reported the post-insertion of a PEGylated 
phospholipid into OMVs derived from a Salmonella enterica serovar Typhimurium strain, which 
was modified by the deletion of a gene important for the generation of native LPS (385). It 
seems plausible that such modified OMVs might be more susceptible to post-insertion than 
native OMVs. However, as the post-insertion method used in their paper was omitted from it, 
further evaluation in relation to the work presented in this thesis is not possible. 
5.2.2. Surface functionalization using Sulfo Cy-7 NHS ester 
Compared to post-insertion, a one-step modification is more elusive for chemical 
functionalization of EVs. As explained in chapter 1.9.2, chemical surface modification with 
complex molecules is best carried out in two steps, as the functional groups naturally available 
for coupling on the EV-surface are likely present in the targeting moiety as well and would lead 
to undesired cross-reactivity. 
Amino groups are abundant on the vesicle surface, easily addressable and have already been 
successfully used for the introduction of groups for bioorthogonal chemistry to mammalian EVs 
(225, 333). Thus, the modification of OMVs was tested using sulfo-cyanine 7 NHS ester, a 
water-soluble fluorescent dye.  
 Amino groups are however also present in the co-pelleted impurities and residual medium 
encountered in the pellet after UC. Thus, OMVs were first purified by SEC and then modified, 
followed by another step of SEC. While this method was very successful for OMV-modification, 
with low unspecific labeling, it already required two steps of SEC. Thus, the actual introduction 
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of a targeting moiety after NHS ester modification would increase this to three steps of SEC 
and a roughly 1 in 1000 dilution of OMVs. This could be circumvented by either performing 
NHS ester modification in the pellet or by finding a suitable protection strategy for amino groups 
of the targeting moiety, which would allow performing the surface modification in one step. 
As it was anticipated that using the pellet instead of purified OMVs would greatly increase the 
amount of NHS ester needed to achieve the same degree of modification, which was later 
confirmed (Figure 39), a suitable amine-protection group was sought. With its mild deprotection 
through Staudinger reduction, the azide group was reckoned as the best-suited variant (386). 
The overall plan was to protect amino groups of the targeting moiety through diazotransfer and 
regenerate the amines in situ after installation on the vesicles. When literature research into 
diazotransfer revealed that it could also be performed in aqueous media (371), the question 
was raised, whether diazotransfer could also be used on the vesicles to generate AzideOMVs 
and replace NHS ester modification. 
5.2.3. Diazotransfer 
The aim of diazotransfer-modification of OMVs was to introduce a new method for the 
introduction of azide groups to the surface of OMVs that would be insensitive to co-isolated 
impurities and more economical than using expensive NHS esters. While the synthesis of ISA 
used in aqueous diazotransfer is straightforward, as with many low molecular weight azide-
compounds (387), there are some safety concerns for this molecule. While ISA HCl was 
originally considered insensitive to impact and friction (365), reports of its explosive behavior 
prompted a further investigation. Fischer et al. studied the sensitivities of different salts of ISA 
and determined that the hydrochloride was indeed more sensitive than initially estimated and 
that other salts, particularly the sulfate and mesylate exhibited a better safety profile (370). 
Thus it was originally decided to use ISA sulfate in the present study synthesized according to 
the protocol of Potter et al. (379). The precipitation of ISA sulfate however failed in two 
attempts. Thus, ISA HCl was prepared instead by precipitation with 4 M HCl in dioxane. To 
enhance its shelf life, ISA HCl was stored under argon at -20 °C and part of it aliquoted in 
portions of several milligrams to limit freeze-thawing. Despite its volatile properties, no 
problems in its handling occurred in the approximately two years of its use. Compared to 
diazotransfer used in chemical synthesis, diazotransfer to OMVs has the advantage that only 
very small amounts of ISA are needed per reaction and thus the risk in handling is reduced. 
Indeed, the yield of 355 mg ISA HCl would be sufficient to perform over 4000 diazotransfer 
reactions at a scale of 500 µl per reaction.  
Already before the synthesis of ISA the diazotransfer conditions described by van Dongen et 
al. were applied to SBCy050 OMVs to make sure that the presence of CuSO4 and base would 
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not affect them (371). A particle-recovery of approx. 80% was deemed acceptable and the 
issue of precipitation was successfully tackled by replacing K2CO3 with NaOH (Figure 32).  
After successful synthesis of ISA HCl, assessment of diazotransfer started. Assuming that 
diazotransfer would lead to a similar density of azide groups on the vesicle surface as 
modification with sulfo-cyanine 7 NHS ester – approx. 200 per particle – and assuming a 
concentration of approx. 2*10^11 particle per ml, the azide concentration would be at around 
66 pmol/ml after diazotransfer. Quantifying azide groups by FTIR at this low concentration in 
complex OMV samples would be very difficult and unreliable. Thus, the effectiveness of the 
diazotransfer process was evaluated by derivatization of the vesicles by SPAAC with a 
fluorescent dye. Due to its high fluorescence and good solubility, the alexafluor derivative 
DBCO AF594 was chosen. It had the additional advantage of allowing the visualization of 
modified particles using the 532 nm laser of the nanosight instrument. DBCO AF594 was used 
at 4.9 µM, the concentration determined as optimal for surface modification of OMVs with sulfo-
cyanine 7 NHS ester. 
To determine the concentration of ISA HCl used in the assay, some assumptions based on the 
protocol of van Dongen et al. were made (371). In their diazotransfer to horseradish 
peroxidase, they used an excess of 1.75 equivalents of ISA HCl compared to the amount of 
amines available in the enzyme. Assuming that the density of amino groups in the proteins 
encountered in the OMV-pellet would be similar to horseradish peroxidase and based on a 
protein-concentration of approx. 400 µg/ml in the pellet as indicated by BCA assay, the ISA 
HCl concentration was calculated. To account to the potentially less ideal conditions in the 
OMV pellet compared to an isolated protein in water, the amount of ISA was increased to “10 
equivalents” instead of “1.75 equivalents”. As diazotransfer to SBCy050 OMVs was quite 
successful after the optimization of the reaction pH and the incubation time, the initial ISA 
concentration was used throughout all experiments and was not further optimized. In his 
master thesis, Philipp Lapuhs tested diazotransfer on OMVs derived from another strain of 
Myxobacteria. There he also began evaluating the effect of varying the ISA HCl concentration 
between 0.08 mM and 1.62 mM compared to the standard concentration of 0.81 mM. He found 
a decrease to 56% for 0.08 mM and an increase to 142 % for 1.62 mM, suggesting that further 
optimization might be possible (Supp. figure 52 D). 
As conditions of diazotransfer might negatively affect vesicle stability, its effect was measured 
in two ways. NTA was employed to assess the effect diazotransfer had on particle-recovery 
and the AUC of OMV-samples on the ÄKTA instrument measured at 280 nm gave a general 
approximation of the intactness of the vesicle surface-proteins and their cargo.  
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As the mechanism for diazotransfer involves the nucleophilic attack of the amine on the 
terminal nitrogen of ISA (364), increasing the nucleophilicity of amino groups through 
deprotonation at a high pH was likely beneficial. Consequently, the pH was the first parameter 
to be optimized. Initial experiments using the original protocol by van Dongen et al. showed 
only a low modification. Due to the presence of buffer-salts and soluble impurities, the OMV-
pellet was buffered and would require the addition of considerably more base than in the 
original protocol (371). Increasing the pH increased the modification efficiency greatly. This 
finding was in accordance to the work of Schoffelen et al., who investigated diazotransfer at 
pH 11 and 8.5 (388). However, as to be expected, the increased pH also led to a decrease in 
vesicle-stability, visible in NTA- and ÄKTA-analysis. In most cases, vesicle-stability as 
indicated by NTA was higher than measured by ÄKTA AUC. This could indicate that while the 
increased pH and copper-ions could lead to the alteration and loss of surface-proteins of the 
vesicles, they would have less of an effect on the overall integrity of the vesicles as a particle.  
To balance both modification efficiency and vesicle-stability, a pH of 9.5 was chosen for 
subsequent modification of SBCy050 OMVs. In his master thesis Philipp Lapuhs observed the 
same increase in modification efficiency with increasing pH, however the Stigmatella 
aurantiaca-dervied OMVs he used in his experiments better tolerated high pH-environments, 
as no decrease in recovery rate was found between pH 9.5 and pH 11.0 (Supp. figure 52 A-
C). This indicates that diazotransfer can be transferred to OMVs from other bacterial strains, 
however they might differ in their susceptibility to the diazotransfer-conditions. 
At the same time as the pH, the incubation time for diazotransfer was optimized. A shorter 
incubation time was desired, to speed up the process of OMV modification and to reduce the 
strain of incubation at increased pH. The incubation time was gradually reduced from 20 h – 
employed by van Dongen et al. (371) – to 2 h and then 30 minutes. Interestingly, the step from 
20 h to the two shorter incubation times led to an increase in modification efficiency (Figure 
35), hinting that the degradation of OMVs under longer incubation would outweigh the 
potentially higher amount of installed azides. The recovery rate at 30 min was only slightly 
increased by the change in incubation time, indicating that the incubation pH had a greater 
impact on OMV-stability than the incubation time. 
As a further parameter to show the mild effect of diazotransfer on SBCy050 OMVs, the 
autofluorescence of treated and untreated OMVs was compared (Figure 36). The 
autofluorescence of the OMVs, discovered by Eilien Heinrich in her master thesis, is based on 
protoporphyrin IX, which due to its lipophilicity is likely associated with the membrane of the 
vesicles. The observed reduction to 85% of the control was well in line with the vesicle recovery 
measured by NTA and ÄKTA.  
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The actual association of the DBCO AF594 with the vesicles as opposed to the co-elution of 
dye-particles formed during incubation with the vesicles was confirmed using the fluorescence 
mode of the NTA instrument (Figure 34). The fluorescence mode showed that AF594 was 
generally associated with particles in the same size-range as the vesicles and that the 
fluorescence of the particles varied depending on the diazotransfer conditions, confirming the 
bulk fluorescence measured by plater reader.  
To confirm the suitability of diazotransfer as a method to introduce azide groups to the surface 
of OMVs, the optimized protocol was compared to surface modification using sulfo-cyanine 7 
NHS ester (Figure 39). While diazotransfer unsurprisingly led to a lower modification than 
application of the NHS ester to purified OMVs, it performed significantly better than both 4.9 
µM and 49 µM sulfo-cyanine 7 NHS ester applied to the OMV pellet. These results assume 
that the SPAAC reaction performed as a second step for diazotransfer would be as effective 
in addressing azides as the NHS ester is at addressing amines. This is likely not the case, thus 
the effectiveness of diazotransfer was underestimated in this assay. Still, these results clearly 
indicate that at least for the modification of OMV-samples containing soluble impurities from 
the conditioned medium diazotransfer is superior in terms of vesicle surface engineering 
compared to NHS esters. While azidoacetic acid NHS ester and similar molecules are more 
widely commercially available than ISA, the lower consumption of material as well as the cheap 
and easy synthesis of ISA outweigh this disadvantage. This makes diazotransfer the more 
economical variant, which is an important consideration for industrial application. Additionally 
the application of ISA sulfate or mesylate would reduce problems associated with the volatile 
nature of ISA HCl. 
In conclusion, it was demonstrated that OMVs can be effectively modified by diazotransfer and 
their integrity can be conserved through optimization of the experimental parameters. NHS 
esters, while effective for the modification of purified OMVs are very sensitive to soluble 
impurities. Cholesterol-insertion was shown to be not suitable for OMVs derived from SBCy050 
myxobacteria, while it worked as expected with EVs derived from mammalian cells. Compared 
to modification with an NHS ester and diazotransfer, cholesterol-insertion however only 
showed a low modification efficiency. 
5.3. Introduction of targeting moieties to OMVs 
5.3.1. Design rationale of the linker and targeting moiety 
construct 
After the successful optimization of diazotransfer, the next aim was the introduction of bacteria-
specific targeting moieties to SBCy050 OMVs using a modular linker molecule (Box 2). As the 
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surface engineering of bacterial vesicles and chemical surface modification of EVs in general 
have not been explored in much detail yet, it was deemed worthwhile to design a molecule 
that would not only be applicable in this specific case of targeting SBCy050 OMVs to bacteria 
but that could find general applicability in the EV-field. To achieve this, the desired properties 
of the linker molecule were: 
1) Sufficient solubility, so that non-reacted linker could be removed by SEC. This property 
is crucial, as co-eluting unbound molecules would interfere with the assessment of EV-
targeting 
2) A very fast and bioorthogonal linkage between linker and targeting moiety that would 
allow for the modular introduction of different targeting moieties, reaching from small 
molecules to antibodies. Ideally, it should be possible to generate the conjugate in situ 
by mixing an aliquot of linker and targeting moiety each and after their reaction applying 
them to AzideOMVs without further purification. 
3) Incorporation of a fluorescent dye. As with the optimization of the diazotransfer 
protocol, fluorescence measurement would be a convenient read-out, both for the 
modification efficiency and the targeting ability. Knowing the effectiveness of the 
labeling, one can determine if unsuccessful targeting is caused by an insufficient 
amount of targeting moieties on the vesicle-surface or the general inactivity of the 
chosen targeting moiety. Fluorescent labeling of OMVs would also allow following their 
fate in future in vivo experiments.  
Derivatives of cyanine 5 were chosen as the fluorescent dye. They show high fluorescence 
paired with relatively high photostability while being considerably cheaper than alexafluor dyes 
such as AF594 that were used in the initial experiments. Cyanine 5 in particular was chosen, 
because its excitation and emission wavelengths were compatible both with common 
fluorophores such as fluorescein and GFP that could be used to label bacteria in targeting 
experiments and the confocal microscope and FACS instrument available at the institute. 
To both increase solubility and flexibility of the linker, short monodisperse PEG-chains were 
included into the molecule. While for the PEGylation of nanoparticles usually PEGs in the size 
range of 1000 Da or more are used (270), a shorter chain-length was chosen, to make 
synthetic handling of the linker easier and to reduce the shielding-effect, longer PEGs might 
have. The rationale behind this was that the natural ability of myxobacterial OMVs to interact 
with their prey might be beneficial for antibacterial drug-delivery. 
An ideal fast and bioorthogonal reaction to link targeting moiety and linker is IEDDA. To make 
it orthogonal also to SPAAC and CuAAC, TCO would be used as the dienophile in IEDDA and 
DBCO as the strained alkyne in SPAAC (349). Both show no cross-reactivity towards azides 
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and tetrazines respectively.  Tetrazine was chosen to be anchored on the targeting moiety due 
to the broader catalogue of commercially available tetrazine-derivatives with different 
functional groups. 
 
Figure 56: Schematic structures of the linear and branched linker molecule. For the surface 
modification of AzideOMVs, first, the linker would be reacted with the methyltetrazine-labeled 
targeting moiety via IEDDA, then the resulting molecule would react with the vesicles via 
SPAAC. 
With all its parts determined only the overall make-up of the linker was left to be determined. 
With the alkyne and TCO to be located on opposite ends of the molecule either a linear 
molecule that incorporates the dye in its backbone or a branched molecule with three branches 
holding the alkyne, TCO and dye could be synthesized (Figure 56). The linear variant would 
rely on a bifunctional fluorescent dye forming a bridge between TCO and alkyne, while in the 
branched variant a trifunctional molecule would take over this duty. 
5.3.2. Synthesis methyltetrazine-vancomycin 
Parallel to the synthesis of the first linker molecule, methyltetrazine-vancomycin was 
synthesized as a model targeting moiety. Its wide application for the targeting of antibacterial 
nanoparticles and the possibility to precisely control its modification made it an ideal starting 
point and potential “positive control” to other targeting moieties employed later. Two distinct 
architectures of vancomycin are possible by addressing either its amino or carboxylic acid 
function (see 1.7.1). While attachment at the carboxylic acid is more widely applied, both 
variants showed bacterial binding in literature and attachment to the amine led to a higher 
specificity towards gram-negative bacteria. Thus, this variant was synthesized first to 
determine its applicability for OMV-targeting. While the yield of the reaction was quite low, 
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sufficient quantities of methyltetrazine-vancomycin were obtained for a first evaluation of its 
applicability as a targeting moiety for OMVs. 
5.3.3. Synthesis of the SPAAC-based linker 
The SPAAC-based linker, the first linker molecule that was synthesized, was based on the 
linear linker-variant (Figure 56). The main reason for this was to reduce the amount of steps 
of the synthesis. As no suitable molecules incorporating both DBCO and two other 
functionalities to attach TCO and fluorescent dye are commercially available (or vice versa for 
TCO), the synthesis was based on azide-PEG3-cyanine5-PEG4-amine. While this allowed for 
reaching the desired linker-molecule in two steps, it greatly limited the reaction, as due to its 
exceedingly high price, the synthesis had to be carried out on a scale of just 2 mg. While the 
desired product was obtained, the yield obtained was very low. 
This low yield was probably at least partially caused by the degradation of the product during 
HPLC. The ions observed in LC/MS can be assigned to the molecule lacking the DBCO group 
(see 4.5.2 and Figure 40), which is supported by the participation of the degradation product 
in the IEDDA reaction with methyltetrazine vancomycin. Apparently, the degradation of the 
linker was increased by longer dwelling-time on the column as the ratio of intact linker to 
degradation product strongly decreased, when the HPLC-method was made longer. This on-
column degradation would also explain why the degradation product was found in all fractions 
of the prepHPLC – the observed degradation product was generated in situ during the analysis 
of the fractions.  
Besides its low yield, the SPAAC-based linker 
demonstrated that the generation of the linker-targeting 
moiety-conjugate directly before the vesicle modification 
was indeed possible by simple mixing of 1 µl aliquots of 
the reaction partners for 1 h. LC/MS showed the 
generation of three peaks each for the SPAAC-based 
linker and its degradation product (Supp. figure 9). 
Multiple peaks with the mass corresponding to the 
product were indeed visible in all IEDDA reactions 
(Supp. figure 23, Supp. figure 45 & Supp. figure 47). 
Based on the possibilities for association between 
tetrazine and TCO, the reaction can lead to four 
diastereomeric products (Figure 57). The formation of 
different IEDDA-products was also observed by other 
researchers, who used norbornene instead of TCO as 
Figure 57: Possible products of the 
IEDDA reaction between 
methyltetrazine and TCO. R1
represents the targeting moiety, R2
represents the linker molecule. 
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the dienophile (389, 390). Due to the high amounts of compound needed to isolate and assign 
the respective isomer to the different peaks, no further analysis was performed in this regard.  
It seems clear however, that depending on the educts the formation of some variants seem to 
be favored under the reaction-conditions employed. Generally, only three major peaks of the 
product were observed. This might however also be an issue of the resolution of the LC/MS-
method employed for analysis. While different isomers might differentially impact the targeting 
ability of targeting moieties attached to vesicle surface, this effect should be greatly mitigated 
by the flexibility of the PEG-chains incorporated into the linker. 
Test-experiments for the modification of AzideOMVs demonstrated the insufficient solubility of 
the SPAAC-based linker. From the early elution of linker molecules in the absence of OMVs, 
it can be inferred that the linker formed particles when mixed with PBS at 4.9 µM. Even though 
there was a higher fluorescence measured for AzideOMVs compared to the control OMVs and 
the PBS control (Figure 41), which would indicate a preferred interaction through SPAAC, the 
presence of unbound linker would lead to artifacts and wrong assumptions during the 
evaluation of OMV-targeting. The conjugation of vancomycin, which was supposed to increase 
the hydrophilicity of the linker, did not sufficiently improve the situation (Figure 42). Thus, a 
new, more soluble linker-molecule was needed. 
5.3.4. Considerations for a more soluble linker molecule 
The low solubility of the SPAAC-based linker indicated that short PEG-chains alone would not 
be enough to get a sufficiently soluble molecule. An easy way to increase the solubility of the 
molecule would be replacing the cyanine 5 dye with its water-soluble sulfonated version that 
would carry out the dual function of increasing solubility and providing fluorescence. This 
change meant also the transition from a linear to a branched linker-design, as no suitable 
heterobifunctional sulfo-cyanine derivatives are available and their de-novo-synthesis seemed 
too laborious to be worthwhile. A convenient branching point for the linker would be amino acid 
derivatives, as they contain three different branches and are widely available. 
Another possible culprit for the low solubility of the SPAAC-based linker was the DBCO group. 
An alternative, less bulky cyclooctyne derivative would likely be less reactive and show cross-
reactivity towards tetrazine and thus could not replace it (349). Thus, the only alternative would 
be changing from SPAAC to CuAAC and using a much less bulky alkyne to perform the linkage 
between linker and OMV. While this course of action entailed evaluating, if CuAAC would work 
with OMVs, the prospect of ensuring the sufficient solubility of the new linker made this a 
worthwhile endeavor. Moreover, as opposed to DBCO, where its introduction to the linker 
would require an extra step in the synthesis, propargyl glycine could be used as convenient, 
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alkyne-containing starting material. To extent the targeting moiety from the vesicle surface, a 
TCO-PEG-derivative would be used to introduce the TCO-group. Of the commercially available 
molecules, TCO-PEG8-amine offered the best ratio of price and PEG-length. 
5.3.5. Optimization of CuAAC 
Before the CuAAC-based linker molecule was to be synthesized, first CuAAC for OMV 
modification needed evaluation. 
CuAAC has been successfully performed with EVs before by Smyth and coworkers (333), but 
neither was their protocol very optimized, nor did they evaluate EV-stability beyond the size-
distribution of treated and untreated EVs. The biggest concern in CuAAC is oxidative damage 
to biomolecules through copper and ascorbic acid, thus their concentrations should be as low 
as possible. Compared to the protocol of Hong et al., who recommend the usage of 0.1 mM 
CuSO4 and a five-times excess of the copper-ligand (340), Smyth et al. used a 100 times 
higher copper-concentration with only two times excess of bathophenantroline, which acted as 
the copper-ligand in their protocol.  
Initial CuAAC-experiments directly followed the protocol of Hong et al. (340), but even after 
increasing the alkyne-concentration by a factor of four, only about 30% of the modification 
efficiency of the SPAAC reaction were reached. Two factors most likely greatly influenced the 
completion of the CuAAC reaction: The very low azide-concentration and the complexity of the 
OMV-sample. To counteract these issues, a modified protocol was devised. Cu(I) ions were 
generated directly and after complexation with THPTA were mixed with the concentrated 
alkyne, to effectively generate the active complex of copper and alkyne that would be able to 
directly react with the azides in the OMV sample. This measure increased the modification 
efficiency to approx. 50% of SPAAC, which was not deemed sufficient. Thus, further 
optimization was desired.  
During the activation of the alkyne, its proton is replaced with a copper ion. It seemed likely 
that by making the solution of alkyne, THPTA, Cu(I) and ascorbate alkaline, the acidity of the 
alkyne would lead to the more effective generation of the alkyne-copper complex. As visible in 
Figure 43, this was indeed the case and using this approach, the same modification efficiency 
as with SPAAC was reached. While alkaline conditions lead to an increased oxidation of 
sodium ascorbate visible by an increasing yellow discoloration of the solution, sufficient 
amounts of ascorbate for the reduction of Cu(II) were evidently present.  
The increase in pH was accompanied by a reduction in OMV-stability compared to SPAAC 
and CuAAC performed in the absence of NaOH. While this instability could be partially 
circumvented by decreasing the incubation time to 2 h, this also led to a decrease in 
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modification efficiency. Thus, the CuAAC-protocol with 4 h incubation and the inclusion of 
NaOH was adopted as the standard protocol. 
Unfortunately, the effect of CuAAC on the autofluorescence of SBCy050 OMVs became 
apparent only later, during the evaluation of the PEG6-linker. Compared to SPAAC, the 
autofluorescence of the vesicles was lost almost completely. As the recovery rate measured 
by ÄKTA AUC indicated that there was not a pronounced loss of vesicle-contents, the reduced 
autofluorescence suggests that the generation of reactive oxygen species during CuAAC could 
have led to its degradation. Omitting NaOH during CuAAC only slightly increased the 
recovered autofluorescence, indicating that indeed the presence of copper and ascorbate 
seemed to cause the loss in fluorescence. It is likely that CuAAC also caused oxidative damage 
to the vesicles beyond this easily assessable parameter. Thus, while unfortunate, this finding 
at least circumvented the laborious evaluation of modified OMVs for oxidative damage and 
clearly indicated that CuAAC is not suitable for the surface modification of EVs beyond prove-
of-concept experiments. 
5.3.6. Synthesis of linkers for CuAAC 
Based on the initial positive assessment of CuAAC and the considerations for the design of a 
branched linker molecule, two attempts for the synthesis of a suitable CuAAC-linker were 
made, with the first unsuccessful iteration giving important insights for the second one. 
Initially the synthesis was performed using TCO-PEG8-amine and Boc-propargyl glycine. The 
Boc protection group, compared to using an Fmoc group to protect the amine, has the 
advantage that the byproducts generated during deprotection can be readily removed through 
evaporation on a rotavapor. However, the effect the deprotection-conditions would have on the 
carbamate ester, which attached the TCO group to the molecule, was underestimated. This 
led to the significant production of the diamine byproduct that, not being removed prior to the 
attachment of the dye, resulted in the formation of byproducts (Figure 44). While these were 
successfully removed and the pure PEG8-linker acquired, the high acid-concentration during 
deprotection likely also had a more profound effect on the molecule, by most likely changing 
the cyclooctene from its reactive trans-isomer to the unreactive cis-isomer. No reactivity 
whatsoever in IEDDA reactions was found for the finished linker molecule, while the Boc-
protected intermediate was still active (Supp. figure 22 & Supp. figure 23). NMR-analysis of 
both compounds revealed a change of the two protons associated with the double bond (Figure 
45). The observed change in the NMR-spectrum  conformed to the change observed by Nikić 




Besides the Boc deprotection conditions, light exposure was deemed another potential 
corroborator of the isomerization of TCO. TCO is typically prepared from cis-cyclooctene 
through UV-irradiation at 254 nm (392). In the same way, light-exposure might lead the 
molecule to isomerize back to the inactive form. 
Thus, for the second synthesis attempt, Fmoc-propargyl glycine was chosen as the branching 
point, after test-experiments with the Boc-protected intermediate showed no loss of IEDDA-
reactivity upon incubation under Fmoc-deprotection conditions. In addition, all reaction-steps 
were carried out protected from light as far as possible. As no TCO-PEG8-amine was available 
at the time of the second linker-synthesis, it was carried out using TCO-PEG6-amine instead, 
assuming similar properties of the finished linker molecule. 
Despite the precautions taken, NMR-analysis of the intermediates before and after Fmoc-
deprotection and purification again showed a change in the protons associated with the double 
bond, suggesting the partial isomerization of TCO during these synthesis steps (Supp. figure 
30). The presence of both isomers was confirmed by LC/MS of the crude PEG6-linker after the 
attachment of sulfo-cyanine 5. There, the UV-channel showed the presence of two peaks, both 
corresponding with the mass of the linker (Supp. figure 31). The identity of the cis- and trans-
isomer were confirmed by derivatization of a prepHPLC-fraction obtained from a test-
purification that contained both molecules (Supp. figure 32). While the earlier eluting peak 
would react with methyltetrazine-vancomycin, the later-eluting peak remained. Thus, the 
prepHPLC-method was optimized to obtain an acceptable separation of both compounds.  
NMR-analysis of the active and inactive PEG6-linker showed the same picture as before 
(Figure 46). Both compounds were further analyzed by 2D-NMR to confirm the differences 
found in the cyclooctene ring (Table 2). There carbons and hydrogens making up the ring could 
be identified and revealed differences that would indicate a change in the conformation of the 
ring. 
In total, the synthesis of the CuAAC-linkers revealed a very high sensitivity of the TCO-group, 
which complicated the whole process and made the synthesis less efficient. For future linker-
molecules, thus a solution to the issue of TCO-isomerization during synthesis is desired. TCO 
in general is prone to inactivation by isomerization, as observed in the experiments presented 
here, but also by other researchers (391, 393). The isomerization-problem has been 
addressed by Darko and coworkers, who synthesized a dioxolane-fused trans-cyclooctene 
with enhanced chemical stability (350). However, the issue of light-sensitivity seems not to be 
resolved by this measure, as irradiation-based isomerization is still part of the synthetic 
procedure. Moreover, their molecule is not commercially available. Thus, two main solutions 
remain to limit the generation of inactive byproducts. 
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1. TCO and methyltetrazine could be exchanged. Attachment of TCO to the respective 
targeting moiety can be achieved in one step, thus limiting the exposure to potentially 
unfavorable conditions. At the same time, methyltetrazine has demonstrated a very 
high chemical stability (351) and in our hands no inactivation due to light-exposure was 
observed during the synthesis of methyltetrazine-vancomycin, neither are there 
descriptions of it in literature. Thus, using a methyltetrazine-PEG-derivative in the linker 
synthesis might lead to better results. 
2. TCO could be replaced with another functional group. There are multiple possible 
dienophiles that could replace TCO (349). One of these, norbornene is commercially 
available, chemically stable and seems not to be as light sensitive as TCO. While the 
rate of the tetrazine-norbornene IEDDA reaction would be considerably slower than 
reactions using TCO, the reaction rate still would reach similar or faster kinetics than 
typical SPAAC-reactions (349). Norbornene has been successfully employed by 
multiple groups (389, 390) and is cheaply commercially available.  
Both variants should be considered for future linker-molecules and also could be combined, 
by preparing a norbornene-labeled targeting moiety and a tetrazine-labeled linker. 
5.3.7. Implementation of CuAAC-linkers 
Despite its unreactivity in IEDDA reactions, the PEG8-linker still was useful in preliminary 
experiments to demonstrate the sufficient solubility of the branched linker-design and its ability 
to react with AzideOMVs via CuAAC. Unspecific labeling of control OMVs was of a similar 
proportion as labeling with DBCO AF594, while only very little early elution of the linker in the 
absence of OMVs was found (Supp. figure 21). The amount of bound molecules using 
AzideOMVs was much higher than for both DBCO and alkyne AF594. The overall positive 
evaluation of the molecule was an important base for the synthesis of the subsequent PEG6-
linker. 
With the IEDDA reactivity preserved, the PEG6-linker was reacted with OMVs both in its native 
state and after IEDDA reaction with methyltetrazine-PEG4-biotin and methyltetrazine-
vancomycin. On its own, modification per particle was about 20% lower than for the PEG8-
linker, while the unspecific labeling stayed in the same range. However, compared to the linker 
incorporating the slightly longer PEG, the early elution in the absence of OMVs was approx. 
four times higher (Supp. figure 21). This would suggest that the small change from PEG6 to 
PEG8 actually had a greater than anticipated impact on the linker’s solubility in aqueous media. 
The issue of early elution was abolished completely by reacting the PEG6-linker with 
methyltetrazine-PEG4-biotin (Supp. figure 21). Modification with the resulting biotinlinker led to 
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a significantly higher degree of modification than the plain PEG6-linker. However, unspecific 
labeling for the biotinlinker was also much higher than for all other molecules employed in 
OMV-labeling so far. This unspecific labeling could be either based on an unspecific interaction 
of the untreated vesicles with biotin or be related to the copper ions and ascorbic acid added 
during the CuAAC-reaction. No further evaluation was conducted on this yet. 
Biotinylated OMVs were employed for a proof-of-concept experiment to provide evidence of 
the covalent attachment of active and accessible biotin to their surface. OMVs modified with 
the biotinlinker or various controls were incubated with FITC-labeled streptavidin and after 
SEC-purification to remove unbound or unspecifically attached streptavidin, FITC-
fluorescence of OMV-containing samples was measured. AzideOMVs modified with the 
biotinlinker showed significantly higher fluorescence than all the controls, albeit also control 
OMVs treated with the biotinlinker showed an increased fluorescence compared to other 
controls, indicating that unspecific labeling also led to the presence of intact biotin on the 
vesicle-surface. 
As leftover TCO-PEG4-DBCO was available from the synthesis of the SPAAC-based linker, it 
was used to generate an alternative “SPAAC-biotinlinker” through reaction with 
methyltetrazine-PEG4-biotin, with which AzideOMVs were modified using the optimized 
SPAAC-protocol. Due to the absence of a fluorescent dye in this molecule, no direct 
information could be inferred about the density of biotin on the surface of these OMVs. Their 
ability to bind labeled streptavidin however was much greater than for OMVs modified with the 
CuAAC-based linker, even after taking into account the slightly lower particle recovery rates of 
the CuAAC-reaction compared to SPAAC (Figure 43 B). From this, it can be concluded that 
either modification by SPAAC was much more effective than CuAAC or that the CuAAC-
conditions led to structural changes of the biotin, reducing the amount of streptavidin-binding 
moieties. 
During the conjugation of the reaction product of the PEG6-linker and methyltetrazine-
vancomycin (vancomycinlinker), more problems were encountered. While the reaction product 
was formed as indicated by LC/MS and HRMS, its application in CuAAC led to a very high 
unspecific labeling of control OMVs. Thus, it was evaluated, whether this finding was based 
on surface features of the OMVs that would interact with vancomycin or if the CuAAC-
conditions were the cause for it. Compared to control OMVs treated with the native PEG6-linker 
or the biotinlinker, incubation with the vancomycinlinker in the absence of CuAAC-excipients 
did not show an increase in unspecific labeling. Conversely, employing CuAAC-conditions with 
or without NaOH led to a significant increase in unspecific labeling. Taken together with the 
findings for modification with the biotinlinker mentioned above, these data suggest that the 
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conditions during CuAAC can lead to the unspecific labeling of OMVs, which is another 
indicator of the unsuitability of CuAAC for OMV-modification. 
Unfortunately, the unspecific labeling of OMVs prevented the implementation of vancomycin-
modified vesicles in experiments evaluating bacterial targeting. 
5.3.8. Conclusions from the synthesis and attachment of 
targeting moieties 
From the syntheses of various different linker-molecules and their implementation for OMV-
labeling, multiple conclusions can be drawn for the future synthesis of optimized linker 
molecules: 
 Due to its harsh conditions, CuAAC is not suitable for the modification of OMVs and 
should be replaced with SPAAC. 
 The branched design of the CuAAC-based linkers and the inclusion of the sulfonated 
cyanine dye were important steps to obtain a linker with sufficient solubility in PBS. As 
the comparison of the elution-profiles of the pure PEG6- and PEG8-linker revealed the 
solubility of the linker seems to be nonetheless in a very delicate balance, thus, 
subsequent molecules should include a longer PEG-chain, to outweigh the 
replacement of the alkyne with a DBCO-group. 
 TCO is very sensitive and prone to isomerization, while methyltetrazine showed no 
obvious instability. Thus, changing from TCO to another less sensitive dienophile, such 
as norbornene could improve yields and stability of the final product. To reduce 
exposure of the dienophile during synthesis, it could be attached to the targeting moiety 
instead of the linker, as the former attachment should generally be achievable in less 
steps. Suitable norbonene-derivatives containing amines or activated esters are 
available. 




Figure 58: Proposed alternative synthesis pathway for a branched SPAAC-based linker. 
5.4. Glucuronidase encapsulation into EVs and evaluation of 
their storage stability 
The third part of this thesis was concerned with the evaluation of the effect different storage 
conditions had on the stability of EVs, with the final aim of developing an optimized protocol 
for the lyophilisation of EVs for long-term storage (Box 2). As discussed above, keeping EVs 
stable during storage is an important factor for their future therapeutic application (1.6.1). 
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To assess the overall stability of EVs during storage, not only their colloidal stability needs to 
be measured, but also the stability of their cargos needs to be evaluated. As relevant cargos 
can greatly vary between EVs from different sources, β-glucuronidase was instead employed 
as a sensitive model-molecule that could be encapsulated into mammalian EVs using saponin 
incubation, as described in previous publications ((223, 224)). Enzyme activity was evaluated 
using the conversion of non-fluorescent fluorescein di-β-D-glucuronide to fluorescent 
fluorescein. 
First, mammalian EVs from different sources were evaluated regarding their stability upon 
storage under different conditions and the stability of encapsulated enzyme, which was 
published in Frank, Richter et al. (377), with a detailed description of a protocol to evaluate the 
general storage-stability of EVs being published in Journal of Visualized Experiments (378). 
Based on the findings obtained in these works, the conditions for lyophilisation were further 
optimized in cooperation with the group of Prof. Frieß at LMU Munich. The resulting manuscript 
by Trenkenschuh, Richter et al. is currently under review. 
5.4.1. Storage stability of A549- and HUVEC-EVs 
The effect of different storage conditions on the stability of mammalian EVs was evaluated 
using A549- and HUVE-EVs. These experiments were conducted as part of the publication of 
Frank, Richter et al., were besides A549 and HUVEC EVs also EVs derived from MSC-cells 
and liposomes were compared (377). Preliminary experiments using A549-EVs stored for only 
48 h already revealed a central finding of this study that lyophilisation of EVs without the 
addition of a cryo- and lyoprotectant puts the vesicles under great strain and leads to particle-
loss and an increase in particle size, which was also reflected in the size-distribution of EVs 
before and after storage (Figure 51). Similar results were obtained for HUVEC-EVs stored for 
14 d (Figure 52). Here the physicochemical changes of EVs were even more profound, with 
only RT-storage showing no increase in mean particle size and especially frozen storage and 
lyophilisation showing a high loss of particles. These findings were in line with the experiments 
conducted by Julia Frank using liposomes and MSC-EVs. The latter however generally 
showed a higher stability than HUVEC- and A549-EVs. Importantly, not only lyophilisation, but 
practically all storage conditions evaluated led to particle loss. This indicates the general need 
for a better understanding of how EV-storage can be optimized. Based on these results, the 
effect of formulating EVs with the cryo- and lyoprotector trehalose was tested (Figure 53 & 
Figure 54). For 7 d storage of HUVEC-EVs, trehalose prevented an increase in vesicles-size, 
but it could not stop the loss of particles compared to storage at 4 °C. As with the other types 
of EVs evaluated by Julia Frank, the addition of trehalose led to an improved preservation of 
β-glucuronidase activity in lyophilized HUVEC-EVs. 
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Based on these results it was concluded that while lyophilisation exhibited some drawbacks 
regarding colloidal stability, other methods of storage also were not without problems and 
especially regarding the stability of encapsulated enzyme, lyophilisation seemed like the best 
alternative. Further optimization of lyophilisation-conditions would be nonetheless needed to 
make it a viable method that could replace the current gold standard, storage at -80 °C. 
Parameters to be optimized included the choice of cryoprotectants and their amounts, as well 
as an evaluation of the parameters of the lyophilisation-process. In the study by Frank et al. 
only trehalose, mannitol and PEG400 were evaluated. Other sugars, but also polymers such 
as PVP and mild detergents such as P188 and PS20, which were shown to stabilize liposome 
membranes (394, 395), potentially could improve EV-stability upon lyophilisation. Regarding 
the lyophilisation process, the basic protocol for the freezing and lyophilisation of the EV-
samples could be optimized further to reflect the more intricate and controlled protocols used 
in industrial settings. 
After the work of Frank Richter et al., more research was published on the lyophilisation of EVs 
(263, 264). These works confirmed the positive effect on trehalose on vesicle-stability. While 
Charoenviriyakul et al. did not evaluate the effect lyophilisation had on the particle-number 
(263), El Baradie et al. found a reduction in particle-concentration compared to samples before 
storage similar to our findings (264). They moreover evaluated PVP as an additional 
cryoprotective agent, which improved the recovery rate compared to trehalose alone. 
5.4.2. Glucuronidase encapsulation into SBCy050 OMVs 
and Ro EVs 
Based on the positive assessment of lyophilisation described in the previous chapter, a 
cooperation with the group of Prof. Frieß at LMU Munich was started to conduct a deeper 
evaluation of all factors that could be optimized to obtain lyophilisation conditions that would 
produce EV-formulations with long-term stability. RO-EVs were chosen as the vesicle-model, 
because their culture in suspension allowed an easier cultivation of the high amount of cells 
required for a large-scale long-term evaluation of different storage conditions. 
Based on preliminary freeze-thaw and lyophilisation experiments conducted in Munich that 
demonstrated that a buffer exchange from PBS to 10 mM phosphate was crucial for obtaining 
stabilized vesicles and that the addition of P188 would further improve colloidal stability, four 
formulations were chosen for long-term storage: 
1. 10 mM Na-phosphate with 5% sucrose and 0.02% P188 
2. 10 mM K-phosphate with 5% sucrose and 0.02% P188 
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3. 10 mM Na-phosphate with 5% sucrose and 0.02% PVP 
4. 10 mM Na-phosphate with 5% PVP and 0.02% P188 
Na- and K-phosphate were differentiated, as they behave differently upon freezing, with Na-
phosphate leading to an acidic pH-shift not found for K-phosphate (396). PVP was employed 
either as an adjuvant to sucrose, which replaced trehalose as a cheaper alternative with similar 
cryo- and lyoprotective properties, or PVP in combination with P188 was used as the main 
protective agent, in the same way as in the publication of El Baradie et al. (264). To obtain an 
assessment of the intactness and retention of EV-cargos, again β-glucuronidase was 
encapsulated in the vesicles. 
Samples were stored up to six months at 2-8 °C and under stress-conditions at 25 and 40 °C. 
Colloidal integrity and enzyme stability were evaluated before and directly after lyophilisation 
and after one and six months of storage. 
The evaluation of enzyme-activity before lyophilisation revealed much higher values for PVP-
containing samples that for formulations 1 and 2 (Figure 55). This could indicate that PVP 
somehow had a protective effect during processing of samples before lyophilisation. Directly 
after lyophilisation however, the relation between the samples was reversed. While enzyme 
activity was reduced for formulations 1 and 2, no enzyme activity whatsoever was recovered 
for formulations 3 and 4, suggesting that PVP offered less protection during the freeze-drying 
process. 
After one month of storage, enzyme activity increased for all samples compared to directly 
after lyophilisation, with formulation 1 at 4 °C showing the best recovery, revealing the same 
enzyme activity as before lyophilisation. The general propensity of the samples to recover their 
enzyme-activity could indicate that at least some of the changes introduced to the enzyme 
during lyophilisation were reversible under the conditions inside the EVs and the active 
conformation of the enzyme was partially recovered during the first month of storage through 
slow structural changes (261, 262). Compared to before lyophilisation, condition 1 performed 
best across all storage-temperatures, conditions 2 and 3 showed a similar reduction in enzyme 
activity and condition 4 lost the biggest fraction of its initial activity. 
After six months of storage, enzyme activity was strongly reduced in all formulations. While 
some activity remained in formulations 1 and 2, 3 and 4 showed almost no recovery of active 
enzyme in their mean values with the individual results showing a broad spread around zero 
fluorescence. This high variance could be linked to the interaction of PVP with the β-
glucuronidase-assay indicated by the values obtained with EV-free placebo samples, which 
showed a higher background than the controls for formulations 1 and 2. Overall, condition 1 




Figure 59: Assessment of the colloidal stability of RO-EVs. Vesicle-concentration was 
measured using TRPS. Panel A displays results obtained using the NP100 nanopore, which 
shows particles in the size-range from 50-330 nm. These correspond with intact EVs. Panel B 
shows results obtained using the NP600 nanopore, which corresponds to particles from 275-
1570 nm and corresponds with vesicle-aggregates. This figure was adapted from 
Trenkenschuh E., Richter, M. et al. (2020). “Formulation development of lyophilized 
extracellular vesicles with long-term stability”, manuscript submitted to Advanced Healthcare 
Materials. 
The negative assessment of formulations 3 and 4 was also reflected in the data on the colloidal 
stability of the formulations obtained by Eduard Trenkenschuh in Munich. Both PVP-containing 
formulations showed a loss of particles, which got more pronounced with longer storage 
(Figure 59 A). While for formulation 4 it led to a high formation of aggregates, aggregate-
formation was the lowest in formulation 3, which would indicate that here small particles were 
predominantly lost by vesicle-disintegration as opposed to aggregation (Figure 59 B). 
Formulation 1 and 2 showed an excellent colloidal stability throughout all time points and 
conditions (Figure 59).  
The discrepancy between high colloidal stability and decreasing enzyme-activity could be 
based on either the loss or the inactivation of β-glucuronidase during freezing, lyophilisation or 
rehydration or it could be caused by slow degradation of the enzyme over time. As high 
enzyme-activity was recovered after one month of storage at least for some formulations, a 
general loss of enzyme through leakage from the vesicles seems unlikely. Thus it can be 
speculated that encapsulated enzyme degraded over time (397). With the high requirements 
of enzymes regarding their tertiary and quaternary structure, it is likely that small changes 
happening over time in the lyophilized state could accumulate and cause a reduction in 
enzyme-stability after six months of storage (261, 262). Enzyme-degradation could potentially 
be mitigated by the co-encapsulation of sufficient amounts of cryo- and lyoprotective agents, 
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as indicated by the study of Kannan et al. who showed that luminal sucrose increased the 
stability of liposomes during lyophilisation (398). 
Due to its sensitivity to conformational changes, β-glucuronidase could potentially 
overestimate the effect lyophilisation has on less sensitive cargos of EVs such as RNA and 
DNA, where hydrolysis would be the main driver of their degradation. However, in this way, β-
glucuronidase enabled a clear indication of potentially unfavorable storage conditions and 
compared to natural EV-cargos it allowed for a sensitive and easily performed assay for its 
quantification. 
In conclusion, in this cooperative effort, optimized conditions for the lyophilisation and storage 
of mammalian EVs were obtained, to produce formulations with long-term stability. Importantly, 
the conditions of formulation 1, also led to a high colloidal stability of SBCy050-OMVs upon 
freeze-thawing and lyophilisation (Trenkenschuh E., Richter, M. et al. (2020). “Formulation 
development of lyophilized extracellular vesicles with long-term stability”, manuscript submitted 
to Advanced Healthcare Materials), which suggests that the optimized conditions derived from 
this study could have general applicability to EVs regardless of their parent-cells. Still, further 
evaluation is needed in this regard. The next step will be the application of the knowledge 
gained on EVs with native biological activity, such as MSC EVs (399) or antibacterial OMVs 




6. Conclusions and outlook 
EVs hold many promises for future medicine and healthcare. Their successful translation from 
the lab to an approved medicinal product however has been lacking so far, despite numerous 
clinical trials. In this work, three main objectives were pursued (Box 2), development of a 
method for the surface modification of myxobacterial OMVs, introduction of bacteria-specific 
targeting moieties to the surface of said OMVs and evaluation of lyophilisation for long-term 
storage of mammalian EVs. While the first two targets mainly aimed at improving the 
pharmaceutical activity of OMVs by endowing them with targeting moieties, the third target is 
concerned with EV-storage as an important factor for their clinical translation.  
After evaluation of cholesterol-insertion and NHS ester based chemical surface modification, 
diazotransfer was introduced to the vesicle-field as a new method for the generation of azide-
labelled OMVs. Diazotransfer showed high efficiency in labeling and left only a low impact on 
vesicle integrity. Combined with SPAAC, it compared favorably to the established method of 
active ester based modification. These results demonstrated the high potential diazotransfer 
has as a fast and low-cost alternative to generate azide-labeled OMVs for subsequent surface 
modification using SPAAC, CuAAC or Staudinger ligation.  
The introduction of bacteria-specific targeting moieties to AzideOMVs generated by 
diazotransfer was hindered by problems in the development of a suitable linker-molecule to 
tether the targeting moiety to the vesicle surface. While initial solubility-problems were 
successfully addressed, by changes in the linker design and the replacement of SPAAC with 
CuAAC, more problems were encountered subsequently. CuAAC, which after optimization 
showed similar efficiency to SPAAC, was shown to be unfavorable to EV-modification due to 
the reactive excipients used in the reaction. These led to changes in the OMVs indicated by a 
loss of autofluorescence and caused unspecific labeling of the vesicles when using 
vancomycin as a targeting moiety. Despite a successful proof of concept experiment using 
biotin as a targeting moiety, more work is needed to reach the goal of surface modification with 
bacteria specific targeting moieties. 
Lyophilisation of EVs was first tested in two mammalian cell-lines, where the stress induced 
by lyophilisation became apparent through changes in vesicle-size and low particle recovery. 
Addition of trehalose as a cryoprotectant afforded some improvement and led to an improved 
preservation of the activity of encapsulated β-glucuronidase. Founded on these findings, in 
cooperation with the group of Prof. Frieß at LMU Munich, the conditions and excipients for 
lyophilisation were successfully optimized to obtain lyophilized EVs with very high colloidal 
stability and good preservation of the encapsulated enzyme. These results mark an important 
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step in the evaluation of lyophilisation for EV-storage, as for the first time mammalian EVs were 
lyophilized and stored without the loss of a substantial amount of particles. 
Taken together, two of the original three main objectives of this work were reached 
successfully. For the second objective, despite not achieving the introduction of vancomycin 
as a targeting moiety to OMVs, nonetheless substantial advances were made towards the 
realization of this aim, as crucial requirements for future linker molecules have been elucidated. 
6.1. Outlook 
For diazotransfer, the next steps will be the synthesis and implementation of another ISA-salt, 
either the sulfate or mesylate, to circumvent the volatile properties of the HCl salt employed in 
this study. Then, based on the work of Philipp Lapuhs, the ISA concentration employed during 
diazotransfer could be studied more closely to further optimize the method. Finally, the most 
important question for diazotransfer is whether it is applicable to mammalian EVs and other 
bacterial EVs, especially ones with innate antibacterial activity, which potentially could be 
further increased by the introduction of targeting moieties. Successful application of 
diazotransfer in mammalian EVs will moreover greatly increase its potential as a method of 
wide application in the vesicle-field. 
Based on the findings presented here, a new linker molecule, potentially based on the example 
described in 5.3.8, needs to be synthesized. Once a linker molecule suitable for the reaction 
with targeting moieties and vesicles has been obtained, the applicability of vancomycin and 
other targeting moieties can be evaluated. The application of the modular linker could 
moreover be expanded beyond targeting bacteria, for example to target cells that might harbor 
bacteria in their cytoplasm. 
The optimized protocol for the lyophilisation of EVs obtained in this work now can be applied 
to EVs with pharmaceutical activity. Additionally its ability to generate dry EV-formulations for 




7. Supplementary data and figures 
 
Supp. figure 1: Size distribution measured by NTA of A549 EVs (A) and liposomes (B). Curves 




Supp. figure 2: Light microscopy of A549 cells. A&B show the cells after 120 h in culture, before 
the exchange to serum-free conditions. C&D show cells after another 48 h in serum-free 




Supp. figure 3: SEC elution profile of injections of the DBCO Af549 (A&B) and alkyne AF594 
(C&D). All samples were dissolved in PBS in the absence of EVs, DBCO AF594 at 4.9 µM, 
alkyne AF549 at 19.6 µM. Plots in the right column show a zoomed view of the region, were 




Supp. figure 4: Calibration curves for DBCO AF594 (A, n=4), alkyne Af549 (B, n=5), the PEG8-
linker (C, n=1), the PEG6-linker (D, n=3) and the product of the IEDDA reaction of the PEG6-
linker and methyltetrazine-PEG4-biotin (E, n=3). All calibration curves were prepared in fresh, 




Supp. figure 5: Calibration curve for the quantification of residual copper in EV-samples. 




Supp. figure 6: Mass peak (A) and UV absorption at 254 nm (B) of purified methyltetrazine-
vancomycin eluting at 2.2 min. Panel C shows the corresponding mass spectrum that shows 




Supp. figure 7: Crude SPAAC-based linker. Panel A shows the peak corresponding to the 
mass of the degradation product eluting at 3.36 min. Panel B shows the peak corresponding 
to the SPAAC-based linker eluting at 3.69 min. Panel C shows the UV-absorption at 649 nm 




Supp. figure 8: Effect of different HPLC-methods on the stability of the SPAAC-based linker. 
A: 5 min HPLC-method. Peaks corresponding to the masses of degradation product (3.38 min; 
1) and intact linker (3.69 min; 2), UV absorption at 649 nm (3). B: 25 min HPLC-method. Peaks 
corresponding to the masses of degradation product (12.36 min; 1) and intact linker (14.13 




Supp. figure 9: IEDDA reaction of the SPAAC-based linker with methyltetrazine vancomycin 
zoomed in to the relevant peaks. A: Mass peak of the product of degradation product and 
methyltetrazine vancomycin (3.07 min). B: Mass peak of unreacted degradation product (3.58 
min, ions with this mass were also measured for the product of the degradation product and 
methyltetrazine vancomycin). C: Mass peak of the product of SPAAC-based linker and 
methyltetrazine vancomycin (3.29 min). D: Mass peak of unreacted SPAAC-based linker (3.91 
min). E: UV absorption at 649 nm of the reaction products of the degraded linker (3.00 min, 
three peaks), the intact SPAAC-based linker (3.37 min, three peaks), unreacted degradation 




Supp. figure 10: Mass spectrum of the reaction-product of the IEDDA reaction with 
methyltetrazine vancomycin of the SPAAC-based linker (A, [M+3H]4+ detected at 861.3 m/z) 




Supp. figure 11: Mass peak (A) and UV absorption at 254 nm (B) of the purified Boc-protected 
intermediate eluting at ~3.2 min. Panel C shows the corresponding mass spectrum that shows 
















Supp. figure 14: LC/MS analysis of the Boc-deprotection test-experiment (A&B) and the bulk 
deprotection of the Boc-protected PEG8-linker (C&D) after 1 and 2 h of deprotection. The 




Supp. figure 15: Mass spectrum of the deprotected PEG8-linker-intermediate (A, [M+H]+ at 




Supp. figure 16: Crude PEG8-linker after reaction of sulfo-cyanine 5 NHS with the deprotected 
intermediate. Negative scan (A) and UV-absorption at 254 nm (B) revealed the intact PEG8-




Supp. figure 17: Mass spectra of the PEG8-linker (A, [M+ACN-2H]2-at 640.9 m/z) and the 




Supp. figure 18: Mass peak (A, 2.90 min) and corresponding mass spectrum of the purified 












Supp. figure 21: SEC elution profile of injections of the PEG8-linker (A&B), PEG6-linker (C&D) 
and the reaction product of the PEG6-linker and methyltetrazine-PEG4-biotin (E&F). All 
samples were dissolved in PBS at 19.6 µM in the absence of EVs. Plots in the right column 




Supp. figure 22: Analysis of the IEDDA reaction of methyltetrazine-vancomycin and the PEG8-
linker. Panels A and B contain the UV-absorption at 254 nm of the PEG8-linker (A, 2.87 min) 
and methyltetrazine-vancomycin (B, 2.24 min) respectively. Panel C shows the chromatogram 
after the IEDDA reaction. Besides the peaks at 2.24 and 2.87 min derived from the educts, no 




Supp. figure 23: Analysis of the IEDDA reaction of methyltetrazine-vancomycin and the Boc-
protected intermediate. Panels A and B contain the UV-absorption at 254 nm of 
methyltetrazine-vancomycin (A, 2.24 min) and the Boc-protected intermediate (B) respectively. 
Panel C shows the chromatogram after the IEDDA reaction. Three peaks belonging to the 




Supp. figure 24: Mass peak (A, 3.84 min) and corresponding mass spectrum of the purified 














Supp. figure 27: Mass peak (A, 2.65 min) and corresponding mass spectrum of the purified 














Supp. figure 30: Zoomed view of the 1H-NMR spectra containing the signals of the protons 
belonging to the alkene-group of cyclooctene. Fmoc-intermediate (A) and deprotected 




Supp. figure 31: Mass peak (A, 2.76 min) and UV-absorption at 254 nm (B) of the crude PEG6-
linker. The UV-spectrum shows two compound eluting at almost the same time, which is not 





Supp. figure 32: Zoomed view of the UV-absorption at 646 nm of a prepHPLC fraction of the 
PEG6-linker before (A) and after reaction with methyltetrazine-vancomycin (B). Panel A shows 
two peaks corresponding with the linker at 2.77 and 2.79 min. Only the peak at 2.79 min 
remained after the IEDDA reaction, while three new peaks emerged at 2.26, 2.47 and 2.52 
min. 
 





Supp. figure 34: LC/MS-analysis of the PEG6-linker after lyophilisation. A degradation product 
with a signal at 520 m/z appeared (A, ~2.10 min). The intact linker eluted at 2.78 min as visible 
in panel B and C. Both molecules exhibited an absorption at 646 nm corresponding to the 



















Supp. figure 38: HSQC spectrum of the active PEG6-linker acquired at 500 MHz (1H) and 126 





Supp. figure 39: HMBC spectrum of the active PEG6-linker acquired at 500 MHz (1H) and 126 


















Supp. figure 43: HSQC spectrum of the inactive PEG6-linker acquired at 500 MHz (1H) and 




Supp. figure 44: Zoomed picture of the UV-absorption of the active PEG6-linker (A, 2.873 min) 
and its inactive variant (B, 2.889 min). The mass spectra of both compounds (C&D) show the 




Supp. figure 45: LC/MS analysis of the IEDDA reaction of the PEG6-linker and methyltetrazine-
vancomycin. Panel A shows the peak corresponding with the [M-2H]2- ion of remaining PEG6-
linker at 2.81 min. Panel B shows the peaks corresponding with the IEDDA-product that was 
detected as the [M+3H]3+ ion at 943 m/z (see also the corresponding mass spectrum D). The 
UV-absorption at 646 nm in panel C reveals that there were three peaks corresponding to the 
IEDDA-product eluting at 2.26, 2.46 and 2.52 min. Additionally the degradation product did not 




Supp. figure 46: Zoomed view of the UV-absorption peak at 646 nm corresponding with the 
PEG6-linker. Before the IEDDA reaction (A), there is a main peak eluting at 2.79 min, with a 
shoulder that elutes later. After the IEDDA reaction (B), the main peak mostly disappeared and 
the shoulder remained (2.82 min). 
 
Supp. figure 47: LC/MS analysis of the IEDDA reaction of the PEG6-linker and methyltetrazine-
PEG4-biotin zoomed to the relevant part of the spectrum. Panel A shows the peak 
corresponding with the [M-2H]2- ion of remaining PEG6-linker at 2.79 min. Panel B shows the 
176 
 
peak corresponding with the [M+FA-H]- ion of remaining methyltetrazine-PEG4-biotin at 2.68 
min (634 m/z). Panel C shows peaks at 2.39 and 2.71 min that corresponding with the [M-2H]2-  
ion at 877 m/z. The UV-absorption at 646 nm in panel D revealed that there were three peaks 
corresponding to the IEDDA-product eluting at 2.41, 2.68 and 2.75 min. 
 
Supp. figure 48: LC/MS analysis of the IEDDA reaction of the PEG6-linker and methyltetrazine-
PEG4-biotin zoomed to the relevant part of the spectrum. Panel A shows peaks at 2.39 and 
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2.71 min that corresponded with the [M-2H]2-  ion at 877 m/z. The mass spectra for the peak at 
2.39 min (B) and 2.71 min (C) show that both peaks contained the IEDDA-product. 
 
Supp. figure 49: Elution-profile of the IEDDA-product of TCO-PEG4-DBCO and 
methyltetrazine-PEG4-biotin. The molecule was dissolved at 4.9 µM in PBS and subjected to 
SEC-purification using the column generally employed for the purification of samples after 




Supp. figure 50: Size distribution of EVs before and after storage. Panel A shows A549 EVs 
that were stored for 2 d at 4 °C, -80 °C or lyophilized without addition of trehalose. Panel B 
shows HUVEC EVs stored for 14 d at RT, 4 °C, -80 °C or lyophilized without addition of 
trehalose. Panel C shows HUVEC EVs stored for 7 d at 4 °C, -80 °C or lyophilized with addition 




Supp. figure 51: Light microscopy of HUVEC cells. A&B show the cells after 120 h in culture, 
before the exchange to serum-free conditions. C&D show cells after another 48 h in serum-




Supp. figure 52: Results of Philipp Lapuhs performing diazotransfer and SPAAC with OMVs 
derived from Stigmatella aurantiaca Sga15 myxobacteria. Panels A and B show the recovery 
rate measured by NTA (A) and ÄKTA (B) compared to the untreated control at different pH-
values (n=3-6). Panel C shows the modification efficiency with DBCO AF594 depending on 
the pH (n=3-6). Panel D shows the modification efficiency depending on the ISA-concentration 
used for diazotransfer conducted at pH 9.5 (n=3). The figure was adapted from the master 
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